U.S. patent application number 16/849349 was filed with the patent office on 2020-11-05 for solid forms of a toll-like receptor modulator.
This patent application is currently assigned to Gilead Sciences, Inc.. The applicant listed for this patent is Gilead Sciences, Inc.. Invention is credited to Sylvie M. Asselin, Pavel R. Badalov, Henry G. Morrison, Christopher S. Regens, Tiago Vieira.
Application Number | 20200345738 16/849349 |
Document ID | / |
Family ID | 1000005003654 |
Filed Date | 2020-11-05 |
![](/patent/app/20200345738/US20200345738A1-20201105-C00001.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00002.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00003.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00004.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00005.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00006.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00007.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00008.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00009.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00010.png)
![](/patent/app/20200345738/US20200345738A1-20201105-C00011.png)
View All Diagrams
United States Patent
Application |
20200345738 |
Kind Code |
A1 |
Asselin; Sylvie M. ; et
al. |
November 5, 2020 |
SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR
Abstract
The present disclosure provides crystalline forms, solvates and
hydrates of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
an-1-ol, and methods of making.
Inventors: |
Asselin; Sylvie M.;
(Broomfield, CO) ; Badalov; Pavel R.; (Edmonton,
CA) ; Morrison; Henry G.; (Dublin, CA) ;
Regens; Christopher S.; (San Francisco, CA) ; Vieira;
Tiago; (Edmonton, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Gilead Sciences, Inc. |
Foster City |
CA |
US |
|
|
Assignee: |
Gilead Sciences, Inc.
Foster City
CA
|
Family ID: |
1000005003654 |
Appl. No.: |
16/849349 |
Filed: |
April 15, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62835335 |
Apr 17, 2019 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/522 20130101;
A61K 45/06 20130101; A61K 31/675 20130101; A61K 31/7072 20130101;
C07D 471/04 20130101; C07B 2200/13 20130101; A61K 31/519
20130101 |
International
Class: |
A61K 31/519 20060101
A61K031/519; A61K 31/675 20060101 A61K031/675; C07D 471/04 20060101
C07D471/04; A61K 45/06 20060101 A61K045/06; A61K 31/522 20060101
A61K031/522; A61K 31/7072 20060101 A61K031/7072 |
Claims
1. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (Compound I): ##STR00021## characterized by an X-ray powder
diffraction (XRPD) pattern comprising three or more peaks at
10.9.degree., 11.5.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.), Form I.
2. The crystalline form of claim 1, characterized by an XRPD
pattern comprising four or more peaks at 10.9.degree.,
11.5.degree., 13.2.degree., 14.7.degree., 15.5.degree.,
21.4.degree., 21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
3. The crystalline form of claim 1, characterized by an XRPD
pattern comprising peaks at 15.5.degree., 21.4.degree., and
21.9.degree. (.+-.0.2.degree. 2.theta.).
4. The crystalline form of claim 3, wherein the XRPD pattern
further comprises one or more additional peaks at 10.9.degree.,
11.5.degree., 13.2.degree., 14.7.degree., 23.2.degree., or
24.9.degree. 2.theta. (0.2.degree. 2.theta.).
5. The crystalline form of claim 3, wherein the XRPD pattern
further comprises two or more additional peaks at 10.9.degree.,
11.5.degree., 13.2.degree., 14.7.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
6. The crystalline form of claim 1, characterized by an XRPD
pattern comprising peaks at 10.9.degree., 13.2.degree., and
14.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
7. The crystalline form of claim 6, wherein the XRPD pattern
further comprises one or more additional peaks at 11.5.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
8. The crystalline form of claim 6, wherein the XRPD pattern
further comprises two or more additional peaks at 11.5.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
9. The crystalline form of claim 1, characterized by an XRPD
pattern comprising peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., and 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
10. The crystalline form of claim 1, characterized by a unit cell
as determined by single crystal X-ray crystallography of the
following dimensions: a=8.0344 (2) .ANG.; b=8.0344 (2) .ANG.;
c=23.7871 (7) .ANG.; .alpha.=90.degree.; .beta.=90.degree.; and
.gamma.=90.degree..
11. The crystalline form of claim 1, characterized by an XRPD
pattern substantially as shown in FIG. 1.
12. The crystalline form of claim 1, characterized by a
differential scanning calorimetry (DSC) thermogram having an
endotherm with an onset of about 164.degree. C.
13. The crystalline form of claim 1, characterized by a DSC
thermogram substantially as shown in FIG. 2.
14. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-olhydrochloride: ##STR00022## characterized by an XRPD pattern
comprising three or more peaks at 6.1.degree., 12.2.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 18.9.degree.,
20.3.degree., 23.2.degree., or 24.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), hydrochloride salt Form I.
15.-25. (canceled)
26. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-olhydrochloride: ##STR00023## characterized by an XRPD pattern
comprising three or more peaks at 7.1.degree., 9.7.degree.,
14.3.degree., 15.3.degree., 16.1.degree., 19.1.degree.,
22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), hydrochloride salt Form II.
27.-37. (canceled)
38. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol tartaric acid: ##STR00024## characterized by an XRPD pattern
comprising three or more peaks at 6.3.degree., 9.9.degree.,
12.5.degree., 17.7.degree., 18.3.degree., 19.2.degree.,
23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I tartaric acid.
39.-49. (canceled)
50. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol maleic acid: ##STR00025## characterized by an XRPD pattern
comprising three or more peaks at 7.3.degree., 8.4.degree.,
8.8.degree., 13.9.degree., 15.6.degree., 17.7.degree.,
20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I maleic acid.
51.-61. (canceled)
62. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol fumaric acid: ##STR00026## characterized by an XRPD pattern
comprising three or more peaks at 6.7.degree., 8.3.degree.,
10.1.degree., 12.6.degree., 16.1.degree., 18.5.degree.,
20.6.degree., 25.2.degree. or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I fumaric acid.
63.-74. (canceled)
75. A crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol methanesulfonic acid: ##STR00027## characterized by an XRPD
pattern comprising three or more peaks at 5.4.degree.,
10.4.degree., 10.8.degree., 15.8.degree., 17.3.degree.,
18.1.degree., 20.5.degree., 20.8.degree., or 23.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I methanesulfonic acid.
76.-87. (canceled)
88. An amorphous solid form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol: ##STR00028##
89. (canceled)
90. (canceled)
91. A pharmaceutical composition comprising the crystalline form of
claim 1 or the amorphous form of claim 88 and one or more
pharmaceutically acceptable excipients.
92. The pharmaceutical composition of claim 91, wherein the
crystalline form is Form I.
93-99. (canceled)
100. A method of treating or preventing a hepatitis B virus (HBV)
infection in a subject in need thereof, comprising administering to
the subject a therapeutically effective amount of the crystalline
form of claim 1, the amorphous form of claim 88, or the
pharmaceutical composition of claim 91.
101. The method of claim 100, further comprising administering a
therapeutically effective amount of one or more additional
therapeutic agents.
102. The method of claim 100, wherein the one or more additional
therapeutic agents are administered simultaneously with the
crystalline form or the pharmaceutical composition.
103. The method of claim 100, wherein the one or more additional
therapeutic agents are selected from the group consisting of: HBV
combination drugs, HBV vaccines, HBV DNA polymerase inhibitors,
immunomodulators, toll-like receptor (TLR) modulators, interferon
alpha receptor ligands, hyaluronidase inhibitors, hepatitis b
surface antigen (HBsAg) inhibitors, cytotoxic
T-lymphocyte-associated protein 4 (ipi4) inhibitors, cyclophilin
inhibitors, HBV viral entry inhibitors, antisense oligonucleotide
targeting viral mRNA, short interfering RNAs (siRNA) and ddRNAi
endonuclease modulators, ribonucleotide reductase inhibitors, HBV E
antigen inhibitors, covalently closed circular DNA (cccDNA)
inhibitors, farnesoid X receptor agonists, HBV antibodies, CCR2
chemokine antagonists, thymosin agonists, cytokines, nucleoprotein
modulators, retinoic acid-inducible gene 1 stimulators, NOD2
stimulators, phosphatidylinositol 3-kinase (PI3K) inhibitors,
indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors, PD-1
inhibitors, PD-L1 inhibitors, recombinant thymosin alpha-1
agonists, Bruton's tyrosine kinase (BTK) inhibitors, KDM
inhibitors, HBV replication inhibitors, arginase inhibitors, and
other HBV drugs.
104. The method of claim 100, wherein the one or more additional
therapeutic agents are selected from the group consisting of:
adefovir (Hepsera.RTM.), tenofovir disoproxil
fumarate+emtricitabine (Truvada.RTM.), tenofovir disoproxil
fumarate (Viread.RTM.), entecavir (Baraclude.RTM.), lamivudine
(Epivir-HBV.RTM.), tenofovir alafenamide, tenofovir, tenofovir
disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, telbivudine (Tyzeka.RTM.), Clevudine.RTM.,
emtricitabine (Emtriva.RTM.), peginterferon alfa-2b
(PEG-Intron.RTM.), Multiferon.RTM., interferon alpha 1b
(Hapgen.RTM.), interferon alpha-2b (Intron A.RTM.), pegylated
interferon alpha-2a (Pegasys.RTM.), interferon alfa-n1
(Humoferon.RTM.), ribavirin, interferon beta-Ia (Avonex.RTM.),
Bioferon, Ingaron, Inmutag (Inferon), Algeron, Roferon-A,
Oligotide, Zutectra, Shaferon, interferon alfa-2b (Axxo),
Alfaferone, interferon alfa-2b, Feron, interferon-alpha 2 (CJ),
Bevac, Laferonum, Vipeg, Blauferon-B, Blauferon-A, Intermax Alpha,
Realdiron, Lanstion, Pegaferon, PDferon-B, alfainterferona 2b,
Kalferon, Pegnano, Feronsure, PegiHep, Optipeg A, Realfa 2B,
Reliferon, peginterferon alfa-2b, Reaferon-EC, Proquiferon,
Uniferon, Urifron, interferon alfa-2b, Anterferon, Shanferon,
MOR-22, interleukin-2 (IL-2), recombinant human interleukin-2
(Shenzhen Neptunus), Layfferon, Ka Shu Ning, Shang Sheng Lei Tai,
Intefen, Sinogen, Fukangtai, Alloferon and celmoleukin.
105. The method of claim 100, wherein the one or more additional
therapeutic agents are selected from the group consisting of:
entecavir, adefovir, tenofovir disoproxil fumarate, tenofovir
alafenamide, tenofovir, tenofovir disoproxil, tenofovir alafenamide
fumarate, tenofovir alafenamide hemifumarate, telbivudine and
lamivudine.
106. The method of claim 100, wherein the one or more additional
therapeutic agents are selected from the group consisting of
tenofovir alafenamide, tenofovir alafenamide fumarate, and
tenofovir alafenamide hemifumarate.
107.-121. (canceled)
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 62/835,335, filed on Apr. 17, 2019, the entire
content of which is hereby incorporated by reference in its
entirety.
FIELD
[0002] This application relates generally to toll-like receptor
modulator compounds, including diamino pyrido[3,2 D] pyrimidine
compounds, and pharmaceutical compositions which, among other
things, modulate toll-like receptors (e.g. TLR-8), and methods of
making and using them.
BACKGROUND
[0003] The toll-like receptor (TLR) family plays a fundamental role
in pathogen recognition and activation of innate immunity.
Toll-like receptor 8 (TLR-8) is predominantly expressed by myeloid
immune cells and activation of this receptor stimulates a broad
immunological response. Agonists of TLR-8 activate myeloid
dendritic cells, monocytes, monocyte-derived dendritic cells and
Kupffer cells leading to the production of proinflammatory
cytokines and chemokines, such as interleukin-18 (IL-18),
interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-.alpha.),
and interferon-gamma (IFN-.gamma.). Such agonists also promote the
increased expression of co-stimulatory molecules such as CD8.sup.+
cells, major histocompatibility complex molecules (MAIT, NK cells),
and chemokine receptors.
[0004] Collectively, activation of these innate and adaptive immune
responses induces an immune response and provides a therapeutic
benefit in various conditions involving autoimmunity, inflammation,
allergy, asthma, graft rejection, graft versus host disease (GvHD),
infection, cancer, and immunodeficiency. For example, with respect
to hepatitis B, activation of TLR8 on professional antigen
presenting cells (pAPCs) and other intrahepatic immune cells is
associated with induction of IL-12 and proinflammatory cytokines,
which is expected to augment HBV-specific T cell responses,
activate intrahepatic NK cells and drive reconstitution of
antiviral immunity. See e.g. Wille-Reece, U. et al. J Exp Med 203,
1249-1258 (2006); Peng, G. et al., Science 309, 1380-1384 (2005);
Jo, J. et al., PLoS Pathogens 10, e1004210 (2014) and Watashi, K.
et al., J Biol Chem 288, 31715-31727 (2013).
[0005] Given the potential to treat a wide array of diseases, there
remains a need for novel modulators of toll-like receptors, for
example TLR-8. Potent and selective modulators of TLR-8 that have
reduced potential for off target liabilities are particularly
desirable.
BRIEF SUMMARY OF THE DISCLOSURE
[0006] In one embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol (Compound I):
##STR00001##
characterized by an X-ray powder diffraction (XRPD) pattern
comprising three or more peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Form I.
[0007] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol hydrochloride:
##STR00002##
characterized by an XRPD pattern comprising three or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I.
[0008] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-olhydrochloride:
##STR00003##
characterized by an XRPD pattern comprising three or more peaks at
7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), hydrochloride salt Form II.
[0009] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol tartaric acid:
##STR00004##
characterized by an XRPD pattern comprising three or more peaks at
6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I tartaric acid.
[0010] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol maleic acid:
##STR00005##
characterized by an XRPD pattern comprising three or more peaks at
7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree., 15.6.degree.,
17.7.degree., 20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I maleic acid.
[0011] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol fumaric acid:
##STR00006##
characterized by an XRPD pattern comprising three or more peaks at
6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I fumaric acid.
[0012] In another embodiment, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol methanesulfonic acid:
##STR00007##
characterized by an XRPD pattern comprising three or more peaks at
5.4.degree., 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 18.1.degree., 20.5.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.), Compound I
methanesulfonic acid.
[0013] In another embodiment, the present disclosure provides an
amorphous solid form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol:
##STR00008##
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1 shows the XRPD pattern for Compound I Form I.
[0015] FIG. 2 shows the DSC thermograph for Compound I Form I.
[0016] FIG. 3 shows the TGA curve for Compound I Form I.
[0017] FIG. 4 shows the DVS curve for Compound I Form I.
[0018] FIG. 5 shows the XRPD pattern for Compound I HCl salt Form
I.
[0019] FIG. 6 shows the DSC thermograph for Compound I HCl salt
Form I.
[0020] FIG. 7 shows the TGA curve for Compound I HCl salt Form
I.
[0021] FIG. 8 shows the DVS curve for Compound I HCl salt Form
I.
[0022] FIG. 9 shows the XRPD pattern for Compound I HCl salt Form
II.
[0023] FIG. 10 shows the DSC thermograph for Compound I HCl salt
Form II.
[0024] FIG. 11 shows the TGA curve for Compound I HCl salt Form
II.
[0025] FIG. 12 shows the DVS curve for Compound I HCl salt Form
II.
[0026] FIG. 13 shows the XRPD pattern for Compound I tartaric
acid.
[0027] FIG. 14 shows the DSC thermograph for Compound I tartaric
acid.
[0028] FIG. 15 shows the TGA curve for Compound I tartaric
acid.
[0029] FIG. 16 shows the DVS curve for Compound I tartaric
acid.
[0030] FIG. 17 shows the XRPD pattern for Compound I maleic
acid.
[0031] FIG. 18 shows the DSC thermograph for Compound I maleic
acid.
[0032] FIG. 19 shows the TGA curve for Compound I maleic acid.
[0033] FIG. 20 shows the DVS curve for Compound I maleic acid.
[0034] FIG. 21 shows the XRPD pattern for Compound I fumaric
acid.
[0035] FIG. 22 shows the DSC thermograph for Compound I fumaric
acid.
[0036] FIG. 23 shows the TGA curve for Compound I fumaric acid.
[0037] FIG. 24 shows the DVS curve for Compound I fumaric acid.
[0038] FIG. 25 shows the XRPD pattern for Compound I
methanesulfonic acid.
[0039] FIG. 26 shows the DSC thermograph for Compound I methane
sulfonic acid.
[0040] FIG. 27 shows the TGA curve for Compound I methanesulfonic
acid.
[0041] FIG. 28 shows the DVS curve for Compound I methanesulfonic
acid.
[0042] FIG. 29 shows the XRPD pattern for amorphous Compound I.
[0043] FIG. 30 shows the DSC curve for amorphous Compound I.
DETAILED DESCRIPTION OF THE DISCLOSURE
I. General
[0044] The present disclosure results from the surprising
discoveries of the solid forms of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (Compound I):
##STR00009##
and salts, solvates or co-crystals thereof. Compound I can adopt a
variety of crystalline forms, including, but not limited to,
crystalline Compound I Form I, crystalline Compound I HCl Form I,
crystalline Compound I HCl Form II, crystalline Compound I tartaric
acid, crystalline Compound I maleic acid, crystalline Compound I
fumaric acid, crystalline Compound I methanesulfonic acid, and
amorphous Compound I. Compound I can form a mixture of two or more
crystalline forms, or form a single crystalline form substantially
free of other crystalline forms.
[0045] The X-ray powder diffraction (XRPD) patterns provided herein
of the solid forms of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (Compound I) were collected using Cu K.alpha. radiation.
II. Definitions
[0046] As used in the present specification, the following words
and phrases are generally intended to have the meanings as set
forth below, except to the extent that the context in which they
are used indicates otherwise.
[0047] "Hydrate" refers to a complex formed by the combining of
Compound I and water. The term includes stoichiometric as well as
non-stoichiometric hydrates.
[0048] "Solvate" refers to a complex formed by the combining of
Compound I and a solvent.
[0049] "Desolvated" refers to a Compound I form that is a solvate
as described herein, and from which solvent molecules have been
partially or completely removed. Desolvation techniques to produce
desolvated forms include, without limitation, exposure of a
Compound I Form (solvate) to vacuum, subjecting the solvate to
elevated temperature, exposing the solvate to a stream of gas, such
as air or nitrogen, or any combination thereof. Thus, a desolvated
Compound I form can be anhydrous, i.e., completely without solvent
molecules, or partially solvated wherein solvent molecules are
present in stoichiometric or non-stoichiometric amounts.
[0050] "Alcohol" refers to a solvent having a hydroxy group.
Representative alcohols can have any suitable number of carbon
atoms, such as C.sub.1-C.sub.6, and any suitable number of hydroxy
groups, such as 1-3. Exemplary alcohols include, but are not
limited to, methanol, ethanol, n-propanol, i-propanol, etc.
[0051] "Therapeutically effective amount" refers to an amount that
is sufficient to effect treatment, as defined below, when
administered to a mammal in need of such treatment. The
therapeutically effective amount will vary depending upon the
subject being treated, the weight and age of the subject, the
severity of the disease condition, the manner of administration and
the like, which can readily be determined by one of ordinary skill
in the art.
[0052] "Substantially free of other crystalline forms of Compound
I" refers to a crystalline form of Compound I that contains less
than 10% of other crystalline forms of Compound I. For example,
substantially free can refer to a crystalline form of Compound I
that contains less than 9, 8, 7, 6, 5, 4, 3, 2, or 1% of other
crystalline forms of Compound I. Preferably, substantially free
refers to a crystalline form of Compound I that contains less than
5% of other crystalline forms of Compound I. Preferably,
substantially free refers to a crystalline form of Compound I that
contains less than 1% of other crystalline forms of Compound I.
III. Solid Forms of Compound I
[0053] The present disclosure provides solid forms of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (Compound I; see U.S. Pat. No. 9,670,205), including
crystalline and amorphous forms, as well as salts, solvate and
hydrate forms. In some embodiments, the present disclosure provides
a crystalline form of Compound I having the structure:
##STR00010##
and salts, solvates or hydrates thereof.
[0054] Compound I can adopt a variety of crystalline forms,
including, but not limited to, Form I, an HCl salt, an HCl salt
Form I, an HCl salt Form II, Compound I tartaric acid, Compound I
maleic acid, Compound I fumaric acid, and Compound I
methanesulfonic acid. Compound I can form a mixture of two or more
crystalline forms, or form a single crystalline form substantially
free of other crystalline forms. Compound 1 can also adopt a solid
amorphous form.
[0055] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol (Compound I):
##STR00011##
or a pharmaceutically acceptable salts or co-crystals thereof. The
crystalline forms of Compound I can be anhydrous, salts, solvates
or co-crystals. In some embodiments, the crystal form of Compound I
can be a salt or co-crystal. In some embodiments, the crystal form
of Compound I can be anhydrous or solvated. In some embodiments,
the crystal form of Compound I can be hydrated.
[0056] In some embodiments, the present disclosure provides a
compound selected from the group consisting of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol Form I;
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol HCl Salt Form I;
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol HCl Salt Form II;
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol tartaric acid;
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol maleic acid;
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol fumaric acid; and
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol methanesulfonic acid. In some embodiments, the present
disclosure provides amorphous
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol.
Form I
[0057] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is Form I. In some
embodiments, the present disclosure provides a crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol (Compound I):
##STR00012##
characterized by an X-ray powder diffraction (XRPD) pattern
comprising three or more peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Form I.
[0058] In some embodiments, Form I is characterized by an XRPD
pattern comprising four, five, six, seven, eight or nine peaks at
10.9.degree., 11.5.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, Form I is characterized by an XRPD pattern comprising
four or more peaks at 10.9.degree., 11.5.degree., 13.2.degree.,
14.7.degree., 15.5.degree., 21.4.degree., 21.9.degree.,
23.2.degree., or 24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, Form I is characterized by an XRPD pattern
comprising five or more peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, Form I is
characterized by an XRPD pattern comprising six or more peaks at
10.9.degree., 11.5.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree.2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, Form I is characterized by an XRPD pattern comprising
seven or more peaks at 10.9.degree., 11.5.degree., 13.2.degree.,
14.7.degree., 15.5.degree., 21.4.degree., 21.9.degree.,
23.2.degree., or 24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, Form I is characterized by an XRPD pattern
comprising eight or more peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0059] In some embodiments, Form I is characterized by an XRPD
pattern comprising peaks at 15.5.degree., 21.4.degree., and
21.9.degree. (.+-.0.2.degree. 2.theta.). In some embodiments, the
XRPD pattern further comprises one, two, three, four or more
additional peaks at 10.9.degree., 11.5.degree., 13.2.degree.,
14.7.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises one or more additional peaks at 10.9.degree.,
11.5.degree., 13.2.degree., 14.7.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises two or more
additional peaks at 10.9.degree., 11.5.degree., 13.2.degree.,
14.7.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises three or more additional peaks at 10.9.degree.,
11.5.degree., 13.2.degree., 14.7.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises four or more
additional peaks at 10.9.degree., 11.5.degree., 13.2.degree.,
14.7.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 23.2.degree., and 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0060] In some embodiments, Form I is characterized by an XRPD
pattern comprising peaks at 10.9.degree., 13.2.degree., and
14.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises one, two, three,
four or more additional peaks at 11.5.degree., 15.5.degree.,
21.4.degree., 21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises one or more additional peaks at 11.5.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises two or more
additional peaks at 11.5.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises three or more additional peaks at 11.5.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., or
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises four or more
additional peaks at 11.5.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., or 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 11.5.degree., 15.5.degree.,
21.4.degree., 21.9.degree., 23.2.degree., and 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0061] In some embodiments, Form I is characterized by an XRPD
pattern comprising three or more peaks at 10.9.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree., or
21.9.degree. (.+-.0.2.degree. 2.theta.). In some embodiments, Form
I is characterized by an XRPD pattern comprising four or more peaks
at 10.9.degree., 13.2.degree., 14.7.degree., 15.5.degree.,
21.4.degree., or 21.9.degree. (.+-.0.2.degree. 2.theta.). In some
embodiments, Form I is characterized by an XRPD pattern comprising
five or more peaks at 10.9.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., or 21.9.degree. (0.2.degree. 2.theta.).
In some embodiments, Form I is characterized by an XRPD pattern
comprising peaks at 10.9.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., and 21.9.degree. (.+-.0.2.degree.
2.theta.).
[0062] In some embodiments, Form I is characterized by an XRPD
pattern comprising peaks at 10.9.degree., 11.5.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., and 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, Form I is
characterized by a unit cell as determined by single crystal X-ray
crystallography of the following dimensions: a=8.0344 (2) .ANG.;
b=8.0344 (2) .ANG.; c=23.7871 (7) .ANG.; .alpha.=90.degree.;
.beta.=90.degree.; and .gamma.=90.degree.. In some embodiments,
Form I is characterized by an XRPD pattern substantially as shown
in FIG. 1.
[0063] In some embodiments, Form I is characterized by a
differential scanning calorimetry (DSC) thermogram having an
endotherm with an onset of about 164.degree. C. In some
embodiments, Form I is characterized by the DSC thermogram
substantially as shown in FIG. 2. In some embodiments, Form I is
characterized by a thermal gravimetric analysis (TGA) curve in FIG.
3. In some embodiments, Form I is characterized by a dynamic vapor
sorption (DVS) curve in FIG. 4.
[0064] In some embodiments, Form I is characterized by one or more
of the following: (a) an XRPD pattern comprising peaks at
10.9.degree., 11.5.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., and
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.); (b) a unit cell
as determined by single crystal X-ray crystallography of the
following dimensions: a=8.0344 (2) .ANG.; b=8.0344 (2) .ANG.;
c=23.7871 (7) X; .alpha.=90.degree.; .beta.=90.degree.; and
.gamma.=90.degree.; and (c) a differential scanning calorimetry
(DSC) thermogram having an endotherm with an onset of about
164.degree. C. In some embodiments, Form I is characterized by two
or more of the following: (a) an XRPD pattern comprising peaks at
10.9.degree., 11.5.degree., 13.2.degree., 14.7.degree.,
15.5.degree., 21.4.degree., 21.9.degree., 23.2.degree., and
24.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.); (b) a unit cell
as determined by single crystal X-ray crystallography of the
following dimensions: a=8.0344 (2) .ANG.; b=8.0344 (2) .ANG.;
c=23.7871 (7) X; .alpha.=90.degree.; .beta.=90.degree.; and
.gamma.=90.degree.; and (c) a differential scanning calorimetry
(DSC) thermogram having an endotherm with an onset of about
164.degree. C. In some embodiments, Form I is characterized by the
following: (a) an XRPD pattern comprising peaks at 10.9.degree.,
13.2.degree., 14.7.degree., 15.5.degree., 21.4.degree.,
21.9.degree., 23.2.degree., and 24.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.); (b) a unit cell as determined by single
crystal X-ray crystallography of the following dimensions: a=8.0344
(2) .ANG.; b=8.0344 (2) .ANG.; c=23.7871 (7); .alpha.=90.degree.;
.beta.=90.degree.; and .gamma.=90.degree.; and (c) a differential
scanning calorimetry (DSC) thermogram having an endotherm with an
onset of about 164.degree. C.
[0065] In some embodiments, Form I is characterized by one or more
of the following: (a) an XRPD pattern substantially as shown in
FIG. 1; (b) a unit cell as determined by single crystal X-ray
crystallography of the following dimensions: a=8.0344 (2) .ANG.;
b=8.0344 (2) .ANG.; c=23.7871 (7); .alpha.=90.degree.;
.beta.=90.degree.; and .gamma.=90.degree.; (c) a DSC thermogram
substantially as shown in FIG. 2; (d) a thermal gravimetric
analysis (TGA) curve substantially as shown in FIG. 3; and (e) a
dynamic vapor sorption (DVS) curve substantially as shown in FIG.
4. In some embodiments, Form I is characterized by two or more of
the following: (a) an XRPD pattern substantially as shown in FIG.
1; (b) a unit cell as determined by single crystal X-ray
crystallography of the following dimensions: a=8.0344 (2) .ANG.;
b=8.0344 (2) .ANG.; c=23.7871 (7) .ANG.; .alpha.=90.degree.;
.beta.=90.degree.; and .gamma.=90.degree.; (c) a DSC thermogram
substantially as shown substantially as shown in FIG. 2; (d) a
thermal gravimetric analysis (TGA) curve substantially as shown in
FIG. 3; and (e) a dynamic vapor sorption (DVS) curve substantially
as shown in FIG. 4. In some embodiments, Form I is characterized by
the following: (a) an XRPD pattern substantially as shown in FIG.
1; (b) a unit cell as determined by single crystal X-ray
crystallography of the following dimensions: a=8.0344 (2) .ANG.;
b=8.0344 (2) .ANG.; c=23.7871 (7); .alpha.=90.degree.;
.beta.=90.degree.; and .gamma.=90.degree.; (c) a DSC thermogram
substantially as shown in FIG. 2; (d) a thermal gravimetric
analysis (TGA) curve substantially as shown in FIG. 3; and (e) a
dynamic vapor sorption (DVS) curve substantially as shown in FIG.
4.
HCl Salt, Form I
[0066] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is HCl Salt Form I. In
some embodiments, the present disclosure provides a crystalline
form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol hydrochloride:
##STR00013##
characterized by an XRPD pattern comprising three or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I.
[0067] In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising four, five, six, seven,
eight or nine peaks at 6.1.degree., 12.2.degree., 15.0.degree.,
17.3.degree., 17.8.degree., 18.9.degree., 20.3.degree.,
23.2.degree., or 24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.),
hydrochloride salt Form I. In some embodiments, hydrochloride salt
Form I is characterized by an XRPD pattern comprising four or more
peaks at 6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I. In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising five or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (10.2.degree. 2.theta.), hydrochloride salt
Form I. In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising six or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I. In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising seven or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I. In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising eight or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.), hydrochloride
salt Form I.
[0068] In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising peaks at 6.1.degree.,
15.0.degree., and 17.8.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, hydrochloride salt Form I is the XRPD pattern
further comprises one or more additional peaks at 12.2.degree.,
17.3.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises two or more additional peaks at 12.2.degree.,
17.3.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises three or more additional peaks at 12.2.degree.,
17.3.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises four or more additional peaks at 12.2.degree.,
17.3.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises five or more additional peaks at 12.2.degree.,
17.3.degree., 18.9.degree., 20.3.degree., 23.2.degree., or
24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
[0069] In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising peaks at 12.2.degree.,
18.9.degree., and 24.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, hydrochloride salt Form I is the XRPD pattern
further comprises one or more additional peaks at 6.1.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 20.3.degree. or
23.2.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises two or more additional peaks at 6.1.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 20.3.degree. or
23.2.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises three or more additional peaks at 6.1.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 20.3.degree. or
23.2.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises four or more additional peaks at 6.1.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 20.3.degree. or
23.2.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form I is the XRPD pattern further
comprises five or more additional peaks at 6.1.degree.,
15.0.degree., 17.3.degree., 17.8.degree., 20.3.degree. or
23.2.degree. 2.theta. (0.2.degree. 2.theta.).
[0070] In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising three or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.8.degree.,
18.9.degree., or 24.1.degree. 2.theta. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising four or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.8.degree.,
18.9.degree., or 24.1.degree. 2.theta. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising five or more peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.8.degree.,
18.9.degree., or 24.1.degree. 2.theta. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising peaks at 6.1.degree.,
12.2.degree., 15.0.degree., 17.8.degree., 18.9.degree., and
24.1.degree. 2.theta. 2.theta. (.+-.0.2.degree. 2.theta.).
[0071] In some embodiments, hydrochloride salt Form I is
characterized by an XRPD pattern comprising peaks at 6.1.degree.,
12.2.degree., 15.0.degree., 17.3.degree., 17.8.degree.,
18.9.degree., 20.3.degree., 23.2.degree., and 24.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form I is characterized by an XRPD pattern substantially as shown
in FIG. 5.
[0072] In some embodiments, hydrochloride salt Form I is
characterized by a differential scanning calorimetry (DSC)
thermogram having an endotherm with an onset of about 135.degree.
C. In some embodiments, hydrochloride salt Form I is characterized
by a DSC thermogram substantially as shown in FIG. 6. In some
embodiments, hydrochloride salt Form I is characterized by a
thermal gravimetric analysis (TGA) curve substantially as shown in
FIG. 7. In some embodiments, hydrochloride salt Form I is
characterized by a dynamic vapor sorption (DVS) curve substantially
as shown in FIG. 8.
[0073] In some embodiments, hydrochloride salt Form I is
characterized by: (a) an XRPD pattern comprising peaks at
6.1.degree., 12.2.degree., 15.0.degree., 17.3.degree.,
17.8.degree., 18.9.degree., 20.3.degree., 23.2.degree., and
24.1.degree. 2.theta. (0.2.degree. 2.theta.); and (b) a
differential scanning calorimetry (DSC) thermogram having an
endotherm with an onset of about 135.degree. C. In some
embodiments, hydrochloride salt Form I is characterized by two or
more of the following: (a) an XRPD pattern substantially as shown
in FIG. 5; (b) a DSC thermogram substantially as shown in FIG. 6;
(c) a thermal gravimetric analysis (TGA) curve substantially as
shown in FIG. 7; and (d) a dynamic vapor sorption (DVS) curve
substantially as shown in FIG. 8.
HCl Salt, Form II
[0074] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is HCl Salt Form II. In
some embodiments, the present disclosure provides a crystalline
form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol hydrochloride:
##STR00014##
characterized by an XRPD pattern comprising three or more peaks at
7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), hydrochloride salt Form II.
[0075] In some embodiments, hydrochloride salt Form II is
characterized by four, five, six, seven, eight or nine peaks at
7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form II is characterized by an XRPD pattern comprising four or more
peaks at 7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree.,
16.1.degree., 19.1.degree., 22.5.degree., 24.0.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form II is characterized by an XRPD
pattern comprising five or more peaks at 7.1.degree., 9.7.degree.,
14.3.degree., 15.3.degree., 16.1.degree., 19.1.degree.,
22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form II is characterized by an XRPD pattern comprising six or more
peaks at 7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree.,
16.1.degree., 19.1.degree., 22.5.degree., 24.0.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form II is characterized by an XRPD
pattern comprising seven or more peaks at 7.1.degree., 9.7.degree.,
14.3.degree., 15.3.degree., 16.1.degree., 19.1.degree.,
22.5.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form II is characterized by an XRPD pattern comprising eight or
more peaks at 7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree.,
16.1.degree., 19.1.degree., 22.5.degree., 24.0.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
[0076] In some embodiments, hydrochloride salt Form II is
characterized by an XRPD pattern comprising peaks at 7.1.degree.,
15.3.degree., and 24.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 9.7.degree., 14.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 9.7.degree.,
14.3.degree., 16.1.degree., 19.1.degree., 22.5.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 9.7.degree., 14.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 9.7.degree.,
14.3.degree., 16.1.degree., 19.1.degree., 22.5.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 9.7.degree., 14.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0077] In some embodiments, hydrochloride salt Form II is
characterized by an XRPD pattern comprising peaks at 14.3.degree.,
16.1, and 26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises one or more
additional peaks at 7.1.degree., 9.7.degree., 15.3.degree.,
19.1.degree., 22.5.degree., or 24.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 7.1.degree.,
9.7.degree., 15.3.degree., 19.1.degree., 22.5.degree., or
24.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 7.1.degree., 9.7.degree., 15.3.degree.,
19.1.degree., 22.5.degree., or 24.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 7.1.degree.,
9.7.degree., 15.3.degree., 19.1.degree., 22.5.degree., or
24.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 7.1.degree., 9.7.degree., 15.3.degree.,
19.1.degree., 22.5.degree., or 24.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0078] In some embodiments, hydrochloride salt Form II is
characterized by an XRPD pattern comprising three or more peaks at
7.1.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
24.0.degree., or 26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, hydrochloride salt Form II is characterized by
an XRPD pattern comprising four or more peaks at 7.1.degree.,
14.3.degree., 15.3.degree., 16.1.degree., 24.0.degree., or
26.0.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, hydrochloride salt Form II is characterized by an XRPD
pattern comprising five or more peaks at 7.1.degree., 14.3.degree.,
15.3.degree., 16.1.degree., 24.0.degree., or 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form II is characterized by an XRPD pattern comprising peaks at
7.1.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
24.0.degree., and 26.0.degree. 2.theta. (.+-.0.2.degree.
2.theta.).
[0079] In some embodiments, hydrochloride salt Form II is
characterized by an XRPD pattern comprising peaks at 7.1.degree.,
9.7.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., 24.0.degree., and 26.0.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, hydrochloride salt
Form II is characterized by an XRPD pattern substantially as shown
in FIG. 9. In some embodiments, hydrochloride salt Form II is
characterized by a differential scanning calorimetry (DSC)
thermogram having an endotherm with an onset of about 58.degree. C.
In some embodiments, hydrochloride salt Form II is characterized by
a DSC thermogram substantially as shown in FIG. 10. In some
embodiments, hydrochloride salt Form II is characterized by a
thermal gravimetric analysis (TGA) curve substantially as shown in
FIG. 11. In some embodiments, hydrochloride salt Form II is
characterized by a dynamic vapor sorption (DVS) curve substantially
as shown in FIG. 12.
[0080] In some embodiments, hydrochloride salt Form II is
characterized by (a) an XRPD pattern comprising peaks at
7.1.degree., 9.7.degree., 14.3.degree., 15.3.degree., 16.1.degree.,
19.1.degree., 22.5.degree., 24.0.degree., and 26.0.degree. 2.theta.
(0.2.degree. 2.theta.); and (b) a differential scanning calorimetry
(DSC) thermogram having an endotherm with an onset of about
58.degree. C. In some embodiments, hydrochloride salt Form II is
characterized by two or more of the following (a) an XRPD pattern
substantially as shown in FIG. 9; (b) a DSC thermogram
substantially as shown in FIG. 10; (c) a thermal gravimetric
analysis (TGA) curve substantially as shown in FIG. 11; and (d) a
dynamic vapor sorption (DVS) curve substantially as shown in FIG.
12.
Tartaric Acid
[0081] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol tartrate, wherein the crystalline form is the Tartrate
Salt. In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
an-1-ol, wherein the crystalline form is the Compound I Tartaric
Acid co-crystal. In some embodiments, the present disclosure
provides a crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol tartaric acid:
##STR00015##
characterized by an XRPD pattern comprising three or more peaks at
6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I tartaric acid.
[0082] In some embodiments, the Compound I tartaric acid is
characterized by an XRPD pattern comprising four or more peaks at
6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
tartaric acid is characterized by an XRPD pattern comprising five
or more peaks at 6.3.degree., 9.9.degree., 12.5.degree.,
17.7.degree., 18.3.degree., 19.2.degree., 23.4.degree.,
25.7.degree., or 28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the Compound I tartaric acid is characterized
by an XRPD pattern comprising six or more peaks at 6.3.degree.,
9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
tartaric acid is characterized by an XRPD pattern comprising seven
or more peaks at 6.3.degree., 9.9.degree., 12.5.degree.,
17.7.degree., 18.3.degree., 19.2.degree., 23.4.degree.,
25.7.degree., or 28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the Compound I tartaric acid is characterized
by an XRPD pattern comprising eight or more peaks at 6.3.degree.,
9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0083] In some embodiments, the Compound I tartaric acid is
characterized by an XRPD pattern comprising peaks at 6.3.degree.,
18.3.degree., and 23.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 9.9.degree., 12.5.degree., 17.7.degree.,
19.2.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 9.9.degree.,
12.5.degree., 17.7.degree., 19.2.degree., 25.7.degree., or
28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 9.9.degree., 12.5.degree., 17.7.degree.,
19.2.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 9.9.degree.,
12.5.degree., 17.7.degree., 19.2.degree., 25.7.degree., or
28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 9.9.degree., 12.5.degree., 17.7.degree.,
19.2.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 9.9.degree., 12.5.degree.,
17.7.degree., 19.2.degree., 25.7.degree., and 28.1.degree. 2.theta.
(0.2.degree. 2.theta.).
[0084] In some embodiments, the Compound I tartaric acid is
characterized by an XRPD pattern comprising peaks at 9.9.degree.,
12.5.degree., and 17.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 6.3.degree., 18.3.degree., 19.2.degree.,
23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 6.3.degree.,
18.3.degree., 19.2.degree., 23.4.degree., 25.7.degree., or
28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 6.3.degree., 18.3.degree., 19.2.degree.,
23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 6.3.degree.,
18.3.degree., 19.2.degree., 23.4.degree., 25.7.degree., or
28.1.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 6.3.degree., 18.3.degree., 19.2.degree.,
23.4.degree., 25.7.degree., or 28.1.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 6.3.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., and 28.1.degree. 2.theta.
(0.2.degree. 2.theta.).
[0085] In some embodiments, the Compound I tartaric acid is
characterized by three or more XRPD peaks at 6.3.degree.,
9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree., or
23.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I tartaric acid is characterized by four
or more XRPD peaks at 6.3.degree., 9.9.degree., 12.5.degree.,
17.7.degree., 18.3.degree., or 23.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
tartaric acid is characterized by five or more XRPD peaks at
6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
or 23.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I tartaric acid is characterized by XRPD
peaks at 6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree.,
18.3.degree., and 23.4.degree. 2.theta. (.+-.0.2.degree.
2.theta.).
[0086] In some embodiments, the Compound I tartaric acid is
characterized by an XRPD pattern comprising peaks at 6.3.degree.,
9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., and 28.1.degree. 2.theta.
(0.2.degree. 2.theta.). In some embodiments, the Compound I
tartaric acid is characterized by an XRPD pattern substantially as
shown in FIG. 13. In some embodiments, the Compound I tartaric acid
is characterized by a differential scanning calorimetry (DSC)
thermogram having an endotherm with an onset of about 157.degree.
C. In some embodiments, the Compound I tartaric acid is
characterized by a DSC thermogram substantially as shown in FIG.
14. In some embodiments, the Compound I tartaric acid is
characterized by a DSC thermogram substantially as shown in FIG.
15. In some embodiments, the Compound I tartaric acid is
characterized by a dynamic vapor sorption (DVS) curve substantially
as shown in FIG. 16.
[0087] In some embodiments, the Compound I tartaric acid is
characterized by: (a) an XRPD pattern comprising peaks at
6.3.degree., 9.9.degree., 12.5.degree., 17.7.degree., 18.3.degree.,
19.2.degree., 23.4.degree., 25.7.degree., and 28.1.degree. 2.theta.
(0.2.degree. 2.theta.); and (b) a differential scanning calorimetry
(DSC) thermogram having an endotherm with an onset of about
157.degree. C. In some embodiments, the Compound I tartaric acid is
characterized by two or more of: (a) an XRPD pattern substantially
as shown in FIG. 13; (b) a DSC thermogram substantially as shown in
FIG. 14; (c) a DSC thermogram substantially as shown in FIG. 15; or
(d) a dynamic vapor sorption (DVS) curve substantially as shown in
FIG. 16.
Maleic Acid
[0088] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is the Maleate Salt. In
some embodiments, the present disclosure provides a crystalline
form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol, wherein the crystalline form is Compound I maleic acid
co-crystal. In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
an-1-ol maleic acid:
##STR00016##
characterized by an XRPD pattern comprising three or more peaks at
7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree., 15.6.degree.,
17.7.degree., 20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I maleic acid.
[0089] In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern comprising four or more peaks at
7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree., 15.6.degree.,
17.7.degree., 20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
maleic acid is characterized by an XRPD pattern comprising five or
more peaks at 7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree.,
15.6.degree., 17.7.degree., 20.7.degree., 24.7.degree., or
27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I maleic acid is characterized by an XRPD
pattern comprising six or more peaks at 7.3.degree., 8.4.degree.,
8.8.degree., 13.9.degree., 15.6.degree., 17.7.degree.,
20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
maleic acid is characterized by an XRPD pattern comprising seven or
more peaks at 7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree.,
15.6.degree., 17.7.degree., 20.7.degree., 24.7.degree., or
27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I maleic acid is characterized by an XRPD
pattern comprising eight or more peaks at 7.3.degree., 8.4.degree.,
8.8.degree., 13.9.degree., 15.6.degree., 17.7.degree.,
20.7.degree., 24.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0090] In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern comprising peaks at 7.3.degree.,
17.7.degree., and 24.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 8.4.degree., 8.8.degree., 13.9.degree.,
15.6.degree., 20.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 8.4.degree.,
8.8.degree., 13.9.degree., 15.6.degree., 20.7.degree., or
27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 8.4.degree., 8.8.degree., 13.9.degree.,
15.6.degree., 20.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 8.4.degree.,
8.8.degree., 13.9.degree., 15.6.degree., 20.7.degree., or
27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 8.4.degree., 8.8.degree., 13.9.degree.,
15.6.degree., 20.7.degree., or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 8.4.degree., 8.8.degree.,
13.9.degree., 15.6.degree., 20.7.degree., and 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0091] In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern comprising peaks at 13.9.degree.,
15.6.degree., and 27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks 7.3.degree., 8.4.degree., 8.8.degree.,
17.7.degree., 20.7.degree., or 24.7.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 7.3.degree.,
8.4.degree., 8.8.degree., 17.7.degree., 20.7.degree., or
24.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 7.3.degree. 8.4.degree., 8.8.degree.,
17.7.degree., 20.7.degree., or 24.7.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 7.3.degree.,
8.4.degree., 8.8.degree., 17.7.degree., 20.7.degree., or
24.7.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 7.3.degree., 8.4.degree., 8.8.degree.,
17.7.degree., 20.7.degree., or 24.7.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 7.3.degree., 8.4.degree.,
8.8.degree., 17.7.degree., 20.7.degree., and 24.7.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0092] In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern comprising three or more peaks at
7.3.degree., 13.9.degree., 15.6.degree., 17.7.degree., 24.7.degree.
or 27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I maleic acid is characterized by an XRPD
pattern comprising four or more peaks at 7.3.degree., 13.9.degree.,
15.6.degree., 17.7.degree., 24.7.degree. or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
maleic acid is characterized by an XRPD pattern comprising five or
more peaks at 7.3.degree., 13.9.degree., 15.6.degree.,
17.7.degree., 24.7.degree. or 27.4.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
maleic acid is characterized by an XRPD pattern comprising peaks at
7.3.degree., 13.9.degree., 15.6.degree., 17.7.degree., 24.7.degree.
and 27.4.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
[0093] In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern comprising peaks at 7.3.degree.,
8.4.degree., 8.8.degree., 13.9.degree., 15.6.degree., 17.7.degree.,
20.7.degree., 24.7.degree., and 27.4.degree. 2.theta. (0.2.degree.
2.theta.). In some embodiments, the Compound I maleic acid is
characterized by an XRPD pattern substantially as shown in FIG. 17.
In some embodiments, the Compound I maleic acid is characterized by
a differential scanning calorimetry (DSC) thermogram having an
endotherm with an onset of about 143.degree. C. In some
embodiments, the Compound I maleic acid is characterized by a DSC
thermogram substantially as shown in FIG. 18. In some embodiments,
the Compound I maleic acid is characterized by a thermal
gravimetric analysis (TGA) curve substantially as shown in FIG. 19.
In some embodiments, the Compound I maleic acid is characterized by
a dynamic vapor sorption (DVS) curve substantially as shown in FIG.
20.
[0094] In some embodiments, the Compound I maleic acid is
characterized by: (a) an XRPD pattern comprising peaks at
7.3.degree., 8.4.degree., 8.8.degree., 13.9.degree., 15.6.degree.,
17.7.degree., 20.7.degree., 24.7.degree., and 27.4.degree. 2.theta.
(0.2.degree. 2.theta.); and (b) a differential scanning calorimetry
(DSC) thermogram having an endotherm with an onset of about
143.degree. C. In some embodiments, the Compound I maleic acid is
characterized by two or more of: (a) an XRPD pattern substantially
as shown in FIG. 17; (b) a DSC thermogram substantially as shown in
FIG. 18; (c) a thermal gravimetric analysis (TGA) curve
substantially as shown in FIG. 19; or (d) a dynamic vapor sorption
(DVS) curve substantially as shown in FIG. 20.
Fumaric Acid
[0095] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is the Fumarate Salt. In
some embodiments, the present disclosure provides a crystalline
form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol, wherein the crystalline form is Compound I fumaric acid
co-crystal. In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhex-
an-1-ol fumaric acid:
##STR00017##
characterized by an XRPD pattern comprising three or more peaks at
6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.), Compound I fumaric acid.
[0096] In some embodiments, the Compound I fumaric acid is
characterized by an XRPD pattern comprising four or more peaks at
6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
fumaric acid is characterized by an XRPD pattern comprising five or
more peaks at 6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree.,
16.1.degree., 18.5.degree., 20.6.degree., 25.2.degree. or
27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I fumaric acid is characterized by an
XRPD pattern comprising six or more peaks at 6.7.degree.,
8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
fumaric acid is characterized by an XRPD pattern comprising seven
or more peaks at 6.7.degree., 8.3.degree., 10.1.degree.,
12.6.degree., 16.1.degree., 18.5.degree., 20.6.degree.,
25.2.degree. or 27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the Compound I fumaric acid is characterized
by an XRPD pattern comprising eight or more peaks at 6.7.degree.,
8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.20 or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0097] In some embodiments, the Compound I fumaric acid is
characterized by an XRPD pattern comprising peaks at 6.7.degree.,
8.3.degree., and 25.2.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 10.1.degree.,
12.6.degree., 16.1.degree., 18.5.degree., 20.6.degree., or
27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 10.1.degree.,
12.6.degree., 16.1.degree., 18.5.degree., 20.6.degree., or
27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises five or more
additional peaks at 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., or 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 10.1.degree., 12.6.degree.,
16.1.degree., 18.5.degree., 20.6.degree., and 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0098] In some embodiments, the Compound I fumaric acid is
characterized by an XRPD pattern comprising peaks at 18.5.degree.,
20.6.degree., and 27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks 6.7.degree., 8.3.degree., 10.1.degree.,
12.6.degree., 16.1, or 25.2.degree. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, the XRPD pattern further comprises
two or more additional peaks at 6.7.degree., 8.3.degree.,
10.1.degree., 12.6.degree., 16.1, or 25.2.degree. 2.theta. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises three or more additional peaks at 6.7.degree.,
8.3.degree., 10.1.degree., 12.6.degree., 16.1, or 25.2.degree.
2.theta. 2.theta. (.+-.0.2.degree. 2.theta.). In some embodiments,
the XRPD pattern further comprises four or more additional peaks at
6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
or 25.2.degree. 2.theta. 2.theta. (.+-.0.2.degree. 2.theta.). In
some embodiments, the XRPD pattern further comprises five or more
additional peaks at 6.7.degree., 8.3.degree., 10.1.degree.,
12.6.degree., 16.1, or 25.2.degree. 2.theta. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises additional peaks at 6.7.degree., 8.3.degree.,
10.1.degree., 12.6.degree., 16.1, or 25.2.degree. 2.theta. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0099] In some embodiments, the Compound I fumaric acid is
characterized by an XRPD pattern comprising three or more peaks at
6.7.degree., 8.3.degree., 18.5.degree., 20.6.degree., 25.2.degree.,
or 27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I fumaric acid is characterized by an
XRPD pattern comprising four or more peaks at 6.7.degree.,
8.3.degree., 18.5.degree., 20.6.degree., 25.2.degree., or
27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I fumaric acid is characterized by an
XRPD pattern comprising five or more peaks at 6.7.degree.,
8.3.degree., 18.5.degree., 20.6.degree., 25.2.degree., or
27.6.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I fumaric acid is characterized by an
XRPD pattern comprising peaks at 6.7.degree., 8.3.degree.,
18.5.degree., 20.6.degree., 25.2.degree., and 27.6.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0100] In some embodiments, the Compound I fumaric acid is
characterized by an XRPD pattern comprising peaks at 6.7.degree.,
8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. and 27.6.degree. 2.theta.
(0.2.degree. 2.theta.). In some embodiments, the Compound I fumaric
acid is characterized by an XRPD pattern substantially as shown in
FIG. 21. In some embodiments, the Compound I fumaric acid is
characterized by a differential scanning calorimetry (DSC)
thermogram having an endotherm with an onset of about 70.degree. C.
In some embodiments, the DSC thermogram has a second endotherm with
an onset of about 167.degree. C. In some embodiments, the Compound
I fumaric acid is characterized by a DSC thermogram substantially
as shown in FIG. 22. In some embodiments, the Compound I fumaric
acid is characterized by a thermal gravimetric analysis (TGA) curve
substantially as shown in FIG. 23. In some embodiments, the
Compound I fumaric acid is characterized by a dynamic vapor
sorption (DVS) curve substantially as shown in FIG. 24.
[0101] In some embodiments, the Compound I fumaric acid is
characterized by: (a) an XRPD pattern comprising peaks at
6.7.degree., 8.3.degree., 10.1.degree., 12.6.degree., 16.1.degree.,
18.5.degree., 20.6.degree., 25.2.degree. and 27.6.degree. 2.theta.
(0.2.degree. 2.theta.); and (b) a differential scanning calorimetry
(DSC) thermogram having an endotherm with a first onset of about
70.degree. C., and a second onset of about 167.degree. C. In some
embodiments, the Compound I fumaric acid is characterized by two or
more of: (a) an XRPD pattern substantially as shown in FIG. 21; (b)
a DSC thermogram substantially as shown in FIG. 22; (c) a thermal
gravimetric analysis (TGA) curve substantially as shown in FIG. 23;
or (d) a dynamic vapor sorption (DVS) curve substantially as shown
in FIG. 24.
Methanesulfonic Acid
[0102] In some embodiments, the present disclosure provides a
crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-meth-
ylhexan-1-ol, wherein the crystalline form is the Mesylate Salt. In
some embodiments, the present disclosure provides a crystalline
form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol, wherein the crystalline form is Compound I methanesulfonic
acid co-crystal. In some embodiments, the present disclosure
provides a crystalline form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol methanesulfonic acid:
##STR00018##
characterized by an XRPD pattern comprising three or more peaks at
5.4.degree., 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 18.1.degree., 20.5.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.), Compound I
methanesulfonic acid.
[0103] In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising four or more peaks at
5.4.degree., 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 18.1.degree., 20.5.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I methanesulfonic acid is characterized
by an XRPD pattern comprising five or more peaks at 5.4.degree.,
10.4.degree., 10.8.degree., 15.8.degree., 17.3.degree.,
18.1.degree., 20.5.degree., 20.8.degree., or 23.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
methanesulfonic acid is characterized by an XRPD pattern comprising
six or more peaks at 5.4.degree., 10.4.degree., 10.8.degree.,
15.8.degree., 17.3.degree., 18.1.degree., 20.5.degree.,
20.8.degree., or 23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising seven or more peaks at
5.4.degree., 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 18.1.degree., 20.5.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the Compound I methanesulfonic acid is characterized
by an XRPD pattern comprising eight or more peaks at 5.4.degree.,
10.4.degree., 10.8.degree., 15.8.degree., 17.3.degree.,
18.1.degree., 20.5.degree., 20.8.degree., or 23.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.).
[0104] In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising peaks at 5.4.degree.,
18.1, and 20.5.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises one or more
additional peaks at 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 20.8.degree., or 23.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises two or more additional peaks at 10.4.degree.,
10.8.degree., 15.8.degree., 17.3.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises three or more
additional peaks at 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 20.8.degree., or 23.9.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises four or more additional peaks at 10.4.degree.,
10.8.degree., 15.8.degree., 17.3.degree., 20.8.degree., or
23.9.degree. 20 (.+-.0.2020). In some embodiments, the XRPD pattern
further comprises five or more additional peaks at 10.4.degree.,
10.8.degree., 15.8.degree., 17.3.degree., 20.8.degree., or
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.). In some
embodiments, the XRPD pattern further comprises additional peaks at
10.4.degree., 10.8.degree., 15.8.degree., 17.3.degree.,
20.8.degree., and 23.9.degree. 2.theta. (.+-.0.2.degree.
2.theta.).
[0105] In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising peaks at 15.8.degree.,
20.8.degree., and 23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises one or more
additional peaks at 5.4.degree., 10.4.degree., 10.8.degree.,
17.3.degree., 18.1, or 20.5.degree. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, the XRPD pattern further comprises
two or more additional peaks at 5.4.degree., 10.4.degree.,
10.8.degree., 17.3.degree., 18.1, or 20.5.degree. 2.theta.
(.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD pattern
further comprises three or more additional peaks at 5.4.degree.,
10.4.degree., 10.8.degree., 17.3.degree., 18.1, or 20.5.degree.
2.theta. (.+-.0.2.degree. 2.theta.). In some embodiments, the XRPD
pattern further comprises four or more additional peaks at
5.4.degree., 10.4.degree., 10.8.degree., 17.3.degree.,
18.1.degree., or 20.5.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
In some embodiments, the XRPD pattern further comprises five or
more additional peaks at 5.4.degree., 10.4.degree., 10.8.degree.,
17.3.degree., 18.1, or 20.5.degree. 2.theta. (.+-.0.2.degree.
2.theta.). In some embodiments, the XRPD pattern further comprises
additional peaks at 5.4.degree., 10.4.degree., 10.8.degree.,
17.3.degree., 18.1, and 20.5.degree. 2.theta. (.+-.0.2.degree.
2.theta.).
[0106] In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising three or more peaks at
5.4.degree., 18.1.degree., 15.8.degree., 20.5.degree.,
20.8.degree., or 23.9.degree. 2.theta. (0.2.degree. 2.theta.). In
some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising four or more peaks at
5.4.degree., 18.1.degree., 15.8.degree., 20.5.degree.,
20.8.degree., or 23.9.degree. 2.theta. (0.2.degree. 2.theta.). In
some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising five or more peaks at
5.4.degree., 18.1.degree., 15.8.degree., 20.5.degree.,
20.8.degree., or 23.9.degree. 2.theta. (0.2.degree. 2.theta.). In
some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising peaks at 5.4.degree.,
18.1.degree., 15.8.degree., 20.5.degree., 20.8.degree., and
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.).
[0107] In some embodiments, the Compound I methanesulfonic acid is
characterized by an XRPD pattern comprising peaks at 5.4.degree.,
10.4.degree., 10.8.degree., 15.8.degree., 17.3.degree.,
18.1.degree., 20.5.degree., 20.8.degree., and 23.9.degree. 26
(.+-.0.2.degree. 2.theta.). In some embodiments, the Compound I
methanesulfonic acid is characterized by an XRPD pattern
substantially as shown in FIG. 25. In some embodiments, the
Compound I methanesulfonic acid is characterized by a differential
scanning calorimetry (DSC) thermogram having an endotherm with an
onset of about 30.degree. C. In some embodiments, the DSC
thermogram has a second endotherm with an onset of about
147.degree. C. In some embodiments, the Compound I methanesulfonic
acid is characterized by a DSC thermogram substantially as shown in
FIG. 26. In some embodiments, the Compound I methanesulfonic acid
is characterized by a thermal gravimetric analysis (TGA) curve
substantially as shown FIG. 27. In some embodiments, the Compound I
methanesulfonic acid is characterized by a dynamic vapor sorption
(DVS) curve substantially as shown in FIG. 28.
[0108] In some embodiments, the Compound I methanesulfonic acid is
characterized by: (a) an XRPD pattern comprising peaks at
5.4.degree., 10.4.degree., 10.8.degree., 15.8.degree.,
17.3.degree., 18.1.degree., 20.5.degree., 20.8.degree., and
23.9.degree. 2.theta. (.+-.0.2.degree. 2.theta.); and (b) a
differential scanning calorimetry (DSC) thermogram having a first
endotherm with an onset of about 30.degree. C. a second endotherm
with an onset of about 147.degree. C. In some embodiments, the
Compound I methanesulfonic acid is characterized by two or more of:
(a) an XRPD pattern substantially as shown in FIG. 25; (b) a DSC
thermogram substantially as shown in FIG. 26; (c) a thermal
gravimetric analysis (TGA) curve substantially as shown FIG. 27; or
(d) a dynamic vapor sorption (DVS) curve substantially as shown in
FIG. 28.
Amorphous Compound I
[0109] In some embodiments, the present disclosure provides an
amorphous solid form of
(R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan--
1-ol:
##STR00019##
[0110] In some embodiments, the amorphous Compound I is
characterized by an XRPD pattern substantially as shown in FIG. 29.
In some embodiments, the amorphous Compound I is characterized by a
DSC thermogram substantially as shown in FIG. 30. In some
embodiments, the amorphous Compound I is characterized by one or
more of: (a) an XRPD pattern substantially as shown in FIG. 29; or
(b) a DSC thermogram substantially as shown in FIG. 30.
IV. Methods of Preparing Solid Forms of Compound I
[0111] The solid forms of Compound I can be prepared by a variety
of methods. For example, Compound I can be dissolved in a single
solvent system and allowed to crystallize. Alternatively, Compound
I can be crystallized from a two-solvent system by dissolving
Compound I in a solvent (a good solvent), and then adding an
anti-solvent (a bad solvent) to the mixture causing Compound I to
crystallize.
[0112] The solvent can be any solvent suitable to form a solution.
Typically the solvent can be a polar solvent, which in some
embodiments is a protic solvent. Other suitable solvents include
non-polar solvents. Suitable solvents include, but are not limited
to, water, alkanes such as heptanes, hexanes, and cyclohexane,
petroleum ether, C.sub.1-C.sub.3 alcohols (methanol, ethanol,
propanol, isopropanol), ethylene glycol and polyethylene glycol
such as PEG400, alkanoates such as ethyl acetate, propyl acetate,
isopropyl acetate, and butyl acetate, acetonitrile, alkanones such
as acetone, butanone, methyl ethyl ketone (MEK), methyl propyl
ketone (MPK) and methyl iso-butyl ketone (MIBK), ethers such as
diethyl ether, methyl-t-butyl ether, tetrahydrofuran,
methyl-tetrahydrofuran, 1,2-dimethoxy ethane and 1,4-dioxane,
aromatics such as benzene and toluene, halogenated solvents such as
methylene chloride, chloroform and carbon tetrachloride,
dimethylsulfoxide (DMSO), and dimethylformamide (DMF). Suitable
solvents also include, but are not limited to halogenated
C.sub.1-C.sub.3 alcohols (trifluoromethanol, trifluoroethanol
(TFE), hexafluoroisopropanol (HFIPA)). For example, the solvent can
be a polar aprotic solvent such as dichloromethane,
N-methylpyrrolidone, tetrahydrofuran, ethyl acetate, acetone,
methyl ethyl ketone, dimethylformamide (DMF), acetonitrile (AcCN),
dimethyl sulfoxide (DMSO), among others. The solvent can also be a
polar protic solvent such as t-butanol, n-propanol, isopropanol,
ethanol, methanol, acetic acid, water, among others. The solvent
can also be a non-polar solvent, such as hexane, pentanes,
petroleum ether, benzene, toluene, diethyl ether, methyl-t-butyl
ether, tetrahydrofuran, methyl-tetrahydrofuran, 1,2-dimethoxy
ethane and 1,4-dioxane, chloroform, and carbon tetrachloride.
[0113] Two or more solvents can be used in a solvent mixture in any
suitable ratio. For example, the ratio of a first solvent and a
second solvent can be from 10:1 to about 1:10 (volume/volume or
weight/weight), or about 10:1 to 1:5, or 10:1 to 1:1, or 10:1 to
5:1, or 5:1 to 1:5, or 5:1 to 1:1, or 4:1 to 1:1, or 3:1 to 1:1, or
2:1 to 1:1. Other solvent ratios include about 10:1, 9:1, 8:1, 7:1,
6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8,
1:9 or about 1:10 (volume/volume or weight/weight).
[0114] The methods of preparing solid forms of Compound I can be
performed under any suitable reaction conditions. For example, the
methods of preparing the crystalline forms of Compound I can be
performed at any suitable temperature, such as, but not limited to,
below room temperature, at room temperature, or above room
temperature. In some embodiments, the temperature can be from about
-78.degree. C. to about 100.degree. C., or from about 0.degree. C.
to about 50.degree. C., or from about 10.degree. C. to about
30.degree. C. For example, the reaction mixture be at a temperature
of about 20.degree. C., or 25, 30, 35, 40, 45, 50, 55, 60, 65, 70,
75, 80, 85, 90, 95 or about 100.degree. C. The reaction mixture can
also be at a temperature of about 20.degree. C., 15, 10, 5, 0, -5,
-10, -20, -30, -40, -50, -60, -70 or about -78.degree. C. In some
embodiments, the temperature can be the reflux temperature of the
particular solvent used in the method. In other embodiments,
crystalline forms of Compound I can be heated above about
100.degree. C. such that one crystalline form of Compound I forms a
second crystalline form of Compound I.
[0115] The methods of preparing solid forms of Compound I can
include a variety of other steps. For example, the solvent can be
evaporated, a seed crystal can be added to the mixture, the mixture
can be heated and cooled a single time or repeatedly, etc. For
example, the methods can include heating the reaction mixture to a
temperature of about 20.degree. C., or 25, 30, 35, 40, 45, 50, 55,
60, 65, 70, 75, 80, 85, 90, 95 or about 100.degree. C. The methods
can also include cooling the reaction mixture to a temperature of
about 20.degree. C., 15, 10, 5, 0, -5, -10, -20, -30, -40, -50,
-60, -70 or about -78.degree. C. The temperature of the reaction
mixture can be changed at any suitable rate. For example, the rate
of temperature change can be from about 0.1.degree. C./min to about
10.degree. C./min.
[0116] The methods of preparing crystalline forms of Compound I can
be performed for any suitable time. For example, the time can be
for minutes, hours or days. In some embodiments, the time can be
several hours, such as overnight. The methods of preparing
crystalline forms of Compound I can be also be performed at any
suitable pressure. For example, the pressure can be below
atmospheric pressure, at about atmospheric pressure, or above
atmospheric pressure.
[0117] Crystallization can be induced by methods known in the art,
for example by mechanical means such as scratching or rubbing the
contact surface of the reaction vessel with e.g. a glass rod.
Optionally the saturated or supersaturated solution may be
inoculated with seed crystals. The method preparing solid forms of
Compound I can also include a seed crystal of crystalline Compound
I.
[0118] Isolation of the desired crystalline form can be
accomplished by removing the solvent and precipitating solvent from
the crystals. Generally this is carried out by known methods, such
as, filtration, suction filtration, decantation or centrifugation.
Further isolation can be achieved by removing any excess of the
solvent(s) from the crystalline form by methods known to the one
skilled in the art as for example application of a vacuum, and/or
by heating.
Form I
[0119] Crystalline Compound I Form I can be prepared by a variety
of methods using a variety of solvents and solvent combinations.
For example, Compound I Form I can be prepared using hexane,
n-heptane, methanol, ethanol, n-propanol, isopropanol, water,
tetrahydrofuran, 2-methyl-tetrahydrofuran, tert-butyl methyl ether,
ethyl acetate, methyl isobutyl ketone, acetonitrile, toluene, and
combinations thereof. In some embodiments, Compound I Form I can be
prepared using n-heptane, methanol, ethanol, isopropanol, water,
tetrahydrofuran, 2-methyl-tetrahydrofuran, tert-butyl methyl ether,
ethyl acetate, methyl isobutyl ketone, acetonitrile, toluene, and
combinations thereof. Solvent combinations useful in the methods of
preparing Compound I Form I include, but are not limited to,
isopropanol and water, ethanol and n-heptane, tetrahydrofuran and
n-heptane, acetone and water, methanol and water, ethanol and
water, 2-methyl tetrahydrofuran and n-heptane, and others. In some
embodiments, the solvent combination can include ethanol and water,
and 2-methyl tetrahydrofuran and n-heptane. When two or more
solvents are used in combination, they can be present in any
suitable ratio, as described above. In some embodiments, the
solvent can be isopropanol:water (9:1), ethanol:n-heptane (1:2),
tetrahydrofuran:n-heptane, acetone:water (9:1), methanol:water
(9:1), ethanol:water (2:1), ethanol:water (1:1), ethanol water
(1:2), ethanol:water (1:3), 2-methyl tetrahydrofuran:n-heptane
(2:1), 2-methyl tetrahydrofuran:n-heptane (1:1), 2-methyl
tetrahydrofuran:n-heptane (1:2), or 2-methyl
tetrahydrofuran:n-heptane (1:3). In some embodiments, the solvent
can be ethanol:water (2:1), ethanol:water (1:1), ethanol water
(1:2), ethanol:water (1:3), 2-methyl tetrahydrofuran:n-heptane
(2:1), 2-methyl tetrahydrofuran:n-heptane (1:1), 2-methyl
tetrahydrofuran:n-heptane (1:2), or 2-methyl
tetrahydrofuran:n-heptane (1:3).
[0120] In some embodiments, the present disclosure provides a
method of preparing a crystalline Compound I Form I of the present
disclosure, including forming a mixture of Compound I of the
present disclosure, and a solvent, under conditions suitable to
prepare Form I. In some embodiments, Compound I is dissolved in the
solvent. In some embodiments, the solvent can be a polar aprotic
solvent. In some embodiments, the solvent can be ethyl acetate.
[0121] The method of preparing Compound I Form I can include a
variety of other steps. In some embodiments, the reaction mixture
can be heated to a temperature of about 85.degree. C. In some
embodiments, the method includes cooling the reaction mixture to a
temperature of about 20.degree. C. In some embodiments, the method
of preparing Compound I Form I also includes heating the mixture to
dissolve Compound I, and cooling the mixture. In some embodiments,
the method of preparing Compound I Form I includes forming a
mixture of Compound I and ethyl acetate, heating the mixture to
dissolve Compound I, and cooling the mixture, thus forming Compound
I Form I.
[0122] In some embodiments, the present disclosure provides a
method of preparing a crystalline Compound I Form I of the present
disclosure, including forming a mixture of Compound I of the
present disclosure, and a solvent, under conditions suitable to
prepare Form I. In some embodiments, Compound I is dissolved in the
solvent. In some embodiments, the solvent can be a polar protic
solvent. In some embodiments, the solvent can be ethanol.
[0123] The method of preparing Compound I Form I can include a
variety of other steps. In some embodiments, the reaction mixture
can be heated to a temperature of about 75.degree. C. In some
embodiments, the method also includes cooling the reaction mixture
to a temperature of about 0.degree. C. In some embodiments, the
method of preparing Compound I Form I also includes heating the
mixture to dissolve Compound I, and cooling the mixture. In some
embodiments, the method of preparing Compound I Form I includes
forming a mixture of Compound I and ethanol, heating the mixture to
dissolve Compound I, and cooling the mixture to a temperature of
about 0.degree. C., thus forming Compound I Form I.
[0124] In some embodiments, the present disclosure provides a
method of preparing a crystalline Compound I Form I of the present
disclosure, including forming a mixture of Compound I of the
present disclosure and a first solvent, and adding a second solvent
to the mixture, under conditions suitable to prepare Form I. In
some embodiments, Compound I is dissolved in the first solvent, a
good solvent. In some embodiments, the first solvent can be a polar
protic solvent. In some embodiments, the first solvent can be
ethanol. In some embodiments, the second solvent is an
anti-solvent. In some embodiments, the second solvent can be
water.
[0125] The mixture can include any suitable ratio of the first
solvent and the second solvent. For example, the ratio of the first
solvent and the second solvent can be from 10:1 to about 1:10
(volume/volume or weight/weight), or about 10:1 to 1:5, or 10:1 to
1:1, or 10:1 to 5:1, or 5:1 to 1:5, or 5:1 to 1:1, or 4:1 to 1:1,
or 3:1 to 1:1, or 2:1 to 1:1. Other solvent ratios include about
10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4,
1:5, 1:6, 1:7, 1:8, 1:9 or about 1:10 (volume/volume or
weight/weight). In some embodiments, the ratio of the first solvent
and the second solvent can be about 2:1 (weight/weight). In some
embodiments, the ratio of the first solvent and the second solvent
can be about 1:1 (weight/weight). In some embodiments, the ratio of
the ethanol and water is about 2:1 (weight/weight). In some
embodiments, the ratio of the ethanol and water is about 1:1
(weight/weight).
[0126] The method of preparing Compound I Form I can include a
variety of other steps. In some embodiments, the reaction mixture
can be heated to a temperature of about 75.degree. C. In some
embodiments, the method also includes cooling the reaction mixture
to a temperature of about 22.degree. C. In some embodiments, the
method of preparing Compound I Form I also includes heating the
mixture to dissolve Compound I, and cooling the mixture. In some
embodiments, the method of preparing Compound I Form I includes
forming a mixture of Compound I and ethanol, heating the mixture to
dissolve Compound I, adding water to the mixture, and cooling the
mixture to room temperature, thus forming Compound I Form I.
HCl Salt Form I
[0127] Compound I HCl salt Form I can be prepared from Compound I
Form I by mixing with hydrochloric acid in a solvent to form
Compound I HCl salt form I. In some embodiments, the present
disclosure provides a method of forming Compound I HCl salt Form I,
including forming a reaction mixture of Compound I Form I,
hydrochloric acid, and a solvent, thereby preparing Compound I HCl
salt Form I. In some embodiments, the solvent can be a polar
aprotic solvent. In some embodiments, the solvent can be methyl
ethyl ketone.
[0128] The method can include a variety of other steps. In some
embodiments, the reaction mixture can be heated to a temperature of
about 50.degree. C. In some embodiments, the reaction mixture can
be cooled to ambient temperature. In some embodiments, the reaction
mixture can be cooled to a temperature of about 10.degree. C. In
some embodiments, the method can include multiple heating and
cooling steps.
HCl Salt Form II
[0129] Compound I HCl salt Form II can be prepared from Compound I
HCl salt Form I by exposing Compound I HCl salt Form I to an
environment with a changing relative humidity. In some embodiments,
the present disclosure provides a method of preparing Compound I
HCl salt Form II by exposing Compound I HCl salt Form I to a low
relative humidity atmosphere and increasing the relative humidity
to form a high relative humidity atmosphere, thereby preparing
Compound I HCl salt Form II. The low relative humidity atmosphere
can be less than 50% relative humidity, including about 5, 10, 15,
20, 25, 30, 35, 40 and 45% relative humidity. The high relative
humidity atmosphere can be greater than 50% relative humidity,
including about 55, 60, 65, 70, 75, 80, 85, 90 or 95% relative
humidity. In some embodiments, the low relative humidity atmosphere
has a relative humidity of about 5%. In some embodiments, the high
relative humidity atmosphere has a relative humidity of about
95%.
Tartaric Acid
[0130] Crystalline Compound I Tartaric Acid can be prepared from
Compound I Form I by dissolving Compound I Form I in a solvent with
tartaric acid. In some embodiments, the present disclosure provides
a method of preparing a crystalline Compound I Tartaric Acid,
including forming a mixture of Compound I Form I, tartaric acid and
a solvent, under conditions suitable to prepare Compound I Tartaric
Acid. In some embodiments, Compound I Form I is dissolved in the
solvent. In some embodiments, the solvent can be a polar aprotic
solvent. In some embodiments, the solvent can be ethyl acetate.
[0131] The method can include a variety of other steps. In some
embodiments, the reaction mixture can be heated to a temperature of
about 50.degree. C. In some embodiments, the reaction mixture can
be cooled to ambient temperature. In some embodiments, the reaction
mixture can be cooled to a temperature of about 10.degree. C. In
some embodiments, the method can include multiple heating and
cooling steps.
[0132] Other steps of the method can include adding a second
solvent to the reaction mixture. In some embodiments, a non-polar
solvent is added to the reaction mixture. In some embodiments,
heptane is added to the reaction mixture.
Maleic Acid
[0133] Crystalline Compound I Maleic Acid can be prepared from
Compound I Form I by dissolving Compound I Form I in a solvent with
maleic acid. In some embodiments, the present disclosure provides a
method of preparing a crystalline Compound I Maleic Acid, including
forming a mixture of Compound I Form I, maleic acid and a solvent,
under conditions suitable to prepare Compound I Maleic Acid. In
some embodiments, Compound I Form I is dissolved in the solvent. In
some embodiments, the solvent can be a polar aprotic solvent. In
some embodiments, the solvent can be ethyl acetate.
[0134] The method can include a variety of other steps. In some
embodiments, the reaction mixture can be heated to a temperature of
about 50.degree. C. In some embodiments, the reaction mixture can
be cooled to ambient temperature. In some embodiments, the reaction
mixture can be cooled to a temperature of about 10.degree. C. In
some embodiments, the method can include multiple heating and
cooling steps.
Fumaric Acid
[0135] Crystalline Compound I Fumaric Acid can be prepared from
Compound I Form I by dissolving Compound I Form I in a solvent with
fumaric acid. In some embodiments, the present disclosure provides
a method of preparing a crystalline Compound I Fumaric Acid,
including forming a mixture of Compound I Form I, fumaric acid and
a solvent, under conditions suitable to prepare Compound I Fumaric
Acid. In some embodiments, Compound I Form I is dissolved in the
solvent. In some embodiments, the solvent can be a polar aprotic
solvent. In some embodiments, the solvent can be acetone.
[0136] The method can include a variety of other steps. In some
embodiments, the reaction mixture can be heated to a temperature of
about 50.degree. C. In some embodiments, the reaction mixture can
be cooled to ambient temperature. In some embodiments, the reaction
mixture can be cooled to a temperature of about 10.degree. C. In
some embodiments, the method can include multiple heating and
cooling steps.
Methanesulfonic Acid
[0137] Crystalline Compound I Methanesulfonic Acid can be prepared
from Compound I Form I by dissolving Compound I Form I in a solvent
with methanesulfonic acid. In some embodiments, the present
disclosure provides a method of preparing a crystalline Compound I
Methanesulfonic Acid, including forming a mixture of Compound I
Form I, methanesulfonic acid and a solvent, under conditions
suitable to prepare Compound I Methanesulfonic Acid. In some
embodiments, Compound I Form I is dissolved in the solvent. In some
embodiments, the solvent can be a polar aprotic solvent. In some
embodiments, the solvent can be ethyl acetate.
[0138] The method can include a variety of other steps. In some
embodiments, the reaction mixture can be heated to a temperature of
about 50.degree. C. In some embodiments, the reaction mixture can
be cooled to ambient temperature. In some embodiments, the reaction
mixture can be cooled to a temperature of about 10.degree. C. In
some embodiments, the method can include multiple heating and
cooling steps.
Amorphous Compound I
[0139] Amorphous Compound I can also be prepared by the methods of
the present disclosure. For example, Compound I Form I can be
dissolved in a solvent and freeze-dried to form the amorphous
Compound I. In some embodiments, the present disclosure provides a
method of preparing an amorphous Compound I, including forming a
mixture of Compound I, and a solvent, under conditions suitable to
prepare Form I. In some embodiments, Compound I is dissolved in the
solvent.
[0140] In some embodiments, the solvent can be a polar protic
solvent. In some embodiments, the solvent can be t-butanol,
n-propanol, isopropanol, ethanol, or methanol. In some embodiments,
the solvent can be t-butanol.
[0141] The method can be performed under any suitable reaction
conditions. For example, the reaction mixture can be at a
temperature of about 0.degree. C., -40.degree. C. or about
-78.degree. C. In some embodiments, the reaction mixture can be at
a temperature of about -78.degree. C.
V. Pharmaceutical Compositions
[0142] The solid forms of Compound I provided herein can be
administered in the form of pharmaceutical compositions. This
disclosure provides pharmaceutical compositions that contain, as
the active ingredient, one or more of the solid forms of Compound I
described or a pharmaceutically acceptable salt or ester thereof
and one or more pharmaceutically acceptable excipients, carriers,
including inert solid diluents and fillers, diluents, including
sterile aqueous solution and various organic solvents, permeation
enhancers, solubilizers and adjuvants. The pharmaceutical
compositions may be administered alone or in combination with other
therapeutic agents (as indicated in the Combination Therapy section
below). Such compositions are prepared in a manner well known in
the pharmaceutical art (see, e.g., Remington's Pharmaceutical
Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985));
and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker
& C. T. Rhodes, Eds.).
[0143] The pharmaceutical compositions may be administered in
either single or multiple doses by any of the accepted modes of
administration of agents having similar utilities, for example as
described in those patents and patent applications incorporated by
reference, including rectal, buccal, intranasal and transdermal
routes, by intra-arterial injection, intravenously,
intraperitoneally, parenterally, intramuscularly, subcutaneously
orally, topically, as an inhalant or via an impregnated or coated
device such as a stent, for example or an artery-inserted
cylindrical polymer.
[0144] One mode for administration is parenteral, particularly by
injection. The forms in which the novel compositions of the present
disclosure may be incorporated for administration by injection
include aqueous or oil suspensions or emulsions, with sesame oil,
corn oil, cottonseed oil or peanut oil, as well as elixirs,
mannitol, dextrose or a sterile aqueous solution and similar
pharmaceutical vehicles. Aqueous solutions in saline are also
conventionally used for injection, but less preferred in the
context of the present disclosure. Ethanol, glycerol, propylene
glycol, liquid polyethylene glycol, and the like (and suitable
mixtures thereof), cyclodextrin derivatives, and vegetable oils may
also be employed. The proper fluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of dispersion
and by the use of surfactants. The prevention of the action of
microorganisms can be brought about by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol,
sorbic acid, thimerosal, and the like.
[0145] Sterile injectable solutions are prepared by incorporating a
compound according to the present disclosure in the required amount
in the appropriate solvent with various other ingredients as
enumerated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the various
sterilized active ingredients into a sterile vehicle which contains
the basic dispersion medium and the required other ingredients from
those enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the general methods of
preparation are vacuum-drying and freeze-drying techniques which
yield a powder of the active ingredient plus any additional desired
ingredient from a previously sterile-filtered solution thereof.
[0146] Oral administration is another route for administration of
compounds in accordance with the disclosure. Administration may be
via capsule or enteric coated tablets or the like. In making the
pharmaceutical compositions that include at least one compound
described herein, the active ingredient is usually diluted by an
excipient and/or enclosed within such a carrier that can be in the
form of a capsule, sachet, paper or other container. When the
excipient serves as a diluent, it can be in the form of a solid,
semi-solid or liquid material (as above), which acts as a vehicle,
carrier or medium for the active ingredient. Thus, the compositions
can be in the form of tablets, pills, powders, lozenges, sachets,
cachets, elixirs, suspensions, emulsions, solutions, syrups,
aerosols (as a solid or in a liquid medium), ointments containing,
for example, up to 10% by weight of the active compound, soft and
hard gelatin capsules, sterile injectable solutions and sterile
packaged powders.
[0147] Some examples of suitable excipients include lactose,
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,
calcium phosphate, alginates, tragacanth, gelatin, calcium
silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, sterile water, syrup and methyl cellulose. The
formulations can additionally include: lubricating agents such as
talc, magnesium stearate and mineral oil; wetting agents;
emulsifying and suspending agents; preserving agents such as methyl
and propylhydroxy-benzoates; sweetening agents; and flavoring
agents.
[0148] The compositions of the disclosure can be formulated so as
to provide quick, sustained or delayed release of the active
ingredient after administration to the patient by employing
procedures known in the art. Controlled release drug delivery
systems for oral administration include osmotic pump systems and
dissolutional systems containing polymer-coated reservoirs or
drug-polymer matrix formulations. Examples of controlled release
systems are given in U.S. Pat. Nos. 3,845,770; 4,326,525;
4,902,514; and 5,616,345. Another formulation for use in the
methods of the present disclosure employs transdermal delivery
devices ("patches"). Such transdermal patches may be used to
provide continuous or discontinuous infusion of the compounds of
the present disclosure in controlled amounts. The construction and
use of transdermal patches for the delivery of pharmaceutical
agents is well known in the art. See, e.g., U.S. Pat. Nos.
5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed
for continuous, pulsatile or on demand delivery of pharmaceutical
agents.
[0149] In some embodiments, the compositions are formulated in a
unit dosage form. The term "unit dosage forms" refers to physically
discrete units suitable as unitary dosages for human subjects and
other mammals, each unit containing a predetermined quantity of
active material calculated to produce the desired therapeutic
effect, in association with a suitable pharmaceutical excipient
(e.g., a tablet, capsule, ampoule). The compounds are generally
administered in a pharmaceutically effective amount. In some
embodiments, each dosage unit contains from 1 mg to 2 g of a
compound described herein and for parenteral administration, in
some embodiments, from 0.1 to 700 mg of a compound a compound
described herein. It will be understood, however, that the amount
of the compound actually administered usually will be determined by
a physician, in the light of the relevant circumstances, including
the condition to be treated, the chosen route of administration,
the actual compound administered and its relative activity, the
age, weight and response of the individual patient, the severity of
the patient's symptoms, and the like.
[0150] For preparing solid compositions such as tablets, the
principal active ingredient is mixed with a pharmaceutical
excipient to form a solid preformulation composition containing a
homogeneous mixture of a compound of the present disclosure. When
referring to these preformulation compositions as homogeneous, it
is meant that the active ingredient is dispersed evenly throughout
the composition so that the composition may be readily subdivided
into equally effective unit dosage forms such as tablets, pills and
capsules.
[0151] The tablets or pills of the present disclosure may be coated
or otherwise compounded to provide a dosage form affording the
advantage of prolonged action or to protect from the acid
conditions of the stomach. For example, the tablet or pill can
comprise an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer that serves to
resist disintegration in the stomach and permit the inner component
to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and
mixtures of polymeric acids with such materials as shellac, cetyl
alcohol and cellulose acetate.
[0152] Compositions for inhalation or insufflation include
solutions and suspensions in pharmaceutically acceptable, aqueous
or organic solvents or mixtures thereof and powders. The liquid or
solid compositions may contain suitable pharmaceutically acceptable
excipients as described supra. In some embodiments, the
compositions are administered by the oral or nasal respiratory
route for local or systemic effect. Compositions in preferably
pharmaceutically acceptable solvents may be nebulized by use of
inert gases. Nebulized solutions may be inhaled directly from the
nebulizing device or the nebulizing device may be attached to a
facemask tent or intermittent positive pressure breathing machine.
Solution, suspension or powder compositions may be administered, in
some embodiments orally or nasally, from devices that deliver the
formulation in an appropriate manner.
[0153] In one embodiment, this disclosure relates to a
pharmaceutical composition comprising a pharmaceutically acceptable
excipient or carrier and a therapeutically effective amount of the
compound of Compound I as described above or a pharmaceutically
acceptable salt, ester, prodrug, stereoisomer or hydrate
thereof.
VI. Methods of Use
[0154] The solid forms of Compound I described herein can be
administered to a subject suffering from a viral infection such as,
but not limited to, hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immuno-deficiency virus (HIV) in either single or
multiple doses by any of the accepted modes of administration known
to those who are skilled in the art and as detailed above.
[0155] As used herein, an "agonist" is a substance that stimulates
its binding partner, typically a receptor. Stimulation is defined
in the context of the particular assay, or may be apparent in the
literature from a discussion herein that makes a comparison to a
factor or substance that is accepted as an "agonist" or an
"antagonist" of the particular binding partner under substantially
similar circumstances as appreciated by those of skill in the art.
Stimulation may be defined with respect to an increase in a
particular effect or function that is induced by interaction of the
agonist or partial agonist with a binding partner and can include
allosteric effects.
[0156] As used herein, an "antagonist" is a substance that inhibits
its binding partner, typically a receptor. Inhibition is defined in
the context of the particular assay, or may be apparent in the
literature from a discussion herein that makes a comparison to a
factor or substance that is accepted as an "agonist" or an
"antagonist" of the particular binding partner under substantially
similar circumstances as appreciated by those of skill in the art.
Inhibition may be defined with respect to a decrease in a
particular effect or function that is induced by interaction of the
antagonist with a binding partner, and can include allosteric
effects.
[0157] As used herein, a "partial agonist" or a "partial
antagonist" is a substance that provides a level of stimulation or
inhibition, respectively, to its binding partner that is not fully
or completely agonistic or antagonistic, respectively. It will be
recognized that stimulation, and hence, inhibition is defined
intrinsically for any substance or category of substances to be
defined as agonists, antagonists, or partial agonists.
[0158] As used herein, "intrinsic activity" or "efficacy" relates
to some measure of biological effectiveness of the binding partner
complex. With regard to receptor pharmacology, the context in which
intrinsic activity or efficacy should be defined will depend on the
context of the binding partner (e.g., receptor/ligand) complex and
the consideration of an activity relevant to a particular
biological outcome. For example, in some circumstances, intrinsic
activity may vary depending on the particular second messenger
system involved. Where such contextually specific evaluations are
relevant, and how they might be relevant in the context of the
present disclosure, will be apparent to one of ordinary skill in
the art.
[0159] As used herein, modulation of a receptor includes agonism,
partial agonism, antagonism, partial antagonism, or inverse agonism
of a receptor.
[0160] As will be appreciated by those skilled in the art, when
treating a viral infection such as HCV, HBV, or HIV, such treatment
may be characterized in a variety of ways and measured by a variety
of endpoints. The scope of the present disclosure is intended to
encompass all such characterizations.
[0161] In one embodiment, the method can be used to induce an
immune response against multiple epitopes of a viral infection in a
human. Induction of an immune response against viral infection can
be assessed using any technique that is known by those of skill in
the art for determining whether an immune response has occurred.
Suitable methods of detecting an immune response for the present
disclosure include, among others, detecting a decrease in viral
load or antigen in a subject's serum, detection of
IFN-gamma-secreting peptide specific T cells, and detection of
elevated levels of one or more liver enzymes, such as alanine
transferase (ALT) and aspartate transferase (AST). In one
embodiment, the detection of IFN-gamma-secreting peptide specific T
cells is accomplished using an ELISPOT assay. Another embodiment
includes reducing the viral load associated with HBV infection,
including a reduction as measured by PCR testing.
[0162] In some embodiments, the present disclosure provides a
method of treating a viral infection, comprising administering to a
human in need thereof, a therapeutically effective amount of a
crystalline form of Compound I or pharmaceutical composition of the
present disclosure. In some embodiments, the present disclosure
provides a crystalline form of Compound I for use in the treatment
of a viral infection, comprising administering a therapeutically
effective amount of a crystalline form of Compound I or a
pharmaceutical composition of the present disclosure. In some
embodiments, the present disclosure provides use of a crystalline
form of Compound I for the treatment of a viral infection. In some
embodiments, the present disclosure provides use of a crystalline
form of Compound I for the manufacture of a medicament for the
treatment of a viral infection.
[0163] In another aspect, the present disclosure provides methods
for treating a hepatitis B viral infection or a hepatitis C viral
infection, wherein each of the methods includes the step of
administering to a human subject infected with hepatitis B virus or
hepatitis C virus a therapeutically effective amount of a
crystalline form of Compound I. Typically, the human subject is
suffering from a chronic hepatitis B infection or a chronic
hepatitis C infection, although it is within the scope of the
present disclosure to treat people who are acutely infected with
HBV or HCV.
[0164] In some embodiments, the present disclosure provides a
crystalline form of Compound I for use in the treatment of a
hepatitis B viral infection or a hepatitis C viral infection. In
some embodiments, the present disclosure provides use of a
crystalline form of Compound I for the manufacture of a medicament
for the treatment of a hepatitis B viral infection or a hepatitis C
viral infection.
[0165] In some embodiments, the present disclosure provides a
crystalline form of Compound I for use in the treatment of a
hepatitis B viral infection. In some embodiments, the present
disclosure provides use of a crystalline form of Compound I for the
manufacture of a medicament for the treatment of a hepatitis B
viral infection.
[0166] Treatment in accordance with the present disclosure
typically results in the stimulation of an immune response against
HBV or HCV in a human being infected with HBV or HCV, respectively,
and a consequent reduction in the viral load of HBV or HCV in the
infected person. Examples of immune responses include production of
antibodies (e.g., IgG antibodies) and/or production of cytokines,
such as interferons, that modulate the activity of the immune
system. The immune system response can be a newly induced response,
or can be boosting of an existing immune response. In particular,
the immune system response can be seroconversion against one or
more HBV or HCV antigens.
[0167] The viral load can be determined by measuring the amount of
HBV DNA or HCV DNA present in the blood. For example, blood serum
HBV DNA can be quantified using the Roche COBAS Amplicor Monitor
PCR assay (version 2.0; lower limit of quantification, 300
copies/mL [57 IU/mL]) and the Quantiplex bDNA assay (lower limit of
quantification, 0.7 MEq/mL; Bayer Diagnostics, formerly Chiron
Diagnostics, Emeryville, Calif.). The amount of antibodies against
specific HBV or HCV antigens (e.g., hepatitis B surface antigen
(HBsAG)) can be measured using such art-recognized techniques as
enzyme-linked immunoassays and enzyme-linked immunoabsorbent
assays. For example, the amount of antibodies against specific HBV
or HCV antigens can be measured using the Abbott AxSYM
microparticle enzyme immunoassay system (Abbott Laboratories, North
Chicago, Ill.).
[0168] Compound I can be administered by any useful route and
means, such as by oral or parenteral (e.g., intravenous)
administration. Therapeutically effective amounts of Compound I are
from about 0.00001 mg/kg body weight per day to about 10 mg/kg body
weight per day, such as from about 0.0001 mg/kg body weight per day
to about 10 mg/kg body weight per day, or such as from about 0.001
mg/kg body weight per day to about 1 mg/kg body weight per day, or
such as from about 0.01 mg/kg body weight per day to about 1 mg/kg
body weight per day, or such as from about 0.05 mg/kg body weight
per day to about 0.5 mg/kg body weight per day, or such as from
about 0.3 .mu.g to about 30 mg per day, or such as from about 30
.mu.g to about 300 .mu.g per day.
[0169] Therapeutically effective amounts of Compound I are also
from about 0.01 mg per dose to about 1000 mg per dose, such as from
about 0.01 mg per dose to about 100 mg per dose, or such as from
about 0.1 mg per dose to about 100 mg per dose, or such as from
about 1 mg per dose to about 100 mg per dose, or such as from about
1 mg per dose to about 10 mg per dose. Other therapeutically
effective amounts of Compound I are about 1 mg per dose, 1.5 mg per
dose, 2 mg per dose, 2.5 mg per dose, 3 mg per dose, or 3.5 mg per
dose or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40,
45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or about 100 mg per
dose. Other therapeutically effective amounts of Compound I are
about 100 mg per dose, or about 125, 150, 175, 200, 225, 250, 275,
300, 350, 400, 450, or about 500 mg per dose. A single dose can be
administered hourly, daily, or weekly. For example, a single dose
can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or
once every 24 hours. A single dose can also be administered once
every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can
also be administered once every 1 week, 2, 3, or once every 4
weeks. A single dose can also be administered once every month.
[0170] The frequency of dosage of Compound I will be determined by
the needs of the individual patient and can be, for example, once
per day or twice, or more times, per day. Administration of
Compound I continues for as long as necessary to treat the HBV or
HCV infection. For example, Compound I can be administered to a
human being infected with HBV or HCV for a period of from 20 days
to 180 days or, for example, for a period of from 20 days to 90
days or, for example, for a period of from 30 days to 60 days.
[0171] Administration can be intermittent, with a period of several
or more days during which a patient receives a daily dose of
Compound I, followed by a period of several or more days during
which a patient does not receive a daily dose of Compound I. For
example, a patient can receive a dose of Compound I every other
day, or three times per week. Again by way of example, a patient
can receive a dose of Compound I each day for a period of from 1 to
14 days, followed by a period of 7 to 21 days during which the
patient does not receive a dose of Compound I, followed by a
subsequent period (e.g., from 1 to 14 days) during which the
patient again receives a daily dose of Compound I. Alternating
periods of administration of Compound I, followed by
non-administration of Compound I, can be repeated as clinically
required to treat the patient.
[0172] As described more fully herein, crystalline forms of
Compound I can be administered with one or more additional
therapeutic agent(s) to a human being infected with hepatitis B
virus or hepatitis C virus. The additional therapeutic agent(s) can
be administered to the infected human being at the same time as the
crystalline form of Compound I, or before or after administration
of the crystalline form of Compound I. In some embodiments, the
present disclosure provides a crystalline form of Compound I, for
use in a method of treating or preventing a hepatitis B viral
infection, wherein the crystalline form of Compound I is
administered simultaneously, separately or sequentially with one or
more additional therapeutic agents for treating a hepatitis B viral
infection. In some embodiments, the present disclosure provides use
of a crystalline form of Compound I for the manufacture of a
medicament for the treatment of a hepatitis B viral infection,
wherein the crystalline form of Compound I is administered
simultaneously, separately or sequentially with one or more
additional therapeutic agents for treating a hepatitis B viral
infection.
[0173] In another aspect, the present disclosure provides a method
for ameliorating a symptom associated with an HBV infection or HCV
infection, wherein the method comprises administering to a human
subject infected with hepatitis B virus or hepatitis C virus a
therapeutically effective amount of the crystalline form of
Compound I, wherein the therapeutically effective amount is
sufficient to ameliorate a symptom associated with the HBV
infection or HCV infection. Such symptoms include the presence of
HBV virus particles (or HCV virus particles) in the blood, liver
inflammation, jaundice, muscle aches, weakness and tiredness.
[0174] In some embodiments, the present disclosure provides a
crystalline form of Compound I for use in ameliorating a symptom
associated with an HBV infection or HCV infection, wherein the
method comprises administering to a human subject infected with
hepatitis B virus or hepatitis C virus a therapeutically effective
amount of the crystalline form of Compound I, wherein the
therapeutically effective amount is sufficient to ameliorate a
symptom associated with the HBV infection or HCV infection. In some
embodiments, the present disclosure provides use of a crystalline
form of Compound I for the manufacture of a medicament for the
ameliorating a symptom associated with an HBV infection or HCV
infection, wherein the method comprises administering to a human
subject infected with hepatitis B virus or hepatitis C virus a
therapeutically effective amount of the crystalline form of
Compound I, wherein the therapeutically effective amount is
sufficient to ameliorate a symptom associated with the HBV
infection or HCV infection.
[0175] In a further aspect, the present disclosure provides a
method for reducing the rate of progression of a hepatitis B viral
infection, or a hepatitis C virus infection, in a human being,
wherein the method comprises administering to a human subject
infected with hepatitis B virus or hepatitis C virus a
therapeutically effective amount of Compound I, or a
pharmaceutically acceptable salt thereof, wherein the
therapeutically effective amount is sufficient to reduce the rate
of progression of the hepatitis B viral infection or hepatitis C
viral infection. The rate of progression of the infection can be
followed by measuring the amount of HBV virus particles or HCV
virus particles in the blood.
[0176] In another aspect, the present disclosure provides a method
for reducing the viral load associated with HBV infection or HCV
infection, wherein the method comprises administering to a human
being infected with HBV or HCV a therapeutically effective amount
of Compound I, or a pharmaceutically acceptable salt thereof,
wherein the therapeutically effective amount is sufficient to
reduce the HBV viral load or the HCV viral load in the human
being.
[0177] In a further aspect, the present disclosure provides a
method of inducing or boosting an immune response against Hepatitis
B virus or Hepatitis C virus in a human being, wherein the method
comprises administering a therapeutically effective amount of
Compound I, or a pharmaceutically acceptable salt thereof, to the
human being, wherein a new immune response against Hepatitis B
virus or Hepatitis C virus is induced in the human being, or a
preexisting immune response against Hepatitis B virus or Hepatitis
C virus is boosted in the human being. Seroconversion with respect
to HBV or HCV can be induced in the human being. Examples of immune
responses include production of antibodies, such as IgG antibody
molecules, and/or production of cytokine molecules that modulate
the activity of one or more components of the human immune
system.
[0178] Induction of seroconversion against HCV or HBV in patients
chronically infected with either of these viruses is an unexpected
property of Compound I. In clinical practice, an HBV patient, or
HCV patient, is treated with Compound I, alone or in combination
with one or more other therapeutic agents, until an immune response
against HBV or HCV is induced or enhanced and the viral load of HBV
or HCV is reduced. Thereafter, although the HBV or HCV virus may
persist in a latent form in the patient's body, treatment with
Compound I can be stopped, and the patient's own immune system is
capable of suppressing further viral replication. In patients
treated in accordance with the present disclosure and who are
already receiving treatment with an antiviral agent that suppresses
replication of the HBV virus or HCV virus, there may be little or
no detectable viral particles in the body of the patient during
treatment with the antiviral agent(s). In these patients,
seroconversion will be evident when the antiviral agent(s) is no
longer administered to the patient and there is no increase in the
viral load of HBV or HCV.
[0179] In the practice of the present disclosure, an immune
response is induced against one or more antigens of HBV or HCV. For
example, an immune response can be induced against the HBV surface
antigen (HBsAg), or against the small form of the HBV surface
antigen (small S antigen), or against the medium form of the HBV
surface antigen (medium S antigen), or against a combination
thereof. Again by way of example, an immune response can be induced
against the HBV surface antigen (HBsAg) and also against other
HBV-derived antigens, such as the core polymerase or x-protein.
[0180] Induction of an immune response against HCV or HBV can be
assessed using any technique that is known by those of skill in the
art for determining whether an immune response has occurred.
Suitable methods of detecting an immune response for the present
disclosure include, among others, detecting a decrease in viral
load in a subject's serum, such as by measuring the amount of HBV
DNA or HCV DNA in a subject's blood using a PCR assay, and/or by
measuring the amount of anti-HBV antibodies, or anti-HCV
antibodies, in the subject's blood using a method such as an
ELISA.
[0181] Additionally, the compounds of this disclosure may be useful
in the treatment of cancer or tumors (including dysplasias, such as
uterine dysplasia). These includes hematological malignancies, oral
carcinomas (for example of the lip, tongue or pharynx), digestive
organs (for example esophagus, stomach, small intestine, colon,
large intestine, or rectum), liver and biliary passages, pancreas,
respiratory system such as larynx or lung (small cell and non-small
cell), bone, connective tissue, skin (e.g., melanoma), breast,
reproductive organs (uterus, cervix, testicles, ovary, or
prostate), urinary tract (e.g., bladder or kidney), brain and
endocrine glands such as the thyroid. In summary, the compounds of
this disclosure are employed to treat any neoplasm, including not
only hematologic malignancies but also solid tumors of all
kinds.
[0182] Hematological malignancies are broadly defined as
proliferative disorders of blood cells and/or their progenitors, in
which these cells proliferate in an uncontrolled manner.
Anatomically, the hematologic malignancies are divided into two
primary groups: lymphomas --malignant masses of lymphoid cells,
primarily but not exclusively in lymph nodes, and
leukemias--neoplasm derived typically from lymphoid or myeloid
cells and primarily affecting the bone marrow and peripheral blood.
The lymphomas can be sub-divided into Hodgkin's Disease and
Non-Hodgkin's lymphoma (NHL). The latter group comprises several
distinct entities, which can be distinguished clinically (e.g.
aggressive lymphoma, indolent lymphoma), histologically (e.g.
follicular lymphoma, mantle cell lymphoma) or based on the origin
of the malignant cell (e.g. B lymphocyte, T lymphocyte). Leukemias
and related malignancies include acute myelogenous leukemia (AML),
chronic myelogenous leukemia (CML), acute lymphoblastic leukemia
(ALL) and chronic lymphocytic leukemia (CLL). Other hematological
malignancies include the plasma cell dyscrasias including multiple
myeloma, and the myelodysplastic syndromes.
VII. Combination Therapy
[0183] In certain embodiments, a method for treating or preventing
an infectious disease, a viral infection, hepatitis B infection,
HIV infection, cancer, or a hyperproliferative disease in a human
having or at risk of having the disease is provided, comprising
administering to the human a therapeutically effective amount of a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, in combination with a therapeutically effective amount of
one or more (e.g., one, two, three, four, one or two, one to three,
or one to four) additional therapeutic agents. In one embodiment, a
method for treating an infectious disease, a viral infection,
hepatitis B infection, HIV infection, cancer, or a
hyperproliferative disease in a human having or at risk of having
the disease is provided, comprising administering to the human a
therapeutically effective amount of a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, four, one or two, one to three, or one to four) additional
therapeutic agents.
[0184] In certain embodiments, the present disclosure provides a
method for treating a viral infection, comprising administering to
a subject in need thereof a therapeutically effective amount of a
compound disclosed herein or a pharmaceutically acceptable salt
thereof, in combination with a therapeutically effective amount of
one or more (e.g., one, two, three, four, one or two, one to three,
or one to four) additional therapeutic agents which are suitable
for treating the viral infection. In some embodiments, the viral
infection is a hepatitis B infection. In some embodiments, the
viral infection is a HIV infection.
[0185] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with one,
two, three, four, or more additional therapeutic agents. In certain
embodiments, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with two additional
therapeutic agents. In other embodiments, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with three additional therapeutic agents. In further embodiments, a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, is combined with four additional therapeutic agents. The
one, two, three, four, or more additional therapeutic agents can be
different therapeutic agents selected from the same class of
therapeutic agents, and/or they can be selected from different
classes of therapeutic agents.
Administration of Combination Therapy
[0186] In certain embodiments, a compound disclosed herein is
administered with one or more additional therapeutic agents.
Co-administration of a compound disclosed herein with one or more
additional therapeutic agents generally refers to simultaneous or
sequential administration of a compound disclosed herein and one or
more additional therapeutic agents, such that therapeutically
effective amounts of the compound disclosed herein and the one or
more additional therapeutic agents are both present in the body of
the subject. When administered sequentially, the combination may be
administered in two or more administrations.
[0187] Co-administration of a compound disclosed herein with one or
more additional therapeutic agents generally refers to simultaneous
or sequential administration of a compound disclosed herein and one
or more additional therapeutic agents, such that therapeutically
effective amounts of each agent are present in the body of the
patient.
[0188] In certain embodiments, a compound as disclosed herein may
be combined with one or more (e.g., one, two, three, four, one or
two, one to three, or one to four) additional therapeutic agents in
any dosage amount of the compound (e.g., from 10 mg to 1000 mg of
compound).
[0189] Co-administration includes administration of unit dosages of
the compounds disclosed herein before or after administration of
unit dosages of one or more additional therapeutic agents. The
compound disclosed herein may be administered within seconds,
minutes, or hours of the administration of one or more additional
therapeutic agents. For example, in some embodiments, a unit dose
of a compound disclosed herein is administered first, followed
within seconds or minutes by administration of a unit dose of one
or more additional therapeutic agents. Alternatively, in other
embodiments, a unit dose of one or more additional therapeutic
agents is administered first, followed by administration of a unit
dose of a compound disclosed herein within seconds or minutes. In
some embodiments, a unit dose of a compound disclosed herein is
administered first, followed, after a period of hours (e.g., 1-12
hours), by administration of a unit dose of one or more additional
therapeutic agents. In other embodiments, a unit dose of one or
more additional therapeutic agents is administered first, followed,
after a period of hours (e.g., 1-12 hours), by administration of a
unit dose of a compound disclosed herein.
[0190] In certain embodiments, a compound disclosed herein is
combined with one or more additional therapeutic agents in a
unitary dosage form for simultaneous administration to a subject,
for example as a solid dosage form for oral administration.
[0191] In certain embodiments a compound as described herein is
formulated as a tablet, which may optionally contain one or more
other compounds useful for treating the disease being treated. In
certain embodiments, the tablet can contain another active
ingredient for treating a viral disease, e.g., hepatitis B virus or
HIV.
[0192] In certain embodiments, such tablets are suitable for once
daily dosing.
[0193] In one embodiment, pharmaceutical compositions comprising a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, in combination with one or more (e.g., one, two, three,
one or two, or one to three) additional therapeutic agents, and a
pharmaceutically acceptable carrier, diluent, or excipient are
provided.
[0194] In one embodiment, kits comprising a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, in
combination with one or more (e.g., one, two, three, four, one or
two, or one to three, or one to four) additional therapeutic agents
are provided.
Viral Combination Therapy
[0195] The compounds described herein may be used or combined with
one or more of an antiviral agents including abacavir, aciclovir,
adefovir, amantadine, amprenavir, arbidol, atazanavir, atripla,
brivudine, cidofovir, combivir, edoxudine, efavirenz,
emtricitabine, enfuvirtide, entecavir, fomvirsen, fosamprenavir,
foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, immunovir,
idoxuridine, imiquimod, indinavir, inosine, integrase inhibitors,
interferons, including interferon type III, interferon type II,
interferon type I, lamivudine, lopinavir, loviride, MK-0518,
maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleoside
analogues, oseltamivir, penciclovir, peramivir, pleconaril,
podophyllotoxin, protease inhibitors, reverse transcriptase
inhibitors, ribavirin, rimantadine, ritonavir, saquinavir,
stavudine, tenofovir, tenofovir disoproxil, tipranavir,
trifluridine, trizivir, tromantadine, truvada, valganciclovir,
vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir,
zidovudine, and combinations thereof.
[0196] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 5-30 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide. In certain embodiments, a compound
disclosed herein, or a pharmaceutically acceptable salt thereof, is
combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30
mg tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, or tenofovir alafenamide. In certain embodiments, a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, is combined with 10 mg tenofovir alafenamide fumarate,
tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In
certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 25 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide. A compound as disclosed herein may be
combined with the agents provided herein in any dosage amount of
the compound (e.g., from 50 mg to 500 mg of compound) the same as
if each combination of dosages were specifically and individually
listed.
[0197] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 100-400
mg tenofovir disoproxil fumarate, tenofovir disoproxil
hemifumarate, or tenofovir disoproxil. In certain embodiments, a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, is combined with 100-150; 100-200, 100-250; 100-300;
100-350; 150-200; 150-250; 150-300; 150-350; 150-400; 200-250;
200-300; 200-350; 200-400; 250-350; 250-400; 350-400 or 300-400 mg
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
or tenofovir disoproxil. In certain embodiments, a compound
disclosed herein, or a pharmaceutically acceptable salt thereof, is
combined with 300 mg tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, or tenofovir disoproxil. In certain
embodiments, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with 250 mg tenofovir
disoproxil fumarate, tenofovir disoproxil hemifumarate, or
tenofovir disoproxil. In certain embodiments, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with 150 mg tenofovir disoproxil fumarate, tenofovir disoproxil
hemifumarate, or tenofovir disoproxil. A compound as disclosed may
be combined with the agents provided herein in any dosage amount of
the compound (e.g., from 50 mg to 500 mg of compound) the same as
if each combination of dosages were specifically and individually
listed.
HIV Combination Therapy
[0198] In certain embodiments, a method for treating or preventing
an HIV infection in a human or animal having or at risk of having
the infection is provided, comprising administering to the human or
animal a therapeutically effective amount of a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, one or two, or one to three) additional
therapeutic agents. In one embodiment, a method for treating an HIV
infection in a human or animal having or at risk of having the
infection is provided, comprising administering to the human or
animal a therapeutically effective amount of a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, one or two, or one to three) additional
therapeutic agents.
[0199] In certain embodiments, the present disclosure provides a
method for treating an HIV infection, comprising administering to a
subject in need thereof a therapeutically effective amount of a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, in combination with a therapeutically effective amount of
one or more additional therapeutic agents which are suitable for
treating an HIV infection.
[0200] In certain embodiments, the compounds disclosed herein are
formulated as a tablet, which may optionally contain one or more
other compounds useful for treating HIV. In certain embodiments,
the tablet can contain another active ingredient for treating HIV,
such as HIV protease inhibitors, HIV non-nucleoside or
non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside
or nucleotide inhibitors of reverse transcriptase, HIV integrase
inhibitors, HIV non-catalytic site (or allosteric) integrase
inhibitors, pharmacokinetic enhancers, and combinations
thereof.
[0201] In certain embodiments, such tablets are suitable for once
daily dosing.
[0202] In the above embodiments, the additional therapeutic agent
may be an anti-HIV agent. In some embodiments, the additional
therapeutic agent is selected from the group consisting of HIV
combination drugs, HIV protease inhibitors, HIV non-nucleoside or
non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside
or nucleotide inhibitors of reverse transcriptase, HIV integrase
inhibitors, HIV non-catalytic site (or allosteric) integrase
inhibitors, HIV entry inhibitors, HIV maturation inhibitors,
immunomodulators, immunotherapeutic agents, antibody-drug
conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc
finger nucleases, homing nucleases, synthetic nucleases, TALENs),
cell therapies (such as chimeric antigen receptor T-cell, CAR-T,
and engineered T cell receptors, TCR-T), latency reversing agents,
compounds that target the HIV capsid (including capsid inhibitors),
immune-based therapies, phosphatidylinositol 3-kinase (PI3K)
inhibitors, alpha-4/beta-7 antagonists, HIV antibodies, bispecific
antibodies and "antibody-like" therapeutic proteins, HIV p17 matrix
protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans
isomerase A modulators, protein disulfide isomerase inhibitors,
complement C5a receptor antagonists, DNA methyltransferase
inhibitor, HIV vif gene modulators, Vif dimerization antagonists,
HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors,
HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage
kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein
inhibitors, integrin antagonists, nucleoprotein inhibitors,
splicing factor modulators, COMM domain containing protein 1
modulators, HIV ribonuclease H inhibitors, retrocyclin modulators,
CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1
inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors,
Complement Factor H modulators, ubiquitin ligase inhibitors,
deoxycytidine kinase inhibitors, cyclin dependent kinase
inhibitors, proprotein convertase PC9 stimulators, ATP dependent
RNA helicase DDX3X inhibitors, reverse transcriptase priming
complex inhibitors, G6PD and NADH-oxidase inhibitors,
pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and
other HIV therapeutic agents, and combinations thereof.
[0203] In some embodiments, the additional therapeutic agent is
selected from the group consisting of combination drugs for HIV,
other drugs for treating HIV, HIV protease inhibitors, HIV reverse
transcriptase inhibitors, HIV integrase inhibitors, HIV
non-catalytic site (or allosteric) integrase inhibitors, HIV entry
(fusion) inhibitors, HIV maturation inhibitors, latency reversing
agents, capsid inhibitors, immune-based therapies, PI3K inhibitors,
HIV antibodies, and bispecific antibodies, and "antibody-like"
therapeutic proteins, and combinations thereof.
[0204] HIV Combination Drugs
[0205] Examples of combination drugs include ATRIPLA.RTM.
(efavirenz, tenofovir disoproxil fumarate, and emtricitabine);
COMPLERA.RTM. (EVIPLERA.RTM.; rilpivirine, tenofovir disoproxil
fumarate, and emtricitabine); STRIBILD.RTM. (elvitegravir,
cobicistat, tenofovir disoproxil fumarate, and emtricitabine);
TRUVADA.RTM. (tenofovir disoproxil fumarate and emtricitabine;
TDF+FTC); DESCOVY.RTM. (tenofovir alafenamide and emtricitabine);
ODEFSEY.RTM. (tenofovir alafenamide, emtricitabine, and
rilpivirine); GENVOYA.RTM. (tenofovir alafenamide, emtricitabine,
cobicistat, and elvitegravir); BIKTARVY.RTM. (bictegravir,
emtricitabine, tenofovir alafenamide); darunavir, tenofovir
alafenamide hemifumarate, emtricitabine, and cobicistat; efavirenz,
lamivudine, and tenofovir disoproxil fumarate; lamivudine and
tenofovir disoproxil fumarate; tenofovir and lamivudine; tenofovir
alafenamide and emtricitabine; tenofovir alafenamide hemifumarate
and emtricitabine; tenofovir alafenamide hemifumarate,
emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate,
emtricitabine, cobicistat, and elvitegravir; COMBIVIR.RTM.
(zidovudine and lamivudine; AZT+3TC); EPZICOM.RTM. (LIVEXA.RTM.;
abacavir sulfate and lamivudine; ABC+3TC); KALETRA.RTM.
(ALUVIA.RTM.; lopinavir and ritonavir); TRIUMEQ.RTM. (dolutegravir,
abacavir, and lamivudine); TRIZIVIR.RTM. (abacavir sulfate,
zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and
cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate
and ritonavir; darunavir and cobicistat; dolutegravir and
rilpivirine; dolutegravir and rilpivirine hydrochloride;
dolutegravir, abacavir sulfate, and lamivudine; lamivudine,
nevirapine, and zidovudine; raltegravir and lamivudine; doravirine,
lamivudine, and tenofovir disoproxil fumarate; doravirine,
lamivudine, and tenofovir disoproxil; dolutegravir+lamivudine,
lamivudine+abacavir+zidovudine, lamivudine+abacavir,
lamivudine+tenofovir disoproxil fumarate,
lamivudine+zidovudine+nevirapine, lopinavir+ritonavir,
lopinavir+ritonavir+abacavir+lamivudine,
lopinavir+ritonavir+zidovudine+lamivudine, tenofovir+lamivudine,
and tenofovir disoproxil fumarate+emtricitabine+rilpivirine
hydrochloride, lopinavir, ritonavir, zidovudine and lamivudine;
Vacc-4x and romidepsin; and APH-0812.
[0206] HIV Protease Inhibitors
[0207] Examples of HIV protease inhibitors include amprenavir,
atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir
calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir,
nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate,
tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, and
TMC-310911.
[0208] HIV Reverse Transcriptase Inhibitors
[0209] Examples of HIV non-nucleoside or non-nucleotide inhibitors
of reverse transcriptase include dapivirine, delavirdine,
delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan,
nevirapine, rilpivirine, ACC-007, AIC-292, KM-023, PC-1005, and
VM-1500.
[0210] Examples of HIV nucleoside or nucleotide inhibitors of
reverse transcriptase include adefovir, adefovir dipivoxil,
azvudine, emtricitabine, tenofovir, tenofovir alafenamide,
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir
disoproxil hemifumarate, VIDEX.RTM. and VIDEX EC.RTM. (didanosine,
ddl), abacavir, abacavir sulfate, alovudine, apricitabine,
censavudine, didanosine, elvucitabine, festinavir, fosalvudine
tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753,
tenofovir disoproxil orotate, fozivudine tidoxil, lamivudine,
phosphazid, stavudine, zalcitabine, zidovudine, GS-9131, GS-9148,
MK-8504 and KP-1461.
[0211] HIV Integrase Inhibitors
[0212] Examples of HIV integrase inhibitors include elvitegravir,
curcumin, derivatives of curcumin, chicoric acid, derivatives of
chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of
3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of
aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives
of caffeic acid phenethyl ester, tyrphostin, derivatives of
tyrphostin, quercetin, derivatives of quercetin, raltegravir,
dolutegravir, JTK-351, bictegravir, AVX-15567, cabotegravir
(long-acting injectable), diketo quinolin-4-1 derivatives,
integrase-LEDGF inhibitor, ledgins, M-522, M-532, NSC-310217,
NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172,
NSC-699173, NSC-699174, stilbenedisulfonic acid, T-169 and
cabotegravir.
[0213] Examples of HIV non-catalytic site, or allosteric, integrase
inhibitors (NCINI) include CX-05045, CX-05168, and CX-14442.
[0214] HIV Entry Inhibitors
[0215] Examples of HIV entry (fusion) inhibitors include
cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment
inhibitors, gp120 inhibitors, and CXCR4 inhibitors.
[0216] Examples of CCR5 inhibitors include aplaviroc, vicriviroc,
maraviroc, cenicriviroc, PRO-140, adaptavir (RAP-101), nifeviroc
(TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07,
MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu).
[0217] Examples of gp41 inhibitors include albuvirtide,
enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide
biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2,
ITV-3, ITV-4, PIE-12 trimer and sifuvirtide.
[0218] Examples of CD4 attachment inhibitors include ibalizumab and
CADA analogs.
[0219] Examples of gp120 inhibitors include Radha-108 (receptol)
3B3-PE38, BanLec, bentonite-based nanomedicine, fostemsavir
tromethamine, IQP-0831, and BMS-663068.
[0220] Examples of CXCR4 inhibitors include plerixafor, ALT-1188,
N15 peptide, and vMIP (Haimipu).
[0221] HIV Maturation Inhibitors
[0222] Examples of HIV maturation inhibitors include BMS-955176 and
GSK-2838232.
[0223] Latency Reversing Agents
[0224] Examples of latency reversing agents include histone
deacetylase (HDAC) inhibitors, proteasome inhibitors such as
velcade, protein kinase C (PKC) activators, Smyd2 inhibitors,
BET-bromodomain 4 (BRD4) inhibitors, ionomycin, PMA, SAHA
(suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic
acid), AM-0015, ALT-803, NIZ-985, NKTR-255, IL-15 modulating
antibodies, JQ1, disulfiram, amphotericin B, and ubiquitin
inhibitors such as largazole analogs, and GSK-343.
[0225] Examples of HDAC inhibitors include romidepsin, vorinostat,
and panobinostat.
[0226] Examples of PKC activators include indolactam, prostratin,
ingenol B, and DAG-lactones.
[0227] Capsid Inhibitors
[0228] Examples of capsid inhibitors include capsid polymerization
inhibitors or capsid disrupting compounds, HIV nucleocapsid p7
(NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein
inhibitors, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15
series;
[0229] Immune-Based Therapies
[0230] Examples of immune-based therapies include toll-like
receptors modulators such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,
TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13; programmed cell
death protein 1 (Pd-1) modulators; programmed death-ligand 1
(Pd-L1) modulators; IL-15 modulators; DermaVir; interleukin-7;
plaquenil (hydroxychloroquine); proleukin (aldesleukin, IL-2);
interferon alfa; interferon alfa-2b; interferon alfa-n3; pegylated
interferon alfa; interferon gamma; hydroxyurea; mycophenolate
mofetil (MPA) and its ester derivative mycophenolate mofetil (MMF);
ribavirin; rintatolimod, polymer polyethyleneimine (PEI); gepon;
rintatolimod; IL-12; WF-10; VGV-1; MOR-22; BMS-936559; CYT-107,
interleukin-15/Fc fusion protein, normferon, peginterferon alfa-2a,
peginterferon alfa-2b, recombinant interleukin-15, RPI-MN, GS-9620,
STING modulators, RIG-I modulators, NOD2 modulators, and
IR-103.
[0231] Examples of TLR8 modulators include motolimod, resiquimod,
3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463 and those
disclosed in US20140045849 (Janssen), US20140073642 (Janssen),
WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189
(Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen),
US20080234251 (Array Biopharma), US20080306050 (Array Biopharma),
US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma),
US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma),
US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma),
US20140088085 (VentirxPharma), US20140275167 (Novira therapeutics),
US20130251673 (Novira therapeutics), U.S. Pat. No. 9,670,205
(Gilead Sciences Inc.), US20160289229 (Gilead Sciences Inc.), U.S.
patent application Ser. No. 15/692,161 (Gilead Sciences Inc.), and
U.S. patent application Ser. No. 15/692,093 (Gilead Sciences
Inc.).
[0232] Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
[0233] Examples of PI3K inhibitors include idelalisib, alpelisib,
buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib,
neratinib, panulisib, perifosine, pictilisib, pilaralisib,
puquitinib mesylate, rigosertib, rigosertib sodium, sonolisib,
taselisib, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457,
CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771,
INCB-040093, LY-3023414, MLN-1117, PQR-309, RG-7666, RP-6530,
RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB-5857,
VS-5584, XL-765, and ZSTK-474.
[0234] Alpha-4/Beta-7 Antagonists
[0235] Examples of Integrin alpha-4/beta-7 antagonists include
PTG-100, TRK-170, abrilumab, etrolizumab, carotegrast methyl, and
vedolizumab.
[0236] HIV Antibodies, Bispecific Antibodies, and "Antibody-Like"
Therapeutic Proteins
[0237] Examples of HIV antibodies, bispecific antibodies, and
"antibody-like" therapeutic proteins include DARTs.RTM.,
DUOBODIES.RTM., BITES.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives, bnABs (broadly neutralizing HIV-1 antibodies),
BMS-936559, TMB-360, and those targeting HIV gp120 or gp41,
antibody-Recruiting Molecules targeting HIV, anti-CD63 monoclonal
antibodies, anti-GB virus C antibodies, anti-GP120/CD4, CCR5
bispecific antibodies, anti-nef single domain antibodies, anti-Rev
antibody, camelid derived anti-CD18 antibodies, camelid-derived
anti-ICAM-1 antibodies, DCVax-001, gp140 targeted antibodies,
gp41-based HIV therapeutic antibodies, human recombinant mAbs
(PGT-121), ibalizumab, Immuglo, and MB-66.
[0238] Examples of those targeting HIV in such a manner include
bavituximab, UB-421, C2F5, 2G12, C4E10, C2F5+C2G12+C4E10, 8ANC195,
3BNC117, 3BNC60, 10-1074, PGT145, PGT121, PGT-151, PGT-133, MDXO10
(ipilimumab), DH511, N6, VRCO1 PGDM1400, A32, 7B2, 10E8, 10E8v4,
CAP256-VRC26.25, DRVIA7, VRC-07-523, VRC-HIVMABO80-00-AB,
VRC-HIVMAB060-00-AB, MGD-014 and VRC07. Example of HIV bispecific
antibodies include MGD014.
[0239] Pharmacokinetic Enhancers
[0240] Examples of pharmacokinetic enhancers include cobicistat and
ritonavir.
[0241] HIV Vaccines
[0242] Examples of HIV vaccines include peptide vaccines,
recombinant subunit protein vaccines, live vector vaccines, DNA
vaccines, CD4-derived peptide vaccines, vaccine combinations,
rgp120 (AIDSVAX), ALVAC HIV (vCP1521)/AIDSVAX B/E (gp120) (RV144),
monomeric gp120 HIV-1 subtype C vaccine, Remune, ITV-1, Contre Vir,
Ad5-ENVA-48, DCVax-001 (CDX-2401), Vacc-4x, Vacc-C5, VAC-3S,
multiclade DNA recombinant adenovirus-5 (rAd5), Pennvax-G,
Pennvax-GP, HIV-TriMix-mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN,
NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImmune,
GTU-multiHIV (FIT-06), gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag
vaccine, SeV-Gag vaccine, AT-20, DNK-4, ad35-Grin/ENV, TBC-M4,
HIVAX, HIVAX-2, NYVAC--HIV-PT1, NYVAC--HIV-PT4, DNA-HIV-PT123,
rAAV1-PG9DP, GOVX-B11, GOVX-B21, TVI-HIV-1, Ad-4 (Ad4-env Clade
C+Ad4-mGag), EN41-UGR7C, EN41-FPA2, PreVaxTat, AE-H, MYM-V101,
CombiHIVvac, ADVAX, MYM-V201, MVA-CMDR, DNA-Ad5 gag/pol/nef/nev
(HVTN505), MVATG-17401, ETV-01, CDX-1401, rcAD26.MOSI.HIV-Env,
Ad26.Mod.HIV vaccine, AGS-004, AVX-101, AVX-201, PEP-6409, SAV-001,
ThV-01, TL-01, TUTI-16, VGX-3300, IHV-001, and virus-like particle
vaccines such as pseudovirion vaccine, CombiVICHvac, LFn-p24 B/C
fusion vaccine, GTU-based DNA vaccine, HIV gag/pol/nef/env DNA
vaccine, anti-TAT HIV vaccine, conjugate polypeptides vaccine,
dendritic-cell vaccines, gag-based DNA vaccine, GI-2010, gp41 HIV-1
vaccine, HIV vaccine (PIKA adjuvant), I i-key/MHC class II epitope
hybrid peptide vaccines, ITV-2, ITV-3, ITV-4, LIPO-5, multiclade
Env vaccine, MVA vaccine, Pennvax-GP, pp71-deficient HCMV vector
HIV gag vaccine, recombinant peptide vaccine (HIV infection), NCI,
rgp160 HIV vaccine, RNActive HIV vaccine, SCB-703, Tat Oyi vaccine,
TBC-M4, therapeutic HIV vaccine, UBI HIV gp120, Vacc-4x+romidepsin,
variant gp120 polypeptide vaccine, rAd5 gag-pol env A/B/C vaccine,
DNA.HTI and MVA.HTI.
[0243] Additional HIV Therapeutic Agents
[0244] Examples of additional HIV therapeutic agents include the
compounds disclosed in WO 2004/096286 (Gilead Sciences), WO
2006/015261 (Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO
2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences), WO
2012/145728 (Gilead Sciences), WO 2013/006738 (Gilead Sciences), WO
2013/159064 (Gilead Sciences), WO 2014/100323 (Gilead Sciences), US
2013/0165489 (University of Pennsylvania), US 2014/0221378 (Japan
Tobacco), US 2014/0221380 (Japan Tobacco), WO 2009/062285
(Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO
2013/006792 (Pharma Resources), US 20140221356 (Gilead Sciences),
US 20100143301 (Gilead Sciences) and WO 2013/091096 (Boehringer
Ingelheim).
[0245] Examples of other drugs for treating HIV include acemannan,
alisporivir, BanLec, deferiprone, Gamimune, metenkefalin,
naltrexone, Prolastin, REP 9, RP-MN, VSSP, Hlviral, SB-728-T,
1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene
therapy, MazF gene therapy, BlockAide, ABX-464, AG-1105, APH-0812,
BIT-225, CYT-107, HGTV-43, HPH-116, HS-10234, IMO-3100, IND-02,
MK-1376, MK-8507, MK-8591, NOV-205, PA-1050040 (PA-040), PGN-007,
SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111,
TEV-90113, RN-18, Immuglo, and VIR-576.
[0246] Gene Therapy and Cell Therapy
[0247] Gene Therapy and Cell Therapy include the genetic
modification to silence a gene; genetic approaches to directly kill
the infected cells; the infusion of immune cells designed to
replace most of the subject's own immune system to enhance the
immune response to infected cells, or activate the subject's own
immune system to kill infected cells, or find and kill the infected
cells; genetic approaches to modify cellular activity to further
alter endogenous immune responsiveness against the infection.
[0248] Examples of dendritic cell therapy include AGS-004.
[0249] Gene Editors
[0250] Examples of gene editing systems include a CRISPR/Cas9
system, a zinc finger nuclease system, a TALEN system, a homing
endonucleases system, and a meganuclease system.
[0251] Examples of HIV targeting CRISPR/Cas9 systems include
EBT101.
[0252] CAR-T Cell Therapy
[0253] CAR-T cell therapy includes a population of immune effector
cells engineered to express a chimeric antigen receptor (CAR),
wherein the CAR comprises an HIV antigen-binding domain. The HIV
antigen include an HIV envelope protein or a portion thereof, gp120
or a portion thereof, a CD4 binding site on gp120, the CD4-induced
binding site on gp120, N glycan on gp120, the V2 of gp120, the
membrane proximal region on gp41. The immune effector cell is a T
cell or an NK cell. In some embodiments, the T cell is a CD4+ T
cell, a CD8+ T cell, or a combination thereof.
[0254] Examples of HIV CAR-T include VC-CAR-T.
TCR-T Cell Therapy
[0255] TCR-T cell therapy includes T cells engineered to target HIV
derived peptides present on the surface of virus-infected
cells.
[0256] It will be appreciated by one of skill in the art that the
additional therapeutic agents listed above may be included in more
than one of the classes listed above. The particular classes are
not intended to limit the functionality of those compounds listed
in those classes.
[0257] In a specific embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with an HIV
nucleoside or nucleotide inhibitor of reverse transcriptase and an
HIV non-nucleoside inhibitor of reverse transcriptase. In another
specific embodiment, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with an HIV
nucleoside or nucleotide inhibitor of reverse transcriptase, and an
HIV protease inhibiting compound. In an additional embodiment, a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, is combined with an HIV nucleoside or nucleotide inhibitor
of reverse transcriptase, an HIV non-nucleoside inhibitor of
reverse transcriptase, and a pharmacokinetic enhancer. In certain
embodiments, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with at least one HIV
nucleoside inhibitor of reverse transcriptase, an integrase
inhibitor, and a pharmacokinetic enhancer. In another embodiment, a
compound disclosed herein, or a pharmaceutically acceptable salt
thereof, is combined with two HIV nucleoside or nucleotide
inhibitors of reverse transcriptase.
[0258] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with one,
two, three, four or more additional therapeutic agents selected
from ATRIPLA.RTM. (efavirenz, tenofovir disoproxil fumarate, and
emtricitabine); COMPLERA.RTM. (EVIPLERA.RTM.; rilpivirine,
tenofovir disoproxil fumarate, and emtricitabine); STRIBILD.RTM.
(elvitegravir, cobicistat, tenofovir disoproxil fumarate, and
emtricitabine); TRUVADA.RTM. (tenofovir disoproxil fumarate and
emtricitabine; TDF+FTC); DESCOVY.RTM. (tenofovir alafenamide and
emtricitabine); ODEFSEY.RTM. (tenofovir alafenamide, emtricitabine,
and rilpivirine); GENVOYA.RTM. (tenofovir alafenamide,
emtricitabine, cobicistat, and elvitegravir); BIKTARVY.RTM.
(bictegravir, emtricitabine, tenofovir alafenamide); adefovir;
adefovir dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovir
disoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide;
tenofovir alafenamide hemifumarate; TRIUMEQ.RTM. (dolutegravir,
abacavir, and lamivudine); dolutegravir, abacavir sulfate, and
lamivudine; raltegravir; raltegravir and lamivudine; maraviroc;
enfuvirtide; ALUVIA.RTM. (KALETRA.RTM.; lopinavir and ritonavir);
COMBIVIR.RTM. (zidovudine and lamivudine; AZT+3TC); EPZICOM.RTM.
(LIVEXA.RTM.; abacavir sulfate and lamivudine; ABC+3TC);
TRIZIVR.RTM. (abacavir sulfate, zidovudine, and lamivudine;
ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir
sulfate and cobicistat; atazanavir and cobicistat; darunavir and
cobicistat; atazanavir; atazanavir sulfate; dolutegravir;
elvitegravir; ritonavir; atazanavir sulfate and ritonavir;
darunavir; lamivudine; prolastin; fosamprenavir; fosamprenavir
calcium efavirenz; etravirine; nelfinavir; nelfinavir mesylate;
interferon; didanosine; stavudine; indinavir; indinavir sulfate;
tenofovir and lamivudine; zidovudine; nevirapine; saquinavir;
saquinavir mesylate; aldesleukin; zalcitabine; tipranavir;
amprenavir; delavirdine; delavirdine mesylate; Radha-108
(receptol); lamivudine and tenofovir disoproxil fumarate;
efavirenz, lamivudine, and tenofovir disoproxil fumarate;
phosphazid; lamivudine, nevirapine, and zidovudine; abacavir; and
abacavir sulfate.
[0259] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with
abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir
disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir
alafenamide, tenofovir alafenamide hemifumarate, or
bictegravir.
[0260] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with
tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate,
tenofovir alafenamide, tenofovir alafenamide hemifumarate, or
bictegravir.
[0261] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with a
first additional therapeutic agent selected from the group
consisting of abacavir sulfate, tenofovir, tenofovir disoproxil,
tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir
alafenamide hemifumarate, and bictegravir and a second additional
therapeutic agent selected from the group consisting of
emtricitabine and lamivudine.
[0262] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with a
first additional therapeutic agent selected from the group
consisting of tenofovir, tenofovir disoproxil, tenofovir disoproxil
fumarate, tenofovir alafenamide, tenofovir alafenamide
hemifumarate, and bictegravir and a second additional therapeutic
agent, wherein the second additional therapeutic agent is
emtricitabine.
[0263] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 5-30 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide, and 200 mg emtricitabine. In certain
embodiments, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with 5-10, 5-15, 5-20, 5-25,
25-30, 20-30, 15-30, or 10-30 mg tenofovir alafenamide fumarate,
tenofovir alafenamide hemifumarate, or tenofovir alafenamide, and
200 mg emtricitabine. In certain embodiments, a compound disclosed
herein, or a pharmaceutically acceptable salt thereof, is combined
with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, or tenofovir alafenamide, and 200 mg emtricitabine.
In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 25 mg
tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate,
or tenofovir alafenamide, and 200 mg emtricitabine. A compound as
disclosed herein may be combined with the agents provided herein in
any dosage amount of the compound (e.g., from 1 mg to 500 mg of
compound) the same as if each combination of dosages were
specifically and individually listed.
[0264] In certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 200-400
mg tenofovir disoproxil fumarate, tenofovir disoproxil
hemifumarate, or tenofovir disoproxil, and 200 mg emtricitabine. In
certain embodiments, a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, is combined with 200-250,
200-300, 200-350, 250-350, 250-400, 350-400, 300-400, or 250-400 mg
tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate,
or tenofovir disoproxil, and 200 mg emtricitabine. In certain
embodiments, a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, is combined with 300 mg tenofovir
disoproxil fumarate, tenofovir disoproxil hemifumarate, or
tenofovir disoproxil, and 200 mg emtricitabine. A compound as
disclosed herein may be combined with the agents provided herein in
any dosage amount of the compound (e.g., from 1 mg to 500 mg of
compound) the same as if each combination of dosages were
specifically and individually listed.
HBV Combination Therapy
[0265] In certain embodiments, a method for treating or preventing
an HBV infection in a human having or at risk of having the
infection is provided, comprising administering to the human a
therapeutically effective amount of a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, four, one or two, one to three, or one to four) additional
therapeutic agents. In one embodiment, a method for treating an HBV
infection in a human having or at risk of having the infection is
provided, comprising administering to the human a therapeutically
effective amount of a compound disclosed herein, or a
pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more (e.g., one, two,
three, four, one or two, one to three, or one to four) additional
therapeutic agents.
[0266] In certain embodiments, the present disclosure provides a
method for treating an HBV infection, comprising administering to a
patient in need thereof a therapeutically effective amount of a
compound disclosed herein or a pharmaceutically acceptable salt
thereof, in combination with a therapeutically effective amount of
one or more (e.g., one, two, three, four, one or two, one to three,
or one to four) additional therapeutic agents which are suitable
for treating an HBV infection.
[0267] The compounds described herein may be used or combined with
one or more of a chemotherapeutic agent, an immunomodulator, an
immunotherapeutic agent, a therapeutic antibody, a therapeutic
vaccine, a bispecific antibody and "antibody-like" therapeutic
protein (such as DARTs.RTM., Duobodies.RTM., Bites.RTM.,
XmAbs.RTM., TandAbs.RTM., Fab derivatives), an antibody-drug
conjugate (ADC), gene modifiers or gene editors (such as CRISPR
Cas9, zinc finger nucleases, homing endonucleases, synthetic
nucleases, TALENs), cell therapies such as CAR-T (chimeric antigen
receptor T-cell), and TCR-T (an engineered T cell receptor) agent
or any combination thereof.
[0268] In certain embodiments, a compound described herein is
formulated as a tablet, which may optionally contain one or more
other compounds useful for treating HBV. In certain embodiments,
the tablet can contain another active ingredient for treating HBV,
such as 3-dioxygenase (IDO) inhibitors, Apolipoprotein A1
modulator, arginase inhibitors, B- and T-lymphocyte attenuator
inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, CCR2
chemokine antagonist, CD137 inhibitors, CD160 inhibitors, CD305
inhibitors, CD4 agonist and modulator, compounds targeting HBcAg,
compounds targeting hepatitis B core antigen (HBcAg), core protein
allosteric modulators, covalently closed circular DNA (cccDNA)
inhibitors, cyclophilin inhibitors, cytotoxic
T-lymphocyte-associated protein 4 (ipi4) inhibitors, DNA polymerase
inhibitor, Endonuclease modulator, epigenetic modifiers, Farnesoid
X receptor agonist, HBsAg inhibitors, HBsAg secretion or assembly
inhibitors, HBV DNA polymerase inhibitors, HBV replication
inhibitors, HBV RNAse inhibitors, HBV viral entry inhibitors, HBx
inhibitors, Hepatitis B large envelope protein modulator, Hepatitis
B large envelope protein stimulator, Hepatitis B structural protein
modulator, hepatitis B surface antigen (HBsAg) inhibitors,
hepatitis B surface antigen (HBsAg) secretion or assembly
inhibitors, hepatitis B virus E antigen inhibitors, hepatitis B
virus replication inhibitors, Hepatitis virus structural protein
inhibitor, HIV-1 reverse transcriptase inhibitor, Hyaluronidase
inhibitor, IAPs inhibitors, IL-2 agonist, IL-7 agonist,
immunomodulators, indoleamine-2 inhibitors, inhibitors of
ribonucleotide reductase, Interleukin-2 ligand, ipi4 inhibitors,
lysine demethylase inhibitors, histone demethylase inhibitors, KDM1
inhibitors, KDM5 inhibitors, killer cell lectin-like receptor
subfamily G member 1 inhibitors, lymphocyte-activation gene 3
inhibitors, lymphotoxin beta receptor activators, modulators of
Axl, modulators of B7-H3, modulators of B7-H4, modulators of CD160,
modulators of CD161, modulators of CD27, modulators of CD47,
modulators of CD70, modulators of GITR, modulators of HEVEM,
modulators of ICOS, modulators of Mer, modulators of NKG2A,
modulators of NKG2D, modulators of OX40, modulators of SIRPalpha,
modulators of TIGIT, modulators of Tim-4, modulators of Tyro,
Na+-taurocholate cotransporting polypeptide (NTCP) inhibitors,
natural killer cell receptor 2B4 inhibitors, NOD2 gene stimulator,
Nucleoprotein inhibitor, nucleoprotein modulators, PD-1 inhibitors,
PD-L1 inhibitors, Peptidylprolyl isomerase inhibitor,
phosphatidylinositol-3 kinase (PI3K) inhibitors, Retinoic
acid-inducible gene 1 stimulator, Reverse transcriptase inhibitor,
Ribonuclease inhibitor, RNA DNA polymerase inhibitor, SLC10A1 gene
inhibitor, SMAC mimetics, Src tyrosine kinase inhibitor, stimulator
of interferon gene (STING) agonists, stimulators of NOD1, T cell
surface glycoprotein CD28 inhibitor, T-cell surface glycoprotein
CD8 modulator, Thymosin agonist, Thymosin alpha 1 ligand, Tim-3
inhibitors, TLR-3 agonist, TLR-7 agonist, TLR-9 agonist, TLR9 gene
stimulator, toll-like receptor (TLR) modulators, Viral
ribonucleotide reductase inhibitor, and combinations thereof.
[0269] HBV Combination Drugs
[0270] Examples of combination drugs for the treatment of HBV
include TRUVADA.RTM. (tenofovir disoproxil fumarate and
emtricitabine); ABX-203, lamivudine, and PEG-IFN-alpha; ABX-203
adefovir, and PEG-IFNalpha; and INO-1800 (INO-9112 and RG7944).
[0271] Other HBV Drugs
[0272] Examples of other drugs for the treatment of HBV include
alpha-hydroxytropolones, amdoxovir, beta-hydroxycytosine
nucleosides, AL-034, CCC-0975, elvucitabine, ezetimibe, cyclosporin
A, gentiopicrin (gentiopicroside), JNJ-56136379, nitazoxanide,
birinapant, NJK14047, NOV-205 (molixan, BAM-205), oligotide,
mivotilate, feron, GST-HG-131, levamisole, Ka Shu Ning, alloferon,
WS-007, Y-101 (Ti Fen Tai), rSIFN-co, PEG-IIFNm, KW-3,
BP-Inter-014, oleanolic acid, HepB-nRNA, cTP-5 (rTP-5), HSK-II-2,
HEISCO-106-1, HEISCO-106, Hepbarna, IBPB-0061A, Hepuyinfen,
DasKloster 0014-01, ISA-204, Jiangantai (Ganxikang), MIV-210,
OB-AI-004, PF-06, picroside, DasKloster-0039, hepulantai, IMB-2613,
TCM-800B, reduced glutathione, RO-6864018, RG-7834, UB-551, and
ZH-2N, and the compounds disclosed in US20150210682, (Roche), US
2016/0122344 (Roche), WO2015173164, WO2016023877, US2015252057A
(Roche), WO16128335A1 (Roche), WO16120186A1 (Roche), US2016237090A
(Roche), WO16107833A1 (Roche), WO16107832A1 (Roche), US2016176899A
(Roche), WO16102438A1 (Roche), WO16012470A1 (Roche), US2016220586A
(Roche), and US2015031687A (Roche).
[0273] HBV Vaccines
[0274] HBV vaccines include both prophylactic and therapeutic
vaccines. Examples of HBV prophylactic vaccines include Vaxelis,
Hexaxim, Heplisav, Mosquirix, DTwP-HBV vaccine, Bio-Hep-B,
D/T/P/HBV/M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine,
Heberpenta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabhay,
hepatitis B prophylactic vaccine (Advax Super D), Hepatrol-07,
GSK-223192A, ENGERIX B.RTM., recombinant hepatitis B vaccine
(intramuscular, Kangtai Biological Products), recombinant hepatitis
B vaccine (Hansenual polymorpha yeast, intramuscular, Hualan
Biological Engineering), recombinant hepatitis B surface antigen
vaccine, Bimmugen, Euforavac, Eutravac, anrix-DTaP-IPV-Hep B,
HBAI-20, Infanrix-DTaP-IPV-Hep B-Hib, Pentabio Vaksin DTP-HB-Hib,
Comvac 4, Twinrix, Euvax-B, Tritanrix HB, Infanrix Hep B, Comvax,
DTP-Hib-HBV vaccine, DTP-HBV vaccine, Yi Tai, Heberbiovac HB,
Trivac HB, GerVax, DTwP-Hep B-Hib vaccine, Bilive, Hepavax-Gene,
SUPERVAX, Comvac5, Shanvac-B, Hebsulin, Recombivax HB, Revac B mcf,
Revac B+, Fendrix, DTwP-HepB-Hib, DNA-001, Shan5, Shan6, rhHBsAG
vaccine, HBI pentavalent vaccine, LBVD, Infanrix HeXa, and
DTaP-rHB-Hib vaccine.
[0275] Examples of HBV therapeutic vaccines include HBsAG-HBIG
complex, ARB-1598, Bio-Hep-B, NASVAC, abi-HB (intravenous),
ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine
(epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC,
Revac B mcf, Revac B+, MGN-1333, KW-2, CVI-HBV-002, AltraHepB,
VGX-6200, FP-02, FP-02.2, TG-1050, NU-500, HBVax,
im/TriGrid/antigen vaccine, Mega-CD40L-adjuvanted vaccine, HepB-v,
RG7944 (INO-1800), recombinant VLP-based therapeutic vaccine (HBV
infection, VLP Biotech), AdTG-17909, AdTG-17910 AdTG-18202,
ChronVac-B, TG-1050, and Lm HBV.
[0276] HBV DNA Polymerase Inhibitors
[0277] Examples of HBV DNA polymerase inhibitors include adefovir
(HEPSERA.RTM.), emtricitabine (EMTRIVA.RTM.), tenofovir disoproxil
fumarate (VIREAD.RTM.), tenofovir alafenamide, tenofovir, tenofovir
disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide
hemifumarate, tenofovir dipivoxil, tenofovir dipivoxil fumarate,
tenofovir octadecyloxyethyl ester, CMX-157, besifovir, entecavir
(BARACLUDE.RTM.), entecavir maleate, telbivudine (TYZEKA.RTM.),
filocilovir, pradefovir, clevudine, ribavirin, lamivudine
(EPIVIR-HBV.RTM.), phosphazide, famciclovir, fusolin, metacavir,
SNC-019754, FMCA, AGX-1009, AR-II-04-26, HIP-1302, tenofovir
disoproxil aspartate, tenofovir disoproxil orotate, and
HS-10234.
[0278] Immunomodulators
[0279] Examples of immunomodulators include rintatolimod, imidol
hydrochloride, ingaron, dermaVir, plaquenil (hydroxychloroquine),
proleukin, hydroxyurea, mycophenolate mofetil (MPA) and its ester
derivative mycophenolate mofetil (MMF), JNJ-440, WF-10, AB-452,
ribavirin, IL-12, INO-9112, polymer polyethyleneimine (PEI), Gepon,
VGV-1, MOR-22, CRV-431, JNJ-0535, TG-1050, ABI-H2158, BMS-936559,
RO-7011785, RG-7854, AB-506, RO-6871765, AIC-649, and IR-103.
[0280] Toll-Like Receptor (TLR) Modulators
[0281] TLR modulators include modulators of TLR1, TLR2, TLR3, TLR4,
TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13.
Examples of TLR3 modulators include rintatolimod, poly-ICLC,
RIBOXXON.RTM., Apoxxim, RIBOXXIM.RTM., IPH-33, MCT-465, MCT-475,
and ND-1.1.
[0282] Examples of TLR7 modulators include GS-9620, GSK-2245035,
imiquimod, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465,
MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, D, telratolimod,
SP-0509, TMX-30X, TMX-202, RG-7863, RG-7795, LHC-165, RG-7854, and
the compounds disclosed in US20100143301 (Gilead Sciences),
US20110098248 (Gilead Sciences), and US20090047249 (Gilead
Sciences).
[0283] Examples of TLR8 modulators include motolimod, resiquimod,
3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, VTX-1463, and the
compounds disclosed in US20140045849 (Janssen), US20140073642
(Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen),
WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813
(Janssen), US20080234251 (Array Biopharma), US20080306050 (Array
Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx
Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx
Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx
Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira
Therapeutics), US20130251673 (Novira Therapeutics), U.S. Pat. No.
9,670,205, US20160289229, U.S. patent application Ser. No.
15/692,161, and U.S. patent application Ser. No. 15/692,093.
[0284] Examples of TLR9 modulators include BB-001, BB-006, CYT-003,
IMO-2055, IMO-2125, IMO-3100, IMO-8400, IR-103, IMO-9200,
agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod
(MGN-1703), litenimod, and CYT-003-QbG10.
[0285] Examples of TLR7, TLR8 and TLR9 modulators include the
compounds disclosed in WO2017047769 (Teika Seiyaku), WO2015014815
(Janssen), WO2018045150 (Gilead Sciences Inc), WO2018045144 (Gilead
Sciences Inc), W2015162075 (Roche), WO2017034986 (University of
Kansas), WO2018095426 (Jiangsu Hengrui Medicine Co Ltd),
WO2016091698 (Roche), WO2016075661 (GaxoSmithKline Biologicals),
WO2016180743 (Roche), WO2018089695 (Dynavax Technologies),
WO2016055553 (Roche), WO2015168279 (Novartis), WO2016107536
(Medshine Discovery), WO2018086593 (Livo (Shanghai)
Pharmaceutical), WO2017106607 (Merck), WO2017061532 (Sumitomo
Dainippon Pharma), WO2016023511 (Chia Tai Tianqing Pharmaceutical),
WO2017076346 (Chia Tai Tianqing Pharmaceutical), WO2017046112
(Roche), WO2018078149 (Roche), WO2017040233 (3M Co), WO2016141092
(Gilead Sciences), WO2018049089 (Bristol Myers Squibb),
WO2015057655 (Eisai Co Ltd), WO2017001307 (Roche), WO2018005586
(Bristol Myers Squibb), WO201704023 (3M Co), WO2017163264 (Council
of Scientific and Industrial Research (India)), WO2018046460
(GlaxoSmithKline Biologicals), WO2018047081 (Novartis),
WO2016142250 (Roche), WO2015168269 (Novartis), WO201804163 (Roche),
WO2018038877 (3M Co), WO2015057659 (Eisai Co Ltd), WO2017202704
(Roche), WO2018026620 (Bristol Myers Squibb), WO2016029077 (Janus
Biotherapeutics), WO201803143 (Merck), WO2016096778 (Roche),
WO2017190669 (Shanghai De Novo Pharmatech), U.S. Ser. No.
09/884,866 (University of Minnesota), WO2017219931 (Sichuan
KelunBiotech Biopharmaceutical), WO2018002319 (Janssen Sciences),
WO2017216054 (Roche), WO2017202703 (Roche), WO2017184735 (IFM
Therapeutics), WO2017184746 (IFM Therapeutics), WO2015088045
(Takeda Pharmaceutical), WO2017038909 (Takeda Pharmaceutical),
WO2015095780 (University of Kansas), WO2015023958 (University of
Kansas).
[0286] Interferon Alpha Receptor Ligands
[0287] Examples of interferon alpha receptor ligands include
interferon alpha-2b (INTRON A.RTM.), pegylated interferon alpha-2a
(PEGASYS.RTM.), PEGylated interferon alpha-1b, interferon alpha 1b
(HAPGEN.RTM.), Veldona, Infradure, Roferon-A, YPEG-interferon
alfa-2a (YPEG-rhIFNalpha-2a), P-1101, Algeron, Alfarona, Ingaron
(interferon gamma), rSIFN-co (recombinant super compound
interferon), Ypeginterferon alfa-2b (YPEG-rhIFNalpha-2b), MOR-22,
peginterferon alfa-2b (PEG-INTRON.RTM.), Bioferon, Novaferon,
Inmutag (Inferon), MULTIFERON.RTM., interferon alfa-n1 (HUMOFERON),
interferon beta-1a (AVONEX.RTM.), Shaferon, interferon alfa-2b
(Axxo), Alfaferone, interferon alfa-2b (BioGeneric Pharma),
interferon-alpha 2 (CJ), Laferonum, VIPEG, BLAUFERON-A,
BLAUFERON-B, Intermax Alpha, Realdiron, Lanstion, Pegaferon,
PDferon-B, interferon alfa-2b (IFN, Laboratorios Bioprofarma),
alfainterferona 2b, Kalferon, Pegnano, Feronsure, PegiHep,
interferon alfa 2b (Zydus-Cadila), interferon alfa 2a, Optipeg A,
Realfa 2B, Reliferon, interferon alfa-2b (Amega), interferon
alfa-2b (Virchow), ropeginterferon alfa-2b, rHSA-IFN alpha-2a
(recombinant human serum albumin interferon alpha 2a fusion
protein), rHSA-IFN alpha 2b, recombinant human interferon
alpha-(1b, 2a, 2b), peginterferon alfa-2b (Amega), peginterferon
alfa-2a, Reaferon-EC, Proquiferon, Uniferon, Urifron, interferon
alfa-2b (Changchun Institute of Biological Products), Anterferon,
Shanferon, Layfferon, Shang Sheng Lei Tai, INTEFEN, SINOGEN,
Fukangtai, Pegstat, rHSA-IFN alpha-2b, SFR-9216, and Interapo
(Interapa).
[0288] Hyaluronidase Inhibitors
[0289] Examples of hyaluronidase inhibitors include astodrimer.
[0290] Hepatitis B Surface Antigen (HBsAg) Inhibitors
[0291] Examples of HBsAg inhibitors include HBF-0259, PBHBV-001,
PBHBV-2-15, PBHBV-2-1, REP-9AC, REP-9C, REP-9, REP-2139,
REP-2139-Ca, REP-2165, REP-2055, REP-2163, REP-2165, REP-2053,
REP-2031 and REP-006, and REP-9AC'.
[0292] Examples of HBsAg secretion inhibitors include BM601.
[0293] Cytotoxic T-Lymphocyte-Associated Protein 4 (Ipi4)
Inhibitors
[0294] Examples of Cytotoxic T-lymphocyte-associated protein 4
(ipi4) inhibitors include AGEN-2041, AGEN-1884, ipilumimab,
belatacept, PSI-001, PRS-010, Probody mAbs, tremelimumab, and
JHL-1155.
[0295] Cyclophilin Inhibitors
[0296] Examples of cyclophilin inhibitors include CPI-431-32,
EDP-494, OCB-030, SCY-635, NVP-015, NVP-018, NVP-019, STG-175, and
the compounds disclosed in U.S. Pat. No. 8,513,184 (Gilead
Sciences), US20140030221 (Gilead Sciences), US20130344030 (Gilead
Sciences), and US20130344029 (Gilead Sciences).
[0297] HBV Viral Entry Inhibitors
[0298] Examples of HBV viral entry inhibitors include Myrcludex
B.
[0299] Antisense Oligonucleotide Targeting Viral mRNA
[0300] Examples of antisense oligonucleotide targeting viral mRNA
include ISIS-HBVRx, IONIS-HBVRx, IONIS-GSK6-LRx, GSK-3389404,
RG-6004.
[0301] Short Interfering RNAs (siRNA) and ddRNAi.
[0302] Examples of siRNA include TKM-HBV (TKM-HepB), ALN-HBV,
SR-008, HepB-nRNA, and ARC-520, ARC-521, ARB-1740, ARB-1467.
[0303] Examples of DNA-directed RNA interference (ddRNAi) include
BB-HB-331.
[0304] Endonuclease Modulators
[0305] Examples of endonuclease modulators include PGN-514.
[0306] Ribonucleotide Reductase Inhibitors
[0307] Examples of inhibitors of ribonucleotide reductase include
Trimidox.
[0308] HBV E Antigen Inhibitors
[0309] Examples of HBV E antigen inhibitors include wogonin.
[0310] Covalently Closed Circular DNA (cccDNA) Inhibitors
[0311] Examples of cccDNA inhibitors include BSBI-25, and
CHR-101.
[0312] Farnesoid X Receptor Agonist
[0313] Examples of farnesoid x receptor agonist such as EYP-001,
GS-9674, EDP-305, MET-409, Tropifexor, AKN-083, RDX-023, BWD-100,
LMB-763, INV-3, NTX-023-1, EP-024297 and GS-8670.
[0314] HBV Antibodies
[0315] Examples of HBV antibodies targeting the surface antigens of
the hepatitis B virus include GC-1102, XTL-17, XTL-19, KN-003, IV
Hepabulin SN, and fully human monoclonal antibody therapy
(hepatitis B virus infection, Humabs BioMed).
[0316] Examples of HBV antibodies, including monoclonal antibodies
and polyclonal antibodies, include Zutectra, Shang Sheng Gan Di,
Uman Big (Hepatitis B Hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect
CP, HepaGam B, igantibe, Niuliva, CT-P24, hepatitis B
immunoglobulin (intravenous, pH4, HBV infection, Shanghai RAAS
Blood Products), and Fovepta (BT-088).
[0317] Fully human monoclonal antibodies include HBC-34.
[0318] CCR2 Chemokine Antagonists
[0319] Examples of CCR2 chemokine antagonists include
propagermanium.
[0320] Thymosin Agonists
[0321] Examples of thymosin agonists include Thymalfasin,
recombinant thymosin alpha 1 (GeneScience).
[0322] Cytokines
[0323] Examples of cytokines include recombinant IL-7, CYT-107,
interleukin-2 (IL-2, Immunex), recombinant human interleukin-2
(Shenzhen Neptunus), IL-15, IL-21, IL-24, and celmoleukin.
[0324] Nucleoprotein Modulators
[0325] Nucleoprotein modulators may be either HBV core or capsid
protein inhibitors. Examples of nucleoprotein modulators include
GS-4882, AB-423, AT-130, GLS4, NVR-1221, NVR-3778, AL-3778, BAY
41-4109, morphothiadine mesilate, ARB-168786, ARB-880, JNJ-379,
RG-7907, HEC-72702, AB-506, ABI-H0731, JNJ-440, ABI-H2158 and
DVR-23.
[0326] Examples of capsid inhibitors include the compounds
disclosed in US20140275167 (Novira Therapeutics), US20130251673
(Novira Therapeutics), US20140343032 (Roche), WO2014037480 (Roche),
US20130267517 (Roche), W2014131847 (Janssen), WO2014033176
(Janssen), W2014033170 (Janssen), W2014033167 (Janssen),
WO2015/059212 (Janssen), WO2015118057 (Janssen), WO2015011281
(Janssen), WO2014184365 (Janssen), WO2014184350 (Janssen),
WO2014161888 (Janssen), WO2013096744 (Novira), US20150225355
(Novira), US20140178337 (Novira), US20150315159 (Novira),
US20150197533 (Novira), US20150274652 (Novira), US20150259324,
(Novira), US20150132258 (Novira), U.S. Pat. No. 9,181,288 (Novira),
WO2014184350 (Janssen), WO2013144129 (Roche), WO2017198744 (Roche),
US 20170334882 (Novira), US 20170334898 (Roche), WO2017202798
(Roche), WO2017214395 (Enanta), WO2018001944 (Roche), WO2018001952
(Roche), WO2018005881 (Novira), WO2018005883 (Novira), WO2018011100
(Roche), WO2018011160 (Roche), WO2018011162 (Roche), WO2018011163
(Roche), WO2018036941 (Roche), WO2018043747 (Kyoto Univ),
US20180065929 (Janssen), WO2016168619 (Indiana University),
WO2016195982 (The Penn State Foundation), WO2017001655 (Janssen),
WO2017048950 (Assembly Biosciences), WO2017048954 (Assembly
Biosciences), WO2017048962 (Assembly Biosciences), US20170121328
(Novira), US20170121329 (Novira).
[0327] Examples of transcript inhibitors include the compounds
disclosed in WO2017013046 (Roche), WO2017016960 (Roche),
WO2017017042 (Roche), WO2017017043 (Roche), WO2017061466 (Toyoma
chemicals), WO2016177655 (Roche), WO2016161268 (Enanta).
WO2017001853 (Redex Pharma), WO2017211791 (Roche), WO2017216685
(Novartis), WO2017216686 (Novartis), WO2018019297 (Ginkgo Pharma),
WO2018022282 (Newave Pharma), US20180030053 (Novartis),
WO2018045911 (Zhejiang Pharma).
[0328] Retinoic Acid-Inducible Gene 1 Stimulators
[0329] Examples of stimulators of retinoic acid-inducible gene 1
include SB-9200, SB-40, SB-44, ORI-7246, ORI-9350, ORI-7537,
ORI-9020, ORI-9198, and ORI-7170, RGT-100.
[0330] NOD2 Stimulators
[0331] Examples of stimulators of NOD2 include SB-9200.
[0332] Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
[0333] Examples of PI3K inhibitors include idelalisib, ACP-319,
AZD-8186, AZD-8835, buparlisib, CDZ-173, CLR-457, pictilisib,
neratinib, rigosertib, rigosertib sodium, EN-3342, TGR-1202,
alpelisib, duvelisib, IPI-549, UCB-5857, taselisib, XL-765,
gedatolisib, ME-401, VS-5584, copanlisib, CAI orotate, perifosine,
RG-7666, GSK-2636771, DS-7423, panulisib, GSK-2269557, GSK-2126458,
CUDC-907, PQR-309, INCB-40093, pilaralisib, BAY-1082439, puquitinib
mesylate, SAR-245409, AMG-319, RP-6530, ZSTK-474, MLN-1117,
SF-1126, RV-1729, sonolisib, LY-3023414, SAR-260301, TAK-117,
HMPL-689, tenalisib, voxtalisib, and CLR-1401.
[0334] Indoleamine-2, 3-Dioxygenase (IDO) Pathway Inhibitors
[0335] Examples of IDO inhibitors include epacadostat (INCB24360),
resminostat (4SC-201), indoximod, F-001287, SN-35837, NLG-919,
GDC-0919, GBV-1028, GBV-1012, NKTR-218, and the compounds disclosed
in US20100015178 (Incyte), US2016137652 (Flexus Biosciences, Inc.),
WO2014073738 (Flexus Biosciences, Inc.), and WO2015188085 (Flexus
Biosciences, Inc.).
[0336] PD-1 Inhibitors
[0337] Examples of PD-1 inhibitors include cemiplimab, nivolumab,
pembrolizumab, pidilizumab, BGB-108, STI-A1014, SHR-1210, PDR-001,
PF-06801591, IBI-308, GB-226, STI-1110, JNJ-63723283, CA-170,
durvalumab, atezolizumab and mDX-400, JS-001, Camrelizumab,
Sintilimab, Sintilimab, tislelizumab, BCD-100, BGB-A333,
JNJ-63723283, GLS-010 (WBP-3055), CX-072, AGEN-2034, GNS-1480
(Epidermal growth factor receptor antagonist; Programmed cell death
ligand 1 inhibitor), CS-1001, M-7824 (PD-L/TGF-0 bifunctional
fusion protein), Genolimzumab, BMS-936559.
[0338] PD-L1 Inhibitors
[0339] Examples of PD-L1 inhibitors include atezolizumab, avelumab,
AMP-224, MEDI-0680, RG-7446, GX-P2, durvalumab, KY-1003, KD-033,
MSB-0010718C, TSR-042, ALN-PDL, STI-A1014, GS-4224, CX-072, and
BMS-936559.
[0340] Examples of PD-1 inhibitors include the compounds disclosed
in WO2017112730 (Incyte Corp), WO2017087777 (Incyte Corp),
WO2017017624, WO2014151634 (Bristol Myers Squibb Co), WO201317322
(BristolMyers Squibb Co), WO2018119286 (Incyte Corp), WO2018119266
(Incyte Corp), WO2018119263 (Incyte Corp), WO2018119236 (Incyte
Corp), WO2018119221 (Incyte Corp), WO2018118848 (BristolMyers
Squibb Co), WO20161266460 (BristolMyers Squibb Co), WO2017087678
(BristolMyers Squibb Co), WO2016149351 (BristolMyers Squibb Co),
WO2015033299 (Aurigene Discovery Technologies Ltd), WO2015179615
(Eisai Co Ltd; Eisai Research Institute), WO2017066227
(BristolMyers Squibb Co), WO2016142886 (Aurigene Discovery
Technologies Ltd), WO2016142852 (Aurigene Discovery Technologies
Ltd), WO2016142835 (Aurigene Discovery Technologies Ltd;
Individual), WO2016142833 (Aurigene Discovery Technologies Ltd),
WO2018085750 (BristolMyers Squibb Co), WO2015033303 (Aurigene
Discovery Technologies Ltd), WO2017205464 (Incyte Corp),
WO2016019232 (3M Co; Individual; Texas A&M University System),
WO2015160641 (BristolMyers Squibb Co), WO2017079669 (Incyte Corp),
WO2015033301 (Aurigene Discovery Technologies Ltd), WO2015034820
(BristolMyers Squibb Co), WO2018073754 (Aurigene Discovery
Technologies Ltd), WO2016077518 (BristolMyers Squibb Co),
WO2016057624 (BristolMyers Squibb Co), WO2018044783 (Incyte Corp),
WO2016100608 (BristolMyers Squibb Co), WO2016100285 (BristolMyers
Squibb Co), WO2016039749 (BristolMyers Squibb Co), WO2015019284
(Cambridge Enterprise Ltd), WO2016142894 (Aurigene Discovery
Technologies Ltd), WO2015134605 (BristolMyers Squibb Co),
WO2018051255 (Aurigene Discovery Technologies Ltd), WO2018051254
(Aurigene Discovery Technologies Ltd), WO2017222976 (Incyte Corp),
WO2017070089 (Incyte Corp), WO2018044963 (BristolMyers Squibb Co),
WO2013144704 (Aurigene Discovery Technologies Ltd), WO2018013789
(Incyte Corp), WO2017176608 (BristolMyers Squibb Co), WO2018009505
(BristolMyers Squibb Co), WO2011161699 (Aurigene Discovery
Technologies Ltd), WO2015119944 (Incyte Corp; Merck Sharp &
Dohme Corp), WO2017192961 (Incyte Corp), WO2017106634 (Incyte
Corp), WO2013132317 (Aurigene Discovery Technologies Ltd),
WO2012168944 (Aurigene Discovery Technologies Ltd), WO2015036927
(Aurigene Discovery Technologies Ltd), WO2015044900 (Aurigene
Discovery Technologies Ltd), WO2018026971 (Arising
International).
[0341] Recombinant Thymosin Alpha-1
[0342] Examples of recombinant thymosin alpha-1 include NL-004 and
PEGylated thymosin alpha-1.
[0343] Bruton's Tyrosine Kinase (BTK) Inhibitors
[0344] Examples of BTK inhibitors include ABBV-105, acalabrutinib
(ACP-196), ARQ-531, BMS-986142, dasatinib, ibrutinib, GDC-0853,
PRN-1008, SNS-062, ONO-4059, BGB-3111, ML-319, MSC-2364447,
RDX-022, X-022, AC-058, RG-7845, spebrutinib, TAS-5315, TP-0158,
TP-4207, HM-71224, KBP-7536, M-2951, TAK-020, AC-0025, and the
compounds disclosed in US20140330015 (Ono Pharmaceutical),
US20130079327 (Ono Pharmaceutical), and US20130217880 (Ono
Pharmaceutical).
[0345] KDM Inhibitors
[0346] Examples of KDM5 inhibitors include the compounds disclosed
in WO2016057924 (Genentech/Constellation Pharmaceuticals),
US20140275092 (Genentech/Constellation Pharmaceuticals),
US20140371195 (Epitherapeutics) and US20140371214
(Epitherapeutics), US20160102096 (Epitherapeutics), US20140194469
(Quanticel), US20140171432, US20140213591 (Quanticel),
US20160039808 (Quanticel), US20140275084 (Quanticel), WO2014164708
(Quanticel).
[0347] Examples of KDM1 inhibitors include the compounds disclosed
in U.S. Pat. No. 9,186,337B2 (Oryzon Genomics), GSK-2879552, and
RG-6016.
[0348] STING Agonists
[0349] Examples of STING agonists include SB-11285, AdVCA0848,
STINGVAX, and the compounds disclosed in WO 2018065360 ("Biolog
Life Science Institute Forschungslabor und Biochemica-Vertrieb
GmbH, Germany), WO 2018009466 (Aduro Biotech), WO 2017186711
(InvivoGen), WO 2017161349 (Immune Sensor), WO 2017106740 (Aduro
Biotech), US 20170158724 (Glaxo Smithkline), WO 2017075477 (Aduro
Biotech), US 20170044206 (Merck), WO 2014179760 (University of
California), WO2018098203 (Janssen), WO2018118665 (Merck),
WO2018118664 (Merck), WO2018100558 (Takeda), WO2018067423 (Merck),
WO2018060323 (Boehringer).
[0350] Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
[0351] Examples of NNRTI include the compounds disclosed in
WO2018118826 (Merck), WO2018080903 (Merck), WO2018119013 (Merck),
WO2017100108 (Idenix), WO2017027434 (Merck), WO2017007701 (Merck),
WO2008005555 (Gilead).
[0352] HBV Replication Inhibitors
[0353] Examples of hepatitis B virus replication inhibitors include
isothiafludine, IQP-HBV, RM-5038, and Xingantie.
[0354] Arginase Inhibitors
[0355] Examples of Arginase inhibitors include CB-1158, C-201, and
resminostat.
[0356] Gene Therapy and Cell Therapy
[0357] Gene therapy and cell therapy includes the genetic
modification to silence a gene; genetic approaches to directly kill
the infected cells; the infusion of immune cells designed to
replace most of the patient's own immune system to enhance the
immune response to infected cells, or activate the patient's own
immune system to kill infected cells, or find and kill the infected
cells; and genetic approaches to modify cellular activity to
further alter endogenous immune responsiveness against the
infection.
[0358] Gene Editors
[0359] Examples of genome editing systems include a CRISPR/Cas9
system, a zinc finger nuclease system, a TALEN system, a homing
endonucleases system, and a meganuclease system; e.g., cccDNA
elimination via targeted cleavage, and altering one or more of the
hepatitis B virus (HBV) viral genes. Altering (e.g., knocking out
and/or knocking down) the PreC, C, X PreSI, PreS2, S, P or SP gene
refers to (1) reducing or eliminating PreC, C, X PreSI, PreS2, S, P
or SP gene expression, (2) interfering with Precore, Core, X
protein, Long surface protein, middle surface protein, S protein
(also known as HBs antigen and HBsAg), polymerase protein, and/or
Hepatitis B spliced protein function (HBe, HBc, HBx, PreS1, PreS2,
S, Pol, and/or HBSP or (3) reducing or eliminating the
intracellular, serum and/or intraparenchymal levels of HBe, HBc,
HBx, LHBs, MHBs, SHBs, Pol, and/or HBSP proteins. Knockdown of one
or more of the PreC, C, X PreSI, PreS2, S, P and/or SP gene(s) is
performed by targeting the gene(s) within HBV cccDNA and/or
integrated HBV DNA.
[0360] CAR-T Cell Therapy
[0361] CAR T cell therapy includes a population of immune effector
cells engineered to express a chimeric antigen receptor (CAR),
wherein the CAR comprises an HBV antigen-binding domain. The immune
effector cell is a T cell or an NK cell. In some embodiments, the T
cell is a CD4+ T cell, a CD8+ T cell, or a combination thereof.
Cells can be autologous or allogeneic.
[0362] TCR-T Cell Therapy
[0363] TCR T cell therapy includes T cells expressing HBV-specific
T cell receptors. TCR-T cells are engineered to target HBV derived
peptides presented on the surface of virus-infected cells. In some
embodiments, the T-cells express HBV surface antigen
(HBsAg)-specific TCR. Examples of TCR-T therapy directed to
treatment of HBV include LTCR-H2-1.
[0364] In another specific embodiment, a compound disclosed herein,
or a pharmaceutically acceptable salt thereof, is combined with an
HBV DNA polymerase inhibitor, one or two additional therapeutic
agents selected from the group consisting of immunomodulators, TLR
modulators, HBsAg inhibitors, HBsAg secretion or assembly
inhibitors, HBV therapeutic vaccines, HBV antibodies including HBV
antibodies targeting the surface antigens of the hepatitis B virus
and bispecific antibodies and "antibody-like" therapeutic proteins
(such as DARTs.RTM., DUOBODIES.RTM., BITES.RTM., XmAbs.RTM.,
TandAbs.RTM., Fab derivatives, or TCR-like antibodies), cyclophilin
inhibitors, stimulators of retinoic acid-inducible gene 1,
stimulators of RIG-I like receptors, PD-1 inhibitors, PD-L1
inhibitors, Arginase inhibitors, PI3K inhibitors, IDO inhibitors,
and stimulators of NOD2, and one or two additional therapeutic
agents selected from the group consisting of HBV viral entry
inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA inhibitors, HBV
antibodies targeting the surface antigens of the hepatitis B virus,
siRNA, miRNA gene therapy agents, sshRNAs, KDM5 inhibitors, and
nucleoprotein modulators (HBV core or capsid protein
modulators).
[0365] In another specific embodiment, a compound disclosed herein,
or a pharmaceutically acceptable salt thereof, is combined with an
HBV DNA polymerase inhibitor and at least a second additional
therapeutic agent selected from the group consisting of:
immunomodulators, TLR modulators, HBsAg inhibitors, HBV therapeutic
vaccines, HBV antibodies including HBV antibodies targeting the
surface antigens of the hepatitis B virus and bispecific antibodies
and "antibody-like" therapeutic proteins (such as DARTs.RTM.,
DUOBODIES.RTM., BITES.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives, or TCR-like antibodies), cyclophilin inhibitors,
stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I
like receptors, PD-1 inhibitors, PD-L1 inhibitors, Arginase
inhibitors, PI3K inhibitors, IDO inhibitors, and stimulators of
NOD2.
[0366] In another specific embodiment, a compound disclosed herein,
or a pharmaceutically acceptable salt thereof, is combined with an
HBV DNA polymerase inhibitor and at least a second additional
therapeutic agent selected from the group consisting of: HBV viral
entry inhibitors, NTCP inhibitors, HBx inhibitors, cccDNA
inhibitors, HBV antibodies targeting the surface antigens of the
hepatitis B virus, siRNA, miRNA gene therapy agents, sshRNAs, KDM5
inhibitors, and nucleoprotein modulators (HBV core or capsid
protein inhibitors).
[0367] In a particular embodiment, a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, is combined with
compounds such as those disclosed in U.S. Publication No.
2010/0143301 (Gilead Sciences), U.S. Publication No. 2011/0098248
(Gilead Sciences), U.S. Publication No. 2009/0047249 (Gilead
Sciences), U.S. Pat. No. 8,722,054 (Gilead Sciences), U.S.
Publication No. 2014/0045849 (Janssen), U.S. Publication No.
2014/0073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221
(Janssen), WO2014/128189 (Janssen), U.S. Publication No.
2014/0350031 (Janssen), WO2014/023813 (Janssen), U.S. Publication
No. 2008/0234251 (Array Biopharma), U.S. Publication No.
2008/0306050 (Array Biopharma), U.S. Publication No. 2010/0029585
(Ventirx Pharma), U.S. Publication No. 2011/0092485 (Ventirx
Pharma), US2011/0118235 (Ventirx Pharma), U.S. Publication No.
2012/0082658 (Ventirx Pharma), U.S. Publication No. 2012/0219615
(Ventirx Pharma), U.S. Publication No. 2014/0066432 (Ventirx
Pharma), U.S. Publication No. 2014/0088085 (Ventirx Pharma), U.S.
Publication No. 2014/0275167 (Novira Therapeutics), U.S.
Publication No. 2013/0251673 (Novira Therapeutics), U.S. Pat. No.
8,513,184 (Gilead Sciences), U.S. Publication No. 2014/0030221
(Gilead Sciences), U.S. Publication No. 2013/0344030 (Gilead
Sciences), U.S. Publication No. 2013/0344029 (Gilead Sciences),
US20140275167 (Novira Therapeutics), US20130251673 (Novira
Therapeutics), U.S. Publication No. 2014/0343032 (Roche),
WO2014037480 (Roche), U.S. Publication No. 2013/0267517 (Roche),
WO2014131847 (Janssen), WO2014033176 (Janssen), WO2014033170
(Janssen), WO2014033167 (Janssen), WO2015/059212 (Janssen),
WO2015118057 (Janssen), WO2015011281 (Janssen), WO2014184365
(Janssen), WO2014184350 (Janssen), WO2014161888 (Janssen),
WO2013096744 (Novira), US20150225355 (Novira), US20140178337
(Novira), US20150315159 (Novira), US20150197533 (Novira),
US20150274652 (Novira), US20150259324, (Novira), US20150132258
(Novira), U.S. Pat. No. 9,181,288 (Novira), WO2014184350 (Janssen),
WO2013144129 (Roche), US20100015178 (Incyte), US2016137652 (Flexus
Biosciences, Inc.), WO2014073738 (Flexus Biosciences, Inc.),
WO2015188085 (Flexus Biosciences, Inc.), U.S. Publication No.
2014/0330015 (Ono Pharmaceutical), U.S. Publication No.
2013/0079327 (Ono Pharmaceutical), U.S. Publication No.
2013/0217880 (Ono pharmaceutical), WO2016057924
(Genentech/Constellation Pharmaceuticals), US20140275092
(Genentech/Constellation Pharmaceuticals), US20140371195
(Epitherapeutics) and US20140371214 (Epitherapeutics),
US20160102096 (Epitherapeutics), US20140194469 (Quanticel),
US20140171432, US20140213591 (Quanticel), US20160039808
(Quanticel), US20140275084 (Quanticel), WO2014164708 (Quanticel),
U.S. Pat. No. 9,186,337B2 (Oryzon Genomics), and other drugs for
treating HBV, and combinations thereof.
Cancer Combination Therapy
[0368] In one embodiment, the compound of the disclosure may be
employed with other therapeutic methods of cancer treatment.
Preferably, combination therapy with chemotherapeutic, hormonal,
antibody, surgical and/or radiation treatments are
contemplated.
[0369] In some embodiments, the further anti-cancer therapy is
surgery and/or radiotherapy.
[0370] In some embodiments, the further anti-cancer therapy is at
least one additional cancer medicament.
[0371] In some embodiments, there is provided a combination
comprising a compound as described herein, or a pharmaceutically
acceptable salt thereof and at least one further cancer
medicament.
[0372] In some embodiments, there is provided a combination
comprising a compound as described herein, or a pharmaceutically
acceptable salt thereof and at least one further cancer medicament,
for use in therapy.
[0373] In some embodiments, there is provided the use of a
combination comprising a compound as described herein, or a
pharmaceutically acceptable salt thereof and at least one cancer
medicament, in the manufacture of a medicament for the treatment of
cancer.
[0374] Examples of further cancer medicaments include intercalating
substances such as anthracycline, doxorubicin, idarubicin,
epirubicin, and daunorubicin; topoisomerase inhibitors such as
irinotecan, topotecan, camptothecin, lamellarin D, etoposide,
teniposide, mitoxantrone, amsacrine, ellipticines and
aurintricarboxylic acid; nitrosourea compounds such as carmustine
(BCNU), lomustine (CCNU), and streptozocin; nitrogen mustards such
as cyclophosphamide, mechlorethamine, uramustine, bendamustine,
melphalan, chlorambucil, mafosfamide, trofosfamid and ifosfamide;
alkyl sulfonates such as busulfan and treosulfan; alkylating agents
such as procarbazin, dacarbazin, temozolomid and thiotepa; platinum
analogues such as cisplatin, carboplatin, nedaplatin, oxaliplatin,
satraplatin, and triplatin tetranitrate; microtubule disruptive
drugs such as vinblastine, colcemid and nocodazole; antifolates
like methotrexate, aminopterin, dichloromethotrexat, pemetrexed,
raltitrexed and pralatrexate: purine analogues like azathioprine,
mercaptopurine, thioguanine, fludarabine, fludarabine phosphate,
pentostatin and cladribine; pyrimidine analogues like
5-fluorouracil, floxuridine, cytarabine, 6-azauracil, gemcitabine;
steroids such as gestagene, androgene, glucocorticoids,
dexamethasone, prednisolone, and prednisone; anti-cancer antibodies
such as monoclonal antibodies, e.g., alemtuzumab, apolizumab,
cetuximab, epratuzumab, galiximab, gemtuzumab, ipilimumab,
labetuzumab, panitumumab, rituximab, trastuzumab, nimotuzumab,
mapatumumab, matuzumab, rhMab ICR62 and pertuzumab, radioactively
labeled antibodies and antibody-drug conjugates; anti-cancer
peptides such as radioactively labeled peptides and peptide-drug
conjugates; and taxane and taxane analogues such as paclitaxel and
docetaxel.
[0375] In certain embodiments, a method for treating or preventing
a hyperproliferative disorder or cancer in a human or animal having
or at risk of having the hyperproliferative disorder or cancer is
provided, comprising administering to the human or animal a
therapeutically effective amount of a compound as disclosed herein,
or a pharmaceutically acceptable salt thereof, in combination with
a therapeutically effective amount of one or more (e.g., one, two,
three, one or two, or one to three) additional therapeutic agents.
In one embodiment, a method for treating a hyperproliferative
disorder or cancer in a human or animal having or at risk of having
the hyperproliferative disorder or cancer is provided, comprising
administering to the human or animal a therapeutically effective
amount of a compound disclosed herein, or a pharmaceutically
acceptable salt thereof, in combination with a therapeutically
effective amount of one or more (e.g., one, two, three, one or two,
or one to three) additional therapeutic agents.
[0376] In certain embodiments, the present disclosure provides a
method for treating a hyperproliferative disorder or cancer,
comprising administering to a subject in need thereof a
therapeutically effective amount of a compound disclosed herein, or
a pharmaceutically acceptable salt thereof, in combination with a
therapeutically effective amount of one or more additional
therapeutic agents which are suitable for treating
hyperproliferative disorder or cancer.
[0377] The compounds described herein may be used or combined with
one or more of a chemotherapeutic agent, an anti-cancer agent, an
anti-angiogenic agent, an anti-fibrotic agent, an immunotherapeutic
agent, a therapeutic antibody, a bispecific antibody and
"antibody-like" therapeutic protein (such as DARTs.RTM.,
Duobodies.RTM., Bites.RTM., XmAbs.RTM., TandAbs.RTM., Fab
derivatives), an antibody-drug conjugate (ADC), a radiotherapeutic
agent, an anti-neoplastic agent, an anti-proliferation agent, an
oncolytic virus, a gene modifier or editor (such as CRISPR/Cas9,
zinc finger nucleases or synthetic nucleases, TALENs), a CAR
(chimeric antigen receptor) T-cell immunotherapeutic agent, an
engineered T cell receptor (TCR-T), or any combination thereof.
These therapeutic agents may be in the forms of compounds,
antibodies, polypeptides, or polynucleotides. In one embodiment,
provided herein is a product comprising a compound described herein
and an additional therapeutic agent as a combined preparation for
simultaneous, separate, or sequential use in therapy.
[0378] The one or more therapeutic agents include, but are not
limited to, an inhibitor, agonist, antagonist, ligand, modulator,
stimulator, blocker, activator or suppressor of a gene, ligand,
receptor, protein, or factor. Non-limiting examples of additional
therapeutic agents include: Abelson murine leukemia viral oncogene
homolog 1 gene (ABL, such as ABL1), Acetyl-CoA carboxylase (such as
ACC1/2), activated CDC kinase (ACK, such as ACK1), Adenosine
deaminase, adenosine receptor (such as A2B, A2a, A3), Adenylate
cyclase, ADP ribosyl cyclase-1, adrenocorticotropic hormone
receptor (ACTH), Aerolysin, AKT1 gene, Alk-5 protein kinase,
Alkaline phosphatase, Alpha 1 adrenoceptor, Alpha 2 adrenoceptor,
Alpha-ketoglutarate dehydrogenase (KGDH), Aminopeptidase N, AMP
activated protein kinase, anaplastic lymphoma kinase (ALK, such as
ALK1), Androgen receptor, Angiopoietin (such as ligand-1,
ligand-2), Angiotensinogen (AGT) gene, murine thymoma viral
oncogene homolog 1 (AKT) protein kinase (such as AKT1, AKT2, AKT3),
apolipoprotein A-I (APOA1) gene, Apoptosis inducing factor,
apoptosis protein (such as 1, 2), apoptosis signal-regulating
kinase (ASK, such as ASK1), Arginase (I), Arginine deiminase,
Aromatase, Asteroid homolog 1 (ASTEl) gene, ataxia telangiectasia
and Rad 3 related (ATR) serine/threonine protein kinase, Aurora
protein kinase (such as 1, 2), Axl tyrosine kinase receptor,
Baculoviral IAP repeat containing 5 (BIRC5) gene, Basigin, B-cell
lymphoma 2 (BCL2) gene, Bcl2 binding component 3, Bcl2 protein,
BCL2L11 gene, BCR (breakpoint cluster region) protein and gene,
Beta adrenoceptor, Beta-catenin, B-lymphocyte antigen CD19,
B-lymphocyte antigen CD20, B-lymphocyte cell adhesion molecule,
B-lymphocyte stimulator ligand, Bone morphogenetic protein-10
ligand, Bone morphogenetic protein-9 ligand modulator, Brachyury
protein, Bradykinin receptor, B-Raf proto-oncogene (BRAF), Brc-Abl
tyrosine kinase, Bromodomain and external domain (BET) bromodomain
containing protein (such as BRD2, BRD3, BRD4), Bruton's tyrosine
kinase (BTK), Calmodulin, calmodulin-dependent protein kinase
(CaMK, such as CAMKII), Cancer testis antigen 2, Cancer testis
antigen NY-ESO-1, cancer/testis antigen 1B (CTAG1) gene,
Cannabinoid receptor (such as CB1, CB2), Carbonic anhydrase, casein
kinase (CK, such as CKI, CKII), Caspase (such as caspase-3,
caspase-7, Caspase-9), caspase 8 apoptosis-related cysteine
peptidase CASP8-FADD-like regulator, Caspase recruitment domain
protein-15, Cathepsin G, CCR5 gene, CDK-activating kinase (CAK),
Checkpoint kinase (such as CHK1, CHK2), chemokine (C-C motif)
receptor (such as CCR2, CCR4, CCR5), chemokine (C--X-C motif)
receptor (such as CXCR4, CXCR1 and CXCR2), Chemokine CC21 ligand,
Cholecystokinin CCK2 receptor, Chorionic gonadotropin, c-Kit
(tyrosine-protein kinase Kit or CD117), Claudin (such as 6, 18),
cluster of differentiation (CD) such as CD4, CD27, CD29, CD30,
CD33, CD37, CD40, CD40 ligand receptor, CD40 ligand, CD40LG gene,
CD44, CD45, CD47, CD49b, CD51, CD52, CD55, CD58, CD66e, CD70 gene,
CD74, CD79, CD79b, CD79B gene, CD80, CD95, CD99, CD117, CD122,
CDwl23, CD134, CDwl37, CD158a, CD158b1, CD158b2, CD223, CD276
antigen; clusterin (CLU) gene, Clusterin, c-Met (hepatocyte growth
factor receptor (HGFR)), Complement C3, Connective tissue growth
factor, COP9 signalosome subunit 5, CSF-1 (colony-stimulating
factor 1 receptor), CSF2 gene, CTLA-4 (cytotoxic T-lymphocyte
protein 4) receptor, Cyclin D1, Cyclin G1, cyclin-dependent kinases
(CDK, such as CDK1, CDK1B, CDK2-9), cyclooxygenase (such as 1, 2),
CYP2B1 gene, Cysteine palmitoyltransferase porcupine, Cytochrome
P450 11B2, Cytochrome P450 17, cytochrome P450 17A1, Cytochrome
P450 2D6, cytochrome P450 3A4, Cytochrome P450 reductase, cytokine
signalling-1, cytokine signalling-3, Cytoplasmic isocitrate
dehydrogenase, Cytosine deaminase, cytosine DNA methyltransferase,
cytotoxic T-lymphocyte protein-4, DDR2 gene, Delta-like protein
ligand (such as 3, 4), Deoxyribonuclease, Dickkopf-1 ligand,
dihydrofolate reductase (DHFR), Dihydropyrimidine dehydrogenase,
Dipeptidyl peptidase IV, discoidin domain receptor (DDR, such as
DDR1), DNA binding protein (such as HU-beta), DNA dependent protein
kinase, DNA gyrase, DNA methyltransferase, DNA polymerase (such as
alpha), DNA primase, dUTP pyrophosphatase, L-dopachrome
tautomerase, echinoderm microtubule like protein 4, EGFR tyrosine
kinase receptor, Elastase, Elongation factor 1 alpha 2, Elongation
factor 2, Endoglin, Endonuclease, Endoplasmin, Endosialin,
Endostatin, endothelin (such as ET-A, ET-B), Enhancer of zeste
homolog 2 (EZH2), Ephrin (EPH) tyrosine kinase (such as Epha3,
Ephb4), Ephrin B2 ligand, epidermal growth factor, epidermal growth
factor receptors (EGFR), epidermal growth factor receptor (EGFR)
gene, Epigen, Epithelial cell adhesion molecule (EpCAM), Erb-b2
(v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2)
tyrosine kinase receptor, Erb-b3 tyrosine kinase receptor, Erb-b4
tyrosine kinase receptor, E-selectin, Estradiol 17 beta
dehydrogenase, Estrogen receptor (such as alpha, beta), Estrogen
related receptor, Eukaryotic translation initiation factor 5A
(EIF5A) gene, Exportin 1, Extracellular signal related kinase (such
as 1, 2), Extracellular signal-regulated kinases (ERK), Factor
(such as Xa, VIIa), farnesoid x receptor (FXR), Fas ligand, Fatty
acid synthase (FASN), Ferritin, FGF-2 ligand, FGF-5 ligand,
fibroblast growth factor (FGF, such as FGF1, FGF2, FGF4),
Fibronectin, Fms-related tyrosine kinase 3 (Flt3), focal adhesion
kinase (FAK, such as FAK2), folate hydrolase prostate-specific
membrane antigen 1 (FOLH1), Folate receptor (such as alpha),
Folate, Folate transporter 1, FYN tyrosine kinase, paired basic
amino acid cleaving enzyme (FURIN), Beta-glucuronidase,
Galactosyltransferase, Galectin-3, Ganglioside GD2, Glucocorticoid,
glucocorticoid-induced TNFR-related protein GITR receptor,
Glutamate carboxypeptidase II, glutaminase, Glutathione
S-transferase P, glycogen synthase kinase (GSK, such as 3-beta),
Glypican 3 (GPC3), gonadotropin-releasing hormone (GNRH),
Granulocyte macrophage colony stimulating factor (GM-CSF) receptor,
Granulocyte-colony stimulating factor (GCSF) ligand, growth factor
receptor-bound protein 2 (GRB2), Grp78 (78 kDa glucose-regulated
protein) calcium binding protein, molecular chaperone groEL2 gene,
Heat shock protein (such as 27, 70, 90 alpha, beta), Heat shock
protein gene, Heat stable enterotoxin receptor, Hedgehog protein,
Heparanase, Hepatocyte growth factor, HERV-H LTR associating
protein 2, Hexose kinase, Histamine H2 receptor, Histone
methyltransferase (DOT1L), histone deacetylase (HDAC, such as 1, 2,
3, 6, 10, 11), Histone H1, Histone H3, HLA class I antigen (A-2
alpha), HLA class II antigen, Homeobox protein NANOG, HSPB1 gene,
Human leukocyte antigen (HLA), Human papillomavirus (such as E6,
E7) protein, Hyaluronic acid, Hyaluronidase, Hypoxia inducible
factor-1 alpha (HIF1a), Imprinted Maternally Expressed Transcript
(H19) gene, mitogen-activated protein kinase 1 (MAP4K1),
tyrosine-protein kinase HCK, I-Kappa-B kinase (IKK, such as IKKbe),
IL-1 alpha, IL-1 beta, IL-12, IL-12 gene, IL-15, IL-17, IL-2 gene,
IL-2 receptor alpha subunit, IL-2, IL-3 receptor, IL-4, IL-6, IL-7,
IL-8, immunoglobulin (such as G, G1, G2, K, M), Immunoglobulin Fc
receptor, Immunoglobulin gamma Fc receptor (such as I, III, IIIA),
indoleamine 2,3-dioxygenase (IDO, such as IDO1), indoleamine
pyrrole 2,3-dioxygenase 1 inhibitor, insulin receptor, Insulin-like
growth factor (such as 1, 2), Integrin alpha-4/beta-1, integrin
alpha-4/beta-7, Integrin alpha-5/beta-1, Integrin alpha-V/beta-3,
Integrin alpha-V/beta-5, Integrin alpha-V/beta-6, Intercellular
adhesion molecule 1 (ICAM-1), interferon (such as alpha, alpha 2,
beta, gamma), Interferon inducible protein absent in melanoma 2
(AIM2), interferon type I receptor, Interleukin 1 ligand,
Interleukin 13 receptor alpha 2, interleukin 2 ligand,
interleukin-1 receptor-associated kinase 4 (IRAK4), Interleukin-2,
Interleukin-29 ligand, isocitrate dehydrogenase (such as IDH1,
IDH2), Janus kinase (JAK, such as JAK1, JAK2), Jun N terminal
kinase, kallikrein-related peptidase 3 (KLK3) gene, Killer cell Ig
like receptor, Kinase insert domain receptor (KDR), Kinesin-like
protein KIF11, Kirsten rat sarcoma viral oncogene homolog (KRAS)
gene, Kisspeptin (KiSS-1) receptor, KIT gene, v-kit Hardy-Zuckerman
4 feline sarcoma viral oncogene homolog (KIT) tyrosine kinase,
lactoferrin, Lanosterol-14 demethylase, LDL receptor related
protein-1, Leukotriene A4 hydrolase, Listeriolysin, L-Selectin,
Luteinizing hormone receptor, Lyase, lymphocyte activation gene 3
protein (LAG-3), Lymphocyte antigen 75, Lymphocyte function
antigen-3 receptor, lymphocyte-specific protein tyrosine kinase
(LCK), Lymphotactin, Lyn (Lck/Yes novel) tyrosine kinase, lysine
demethylases (such as KDM1, KDM2, KDM4, KDM5, KDM6, A/B/C/D),
Lysophosphatidate-1 receptor, lysosomal-associated membrane protein
family (LAMP) gene, Lysyl oxidase homolog 2, lysyl oxidase protein
(LOX), lysyl oxidase-like protein (LOXL, such as LOXL2),
Hematopoietic Progenitor Kinase 1 (HPK1), Hepatocyte growth factor
receptor (MET) gene, macrophage colony-stimulating factor (MCSF)
ligand, Macrophage migration inhibitory fact, MAGEC1 gene, MAGEC2
gene, Major vault protein, MAPK-activated protein kinase (such as
MK2), Mas-related G-protein coupled receptor, matrix
metalloprotease (MMP, such as MMP2, MMP9), Mcl-1 differentiation
protein, Mdm2 p53-binding protein, Mdm4 protein, Melan-A (MART-1)
melanoma antigen, Melanocyte protein Pmel 17, melanocyte
stimulating hormone ligand, melanoma antigen family A3 (MAGEA3)
gene, Melanoma associated antigen (such as 1, 2, 3, 6), Membrane
copper amine oxidase, Mesothelin, MET tyrosine kinase, Metabotropic
glutamate receptor 1, Metalloreductase STEAP1 (six transmembrane
epithelial antigen of the prostate 1), Metastin, methionine
aminopeptidase-2, Methyltransferase, Mitochondrial 3 ketoacyl CoA
thiolase, mitogen-activate protein kinase (MAPK), mitogen-activated
protein kinase (MEK, such as MEK1, MEK2), mTOR (mechanistic target
of rapamycin (serine/threonine kinase), mTOR complex (such as 1,2),
mucin (such as 1, 5A, 16), mut T homolog (MTH, such as MTH1), Myc
proto-oncogene protein, myeloid cell leukemia 1 (MCL1) gene,
myristoylated alanine-rich protein kinase C substrate (MARCKS)
protein, NAD ADP ribosyltransferase, natriuretic peptide receptor
C, Neural cell adhesion molecule 1, Neurokinin 1 (NKI) receptor,
Neurokinin receptor, Neuropilin 2, NF kappa B activating protein,
NIMA-related kinase 9 (NEK9), Nitric oxide synthase, NK cell
receptor, NK3 receptor, NKG2 A B activating NK receptor,
Noradrenaline transporter, Notch (such as Notch-2 receptor, Notch-3
receptor, Notch-4 receptor), Nuclear erythroid 2-related factor 2,
Nuclear Factor (NF) kappa B, Nucleolin, Nucleophosmin,
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), 2 oxoglutarate
dehydrogenase, 2,5-oligoadenylate synthetase, O-methylguanine DNA
methyltransferase, Opioid receptor (such as delta), Ornithine
decarboxylase, Orotate phosphoribosyltransferase, orphan nuclear
hormone receptor NR4A1, Osteocalcin, Osteoclast differentiation
factor, Osteopontin, OX-40 (tumor necrosis factor receptor
superfamily member 4 TNFRSF4, or CD134) receptor, P3 protein, p38
kinase, p38 MAP kinase, p53 tumor suppressor protein, Parathyroid
hormone ligand, peroxisome proliferator-activated receptors (PPAR,
such as alpha, delta, gamma), P-Glycoprotein (such as 1),
phosphatase and tensin homolog (PTEN), phosphatidylinositol
3-kinase (PI3K), phosphoinositide-3 kinase (PI3K such as alpha,
delta, gamma), phosphorylase kinase (PK), PKN3 gene, placenta
growth factor, platelet-derived growth factor (PDGF, such as alpha,
beta), Platelet-derived growth factor (PDGF, such as alpha, beta),
Pleiotropic drug resistance transporter, Plexin B1, PLK1 gene,
polo-like kinase (PLK), Polo-like kinase 1, Poly ADP ribose
polymerase (PARP, such as PARP1, 2 and 3), Preferentially expressed
antigen in melanoma (PRAME) gene, Prenyl-binding protein (PrPB),
Probable transcription factor PML, Progesterone receptor,
Programmed cell death 1 (PD-1), Programmed cell death ligand 1
inhibitor (PD-L1), Prosaposin (PSAP) gene, Prostanoid receptor
(EP4), prostate specific antigen, Prostatic acid phosphatase,
proteasome, Protein E7, Protein famesyltransferase, protein kinase
(PK, such as A, B, C), protein tyrosine kinase, Protein tyrosine
phosphatase beta, Proto-oncogene serine/threonine-protein kinase
(PIM, such as PIM-1, PIM-2, PIM-3), P-Selectin, Purine nucleoside
phosphorylase, purinergic receptor P2X ligand gated ion channel 7
(P2X7), Pyruvate dehydrogenase (PDH), Pyruvate dehydrogenase
kinase, Pyruvate kinase (PYK), 5-Alpha-reductase, Raf protein
kinase (such as 1, B), RAF1 gene, Ras gene, Ras GTPase, RET gene,
Ret tyrosine kinase receptor, retinoblastoma associated protein,
retinoic acid receptor (such as gamma), Retinoid X receptor, Rheb
(Ras homolog enriched in brain) GTPase, Rho (Ras homolog)
associated protein kinase 2, ribonuclease, Ribonucleotide reductase
(such as M2 subunit), Ribosomal protein S6 kinase, RNA polymerase
(such as I, II), Ron (Recepteur d'Origine Nantais) tyrosine kinase,
ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) gene, Rosi
tyrosine kinase, Runt-related transcription factor 3,
Gamma-secretase, S100 calcium binding protein A9, Sarco endoplasmic
calcium ATPase, Second mitochondria-derived activator of caspases
(SMAC) protein, Secreted frizzled related protein-2, Semaphorin-4D,
Serine protease, serine/threonine kinase (STK),
serine/threonine-protein kinase (TBK, such as TBK1), signal
transduction and transcription (STAT, such as STAT-1, STAT-3,
STAT-5), Signaling lymphocytic activation molecule (SLAM) family
member 7, six-transmembrane epithelial antigen of the prostate
(STEAP) gene, SL cytokine ligand, smoothened (SMO) receptor, Sodium
iodide cotransporter, Sodium phosphate cotransporter 2B,
Somatostatin receptor (such as 1, 2, 3, 4, 5), Sonic hedgehog
protein, Son of sevenless (SOS), Specific protein 1 (Spi)
transcription factor, Sphingomyelin synthase, Sphingosine kinase
(such as 1, 2), Sphingosine-1-phosphate receptor-1, spleen tyrosine
kinase (SYK), SRC gene, Src tyrosine kinase, STAT3 gene, Steroid
sulfatase, Stimulator of interferon genes (STING) receptor,
stimulator of interferon genes protein, Stromal cell-derived factor
1 ligand, SUMO (small ubiquitin-like modifier), Superoxide
dismutase, Survivin protein, Synapsin 3, Syndecan-1, Synuclein
alpha, T cell surface glycoprotein CD28, tank-binding kinase (TBK),
TATA box-binding protein-associated factor RNA polymerase I subunit
B (TAF1B) gene, T-cell CD3 glycoprotein zeta chain, T-cell
differentiation antigen CD6, T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3), T-cell surface glycoprotein CD8, Tec protein
tyrosine kinase, Tek tyrosine kinase receptor, telomerase,
Telomerase reverse transcriptase (TERT) gene, Tenascin, TGF beta 2
ligand, Thrombopoietin receptor, Thymidine kinase, Thymidine
phosphorylase, Thymidylate synthase, Thymosin (such as alpha 1),
Thyroid hormone receptor, Thyroid stimulating hormone receptor,
Tissue factor, TNF related apoptosis inducing ligand, TNFR1
associated death domain protein, TNF-related apoptosis-inducing
ligand (TRAIL) receptor, TNFSF11 gene, TNFSF9 gene, Toll-like
receptor (TLR such as 1-13), topoisomerase (such as I, II, III),
Transcription factor, Transferase, Transferrin, Transforming growth
factor (TGF, such as beta) kinase, Transforming growth factor
TGF-.beta. receptor kinase, Transglutaminase, Translocation
associated protein, Transmembrane glycoprotein NMB, Trop-2 calcium
signal transducer, trophoblast glycoprotein (TPBG) gene,
Trophoblast glycoprotein, Tropomyosin receptor kinase (Trk)
receptor (such as TrkA, TrkB, TrkC), Tryptophan 5-hydroxylase,
Tubulin, Tumor necrosis factor (TNF, such as alpha, beta), Tumor
necrosis factor 13C receptor, tumor progression locus 2 (TPL2),
Tumor protein 53 (TP53) gene, Tumor suppressor candidate 2 (TUSC2)
gene, Tyrosinase, Tyrosine hydroxylase, tyrosine kinase (TK),
Tyrosine kinase receptor, Tyrosine kinase with immunoglobulin-like
and EGF-like domains (TIE) receptor, Tyrosine protein kinase ABL1
inhibitor, Ubiquitin, Ubiquitin carboxyl hydrolase isozyme L5,
Ubiquitin thioesterase-14, Ubiquitin-conjugating enzyme E21 (UBE2I,
UBC9), Urease, Urokinase plasminogen activator, Uteroglobin,
Vanilloid VR1, Vascular cell adhesion protein 1, vascular
endothelial growth factor receptor (VEGFR), V-domain Ig suppressor
of T-cell activation (VISTA), VEGF-1 receptor, VEGF-2 receptor,
VEGF-3 receptor, VEGF-A, VEGF-B, Vimentin, Vitamin D3 receptor,
Proto-oncogene tyrosine-protein kinase Yes, Wee-1 protein kinase,
Wilms' tumor antigen 1, Wilms' tumor protein, X-linked inhibitor of
apoptosis protein, Zinc finger protein transcription factor or any
combination thereof.
[0379] Non-limiting examples of additional therapeutic agents may
be categorized by their mechanism of action into, for example, the
following groups: [0380] anti-metabolites/anti-cancer agents, such
as pyrimidine analogs floxuridine, capecitabine, cytarabine,
CPX-351 (liposomal cytarabine, daunorubicin), and TAS-118; [0381]
purine analogs, folate antagonists (such as pralatrexate), and
related inhibitors; [0382] antiproliferative/antimitotic agents
including natural products, such as vinca alkaloids (vinblastine,
vincristine) and microtubule disruptors such as taxane (paclitaxel,
docetaxel), vinblastin, nocodazole, epothilones, vinorelbine
(NAVELBINE.RTM.), and epipodophyllotoxins (etoposide, teniposide);
[0383] DNA damaging agents, such as actinomycin, amsacrine,
busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide
(CYTOXAN.RTM.), dactinomycin, daunorubicin, doxorubicin,
epirubicin, iphosphamide, melphalan, merchlorethamine, mitomycin C,
mitoxantrone, nitrosourea, procarbazine, taxol, Taxotere,
teniposide, etoposide, and triethylenethiophosphoramide; [0384]
DNA-hypomethylating agents, such as guadecitabine (SGI-110),
ASTX727; [0385] antibiotics such as dactinomycin, daunorubicin,
doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycins,
plicamycin (mithramycin); [0386] enzymes such as L-asparaginase
which systemically metabolizes L-asparagine and deprives cells
which do not have the capacity to synthesize their own asparagine;
[0387] antiplatelet agents; [0388] DNAi oligonucleotides targeting
Bcl-2, such as PNT2258; [0389] agents that activate or reactivate
latent human immunodeficiency virus (HIV), such as panobinostat and
romidepsin; [0390] asparaginase stimulators, such as crisantaspase
(Erwinase.RTM.) and GRASPA (ERY-001, ERY-ASP), calaspargase pegol;
[0391] pan-Trk, ROS1 and ALK inhibitors, such as entrectinib,
TPX-0005; [0392] anaplastic lymphoma kinase (ALK) inhibitors, such
as alectinib, ceritinib; [0393] antiproliferative/antimitotic
alkylating agents, such as nitrogen mustard cyclophosphamide and
analogs (melphalan, chlorambucil, hexamethylmelamine, thiotepa),
alkyl nitrosoureas (carmustine) and analogs, streptozocin, and
triazenes (dacarbazine); [0394] antiproliferative/antimitotic
antimetabolites, such as folic acid analogs (methotrexate); [0395]
platinum coordination complexes (cisplatin, oxiloplatinim, and
carboplatin), procarbazine, hydroxyurea, mitotane, and
aminoglutethimide; [0396] hormones, hormone analogs (estrogen,
tamoxifen, goserelin, bicalutamide, and nilutamide), and aromatase
inhibitors (letrozole and anastrozole); [0397] anticoagulants such
as heparin, synthetic heparin salts, and other inhibitors of
thrombin; [0398] fibrinolytic agents such as tissue plasminogen
activator, streptokinase, urokinase, aspirin, dipyridamole,
ticlopidine, and clopidogrel; [0399] antimigratory agents; [0400]
antisecretory agents (breveldin); [0401] immunosuppressives, such
as tacrolimus, sirolimus, azathioprine, and mycophenolate; [0402]
growth factor inhibitors, and vascular endothelial growth factor
inhibitors; [0403] fibroblast growth factor inhibitors, such as
FPA14; [0404] anti-VEGFR antibodies, such as IMC-3C5, GNR-011,
tanibirumab; [0405] anti-VEGF/DDL4 antibodies, such as ABT-165;
[0406] anti-cadherins antibodies, such as HKT-288; [0407] anti-CD70
antibodies, such as AMG-172; anti-leucine-rich repeat containing 15
(LRRC15) antibodies, such as ABBV-085. ARGX-110; [0408] angiotensin
receptor blockers, nitric oxide donors; [0409] antisense
oligonucleotides, such as AEG35156, IONIS-KRAS-2.5Rx, EZN-3042,
RX-0201, IONIS-AR-2.5Rx, BP-100 (prexigebersen), IONIS-STAT3-2.5Rx;
[0410] DNA interference oligonucleotides, such as PNT2258,
AZD-9150; [0411] anti-ANG-2 antibodies, such as MEDI3617, and
LY3127804; [0412] anti-ANG-1/ANG-2 antibodies, such as AMG-780;
[0413] anti-MET/EGFR antibodies, such as LY3164530; [0414]
anti-EGFR antibodies, such as ABT-414, AMG-595, necitumumab,
ABBV-221, depatuxizumab mafodotin (ABT-414), tomuzotuximab,
ABT-806, vectibix, modotuximab, RM-1929; [0415] anti-CSF1R
antibodies, such as emactuzumab, LY3022855, AMG-820, FPA-008
(cabiralizumab); [0416] anti-CD40 antibodies, such as RG7876,
SEA-CD40, APX-005M, ABBV-428; [0417] anti-endoglin antibodies, such
as TRC105 (carotuximab); [0418] anti-CD45 antibodies, such as
131I-BC8 (lomab-B); [0419] anti-HER3 antibodies, such as LJM716,
GSK2849330; [0420] anti-HER2 antibodies, such as margetuximab,
MEDI4276, BAT-8001; [0421] anti-HLA-DR antibodies, such as
IMMU-114; [0422] anti-IL-3 antibodies, such as JNJ-56022473; [0423]
anti-OX40 antibodies, such as MEDI6469, MEDI6383, MEDI0562
(tavolixizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998,
INCAGN1949, BMS-986178, GBR-8383, ABBV-368; [0424] anti-EphA3
antibodies, such as KB-004; [0425] anti-CD20 antibodies, such as
obinutuzumab, IGN-002; [0426] anti-CD20/CD3 antibodies, such as
RG7828; [0427] anti-CD37 antibodies, such as AGS67E, otlertuzumab
(TRU-016); [0428] anti-ENPP3 antibodies, such as AGS-16C3F; [0429]
anti-FGFR-3 antibodies, such as LY3076226, B-701; [0430]
anti-FGFR-2 antibodies, such as GAL-F2; [0431] anti-C5 antibodies,
such as ALXN-1210; [0432] anti-CD27 antibodies, such as varlilumab
(CDX-1127); [0433] anti-TROP-2 antibodies, such as IMMU-132 [0434]
anti-NKG2a antibodies, such as monalizumab; [0435] anti-VISTA
antibodies, such as HMBD-002; [0436] anti-PVRIG antibodies, such as
COM-701; [0437] anti-EpCAM antibodies, such as VB4-845; [0438]
anti-BCMA antibodies, such as GSK-2857916 [0439] anti-CEA
antibodies, such as RG-7813; [0440] anti-cluster of differentiation
3 (CD3) antibodies, such as MGD015; [0441] anti-folate receptor
alpha antibodies, such as IMGN853; [0442] MCL-1 inhibitors, such as
AMG-176, S-64315, and AZD-5991, 483-LM, A-1210477, UMI-77,
JKY-5-037; [0443] epha2 inhibitors, such as MM-310; [0444] anti
LAG-3 antibodies, such as relatlimab (ONO-4482), LAG-525, MK-4280,
REGN-3767; [0445] raf kinase/VEGFR inhibitors, such as RAF-265;
[0446] polycomb protein (EED) inhibitors, such as MAK683; [0447]
anti-fibroblast activation protein (FAP)/IL-2R antibodies, such as
RG7461; [0448] anti-fibroblast activation protein (FAP)/TRATL-R2
antibodies, such as RG7386; [0449] anti-fucosyl-GM1 antibodies,
such as BMS-986012; [0450] p38 MAP kinase inhibitors, such as
ralimetinib; [0451] PRMT1 inhibitors, such as MS203; [0452]
Sphingosine kinase 2 (SK2) inhibitors, such as opaganib; [0453]
FLT3-ITD inhibitors, such as BCI-332; [0454] Nuclear erythroid
2-related factor 2 stimulators, such as omaveloxolone (RTA-408);
[0455] Tropomyosin receptor kinase (TRK) inhibitors, such as
LOXO-195, ONO-7579; [0456] anti-ICOS antibodies, such as JTX-2011,
GSK3359609; [0457] anti-DR5 (TRAIL2) antibodies, such as DS-8273;
[0458] anti-GD2 antibodies, such as APN-301; [0459]
anti-interleukin-17 (IL-17) antibodies, such as CJM-112; [0460]
anti-carbonic anhydrase IX antibodies, such as TX-250; [0461]
anti-CD38-attenukine, such as TAK573; [0462] anti-Mucin 1
antibodies, such as gatipotuzumab; [0463] Mucin 1 inhibitors, such
as GO-203-2C; [0464] MARCKS protein inhibitors, such as BIO-11006;
[0465] Folate antagonists, such as arfolitixorin; [0466] Galectin-3
inhibitors, such as GR-MD-02; [0467] Phosphorylated P68 inhibitors,
such as RX-5902; [0468] CD95/TNF modulators, such as ofranergene
obadenovec; [0469] PI3K/Akt/mTOR inhibitors, such as ABTL-0812;
[0470] pan-PIM kinase inhibitors, such as INCB-053914; [0471] IL-12
gene stimulators, such as EGEN-001, tavokinogene telseplasmid;
[0472] Heat shock protein HSP90 inhibitors, such as TAS-116,
PEN-866; [0473] VEGF/HGF antagonists, such as MP-0250; [0474] SYK
tyrosine kinase/FLT3 tyrosine kinase inhibitors, such as TAK-659;
[0475] SYK tyrosine kinase/JAK tyrosine kinase inhibitors, such as
ASN-002; [0476] FLT3 tyrosine kinase inhibitor, such as FF-10101;
[0477] FLT3 tyrosine kinase agonist, such as CDX-301; [0478]
FLT3/MEK1 inhibitors, such as E-6201; [0479] IL-24 antagonist, such
as AD-IL24; [0480] RIG-I agonists, such as RGT-100; [0481]
Aerolysin stimulators, such as topsalysin; [0482] P-Glycoprotein 1
inhibitors, such as HM-30181A; [0483] CSF-1 antagonists, such as
ARRY-382, BLZ-945; [0484] anti-Mesothelin antibodies, such as
SEL-403; [0485] Thymidine kinase stimulators, such as aglatimagene
besadenovec; [0486] Polo-like kinase 1 inhibitors, such as PCM-075;
[0487] TLR-7 agonists, such as TMX-101 (imiquimod); [0488] NEDD8
inhibitors, such as pevonedistat (MLN-4924), TAS-4464; [0489]
Pleiotropic pathway modulators, such as avadomide (CC-122); [0490]
FoxM1 inhibitors, such as thiostrepton; [0491] Anti-MUC1
antibodies, such as Mab-AR-20.5; [0492] anti-CD38 antibodies, such
as isatuximab, MOR-202; [0493] UBA1 inhibitors, such as TAK-243;
[0494] Src tyrosine kinase inhibitors, such as VAL-201; [0495]
VDAC/HK inhibitors, such as VDA-1102; [0496] BRAF/PI3K inhibitors,
such as ASN-003; [0497] Elf4a inhibitors, such as rohinitib,
eFT226; [0498] TP53 gene stimulators, such as ad-p53; [0499]
PD-L1/EGFR inhibitors, such as GNS-1480; [0500] Retinoic acid
receptor alpha (RAR.alpha.) inhibitors, such as SY-1425; [0501]
SIRT3 inhibitors, such as YC8-02; [0502] Stromal cell-derived
factor 1 ligand inhibitors, such as olaptesed pegol (NOX-A12);
[0503] IL-4 receptor modulators, such as MDNA-55; [0504] Arginase-I
stimulators, such as pegzilarginase; [0505] Topoisomerase I
inhibitor/hypoxia inducible factor-1 alpha inhibitors, such as
PEG-SN38 (firtecan pegol); [0506] Hypoxia inducible factor-1 alpha
inhibitors, such as PT-2977, PT-2385; [0507] CD122 agonists such as
NKTR-214; [0508] p53 tumor suppressor protein stimulators such as
kevetrin; [0509] Mdm4/Mdm2 p53-binding protein inhibitors, such as
ALRN-6924; [0510] kinesin spindle protein (KSP) inhibitors, such as
filanesib (ARRY-520); [0511] CD80-fc fusion protein inhibitors,
such as FPT-155; [0512] Menin and mixed lineage leukemia (MLL)
inhibitors such as KO-539; [0513] Liver x receptor agonists, such
as RGX-104; [0514] IL-10 agonists, such as AM-0010; [0515]
EGFR/ErbB-2 inhibitors, such as varlitinib; [0516] VEGFR/PDGFR
inhibitors, such as vorolanib; [0517] IRAK4 inhibitors, such as
CA-4948; [0518] anti-TLR-2 antibodies, such as OPN-305; [0519]
Calmodulin modulators, such as CBP-501; [0520] Glucocorticoid
receptor antagonists, such as relacorilant (CORT-125134); [0521]
Second mitochondria-derived activator of caspases (SMAC) protein
inhibitors, such as BI-891065; [0522] Lactoferrin modulators, such
as LTX-315; [0523] Kit tyrosine kinase/PDGF receptor alpha
antagonists such as DCC-2618; [0524] KIT inhibitors, such as
PLX-9486; [0525] Exportin 1 inhibitors, such as eltanexor; [0526]
EGFR/ErbB2/Ephb4 inhibitors, such as tesevatinib; [0527] anti-CD33
antibodies, such as IMGN-779; [0528] anti-KMA antibodies, such as
MDX-1097; [0529] anti-TIM-3 antibodies, such as TSR-022,
LY-3321367, MBG-453; [0530] anti-CD55 antibodies, such as PAT-SC;
[0531] anti-PSMA antibodies, such as ATL-101; [0532] anti-CD100
antibodies, such as VX-15; [0533] anti-EPHA3 antibodies, such as
fibatuzumab; [0534] anti-Erbb antibodies, such as CDX-3379, HLX-02,
seribantumab; [0535] anti-APRIL antibodies, such as BION-1301;
[0536] Anti-Tigit antibodies, such as BMS-986207, RG-6058; [0537]
CHST15 gene inhibitors, such as STNM-01; [0538] RAS inhibitors,
such as NEO-100; [0539] Somatostatin receptor antagonist, such as
OPS-201; [0540] CEBPA gene stimulators, such as MTL-501; [0541]
DKK3 gene modulators, such as MTG-201; [0542] p70s6k inhibitors,
such as MSC2363318A; [0543] methionine aminopeptidase 2 (MetAP2)
inhibitors, such as M8891, APL-1202; [0544] arginine
N-methyltransferase 5 inhibitors, such as GSK-3326595; [0545]
anti-programmed cell death protein 1 (anti-PD-1) antibodies, such
as nivolumab (OPDIVO.RTM., BMS-936558, MDX-1106), pembrolizumab
(KEYTRUDA.RTM., MK-3477, SCH-900475, lambrolizumab, CAS Reg. No.
1374853-91-4), pidilizumab, PF-06801591, BGB-A317, GLS-010
(WBP-3055), AK-103 (HX-008), MGA-012, BI-754091, REGN-2810
(cemiplimab), AGEN-2034, JS-001, JNJ-63723283, genolimzumab
(CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, BAT-1306, and
anti-programmed death-ligand 1 (anti-PD-L1) antibodies such as
BMS-936559, atezolizumab (MPDL3280A), durvalumab (MEDI4736),
avelumab, CK-301, (MSB0010718C), MEDIO680, CX-072, CBT-502, PDR-001
(spartalizumab), TSR-042 (dostarlimab), JTX-4014, BGB-A333,
SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308, FAZ-053, and
MDX1105-01; [0546] PD-L1/VISTA antagonists such as CA-170; [0547]
anti-PD-L1/TGF.beta. antibodies, such as M7824; [0548]
anti-transferrin antibodies, such as CX-2029; [0549] anti-IL-8
(Interleukin-8) antibodies, such as HuMax-Inflam; [0550] ATM
(ataxia telangiectasia) inhibitors, such as AZD0156; [0551] CHK1
inhibitors, such as GDC-0575, LY2606368 (prexasertib), SRA737,
RG7741 (CHK1/2); [0552] CXCR4 antagonists, such as BL-8040,
LY2510924, burixafor (TG-0054), X4P-002, X4P-001-IO; [0553] EXH2
inhibitors, such as GSK2816126; [0554] HER2 inhibitors, such as
neratinib, tucatinib (ONT-380); [0555] KDM1 inhibitors, such as
ORY-1001, IMG-7289, INCB-59872, GSK-2879552; [0556] CXCR2
antagonists, such as AZD-5069; [0557] GM-CSF antibodies, such as
lenzilumab; [0558] DNA dependent protein kinase inhibitors, such as
MSC2490484A (nedisertib), VX-984, AsiDNA (DT-01); [0559] protein
kinase C (PKC) inhibitors, such as LXS-196, sotrastaurin; [0560]
Selective estrogen receptor downregulators (SERD), such as
fulvestrant (Faslodex.RTM.), RG6046, RG6047, elacestrant (RAD-1901)
and AZD9496; [0561] Selective estrogen receptor covalent
antagonists (SERCAs), such as H3B-6545; [0562] selective androgen
receptor modulator (SARM), such as GTX-024, darolutamide; [0563]
transforming growth factor-beta (TGF-beta) kinase antagonists, such
as galunisertib; [0564] anti-transforming growth factor-beta
(TGF-beta) antibodies, such as LY3022859, NIS793, XOMA 089; [0565]
bispecific antibodies, such as MM-141 (IGF-1/ErbB3), MM-111
(Erb2/Erb3), JNJ-64052781 (CD19/CD3), PRS-343 (CD-137/HER2), AFM26
(BCMA/CD16A), JNJ-61186372 (EGFR/cMET), AMG-211 (CEA/CD3), RG7802
(CEA/CD3), ERY-974 (CD3/GPC3) vancizumab (angiopoietins/VEGF),
PF-06671008 (Cadherins/CD3), AFM-13 (CD16/CD30), APV0436
(CD123/CD3), flotetuzumab (CD123/CD3), REGN-1979 (CD20/CD3),
MCLA-117 (CD3/CLEC12A), MCLA-128 (HER2/HER3), JNJ-0819, JNJ-7564
(CD3/heme), AMG-757 (DLL3-CD3), MGD-013 (PD-1/LAG-3), AK-104
(CTLA-4/PD-1), AMG-330 (CD33/CD3), AMG-420 (BCMA/CD3), BI-836880
(VEFG/ANG2), JNJ-63709178 (CD123/CD3), MGD-007 (CD3/gpA33), MGD-009
(CD3/B7H3); [0566] Mutant selective EGFR inhibitors, such as
PF-06747775, EGF816 (nazartinib), ASP8273, ACEA-0010, BI-1482694;
[0567] Anti-GITR (glucocorticoid-induced tumor necrosis factor
receptor-related protein) antibodies, such as MEDI1873, FPA-154,
INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323; [0568]
anti-delta-like protein ligand 3 (DDL3) antibodies, such as
rovalpituzumab tesirine; [0569] anti-clusterin antibodies, such as
AB-16B5;
anti-Ephrin-A4 (EFNA4) antibodies, such as PF-06647263; [0571]
anti-RANKL antibodies, such as denosumab; [0572] anti-mesothelin
antibodies, such as BMS-986148, Anti-MSLN-MMAE; [0573] anti-sodium
phosphate cotransporter 2B (NaP2B) antibodies, such as
lifastuzumab; [0574] anti-c-Met antibodies, such as ABBV-399;
[0575] Adenosine A2A receptor antagonists, such as CPI-444,
AZD-4635, preladenant, PBF-509; [0576] Alpha-ketoglutarate
dehydrogenase (KGDH) inhibitors, such as CPI-613; [0577] XPO1
inhibitors, such as selinexor (KPT-330); [0578] Isocitrate
dehydrogenase 2 (IDH2) inhibitors, such as enasidenib (AG-221);
[0579] IDH1 inhibitors such as AG-120, and AG-881 (IDH1 and IDH2),
IDH-305, BAY-1436032; [0580] interleukin-3 receptor (IL-3R)
modulators, such as SL-401; [0581] Arginine deiminase stimulators,
such as pegargiminase (ADI-PEG-20); [0582] antibody-drug
conjugates, such as MLN0264 (anti-GCC, guanylyl cyclase C), T-DM1
(trastuzumab emtansine, Kadcycla), milatuzumab-doxorubicin
(hCD74-DOX), brentuximab vedotin, DCDT2980S, polatuzumab vedotin,
SGN-CD70A, SGN-CD19A, inotuzumab ozogamicin, lorvotuzumab
mertansine, SAR3419, isactuzumab govitecan, enfortumab vedotin
(ASG-22ME), ASG-15ME, DS-8201 (trastuzumab deruxtecan),
225Ac-lintuzumab, U3-1402, 177Lu-tetraxetan-tetuloma, tisotumab
vedotin, anetumab ravtansine, CX-2009, SAR-566658, W-0101,
polatuzumab vedotin, ABBV-085; [0583] claudin-18 inhibitors, such
as claudiximab; [0584] P-catenin inhibitors, such as CWP-291;
[0585] anti-CD73 antibodies, such as MEDI-9447 (oleclumab),
CPX-006, IPH-53, BMS-986179; [0586] CD73 antagonists, such as
AB-680, PSB-12379, PSB-12441, PSB-12425; [0587] CD39/CD73
antagonists, such as PBF-1662; [0588] chemokine receptor 2 (CCR)
inhibitors, such as PF-04136309, CCX-872, BMS-813160 (CCR2/CCR5);
[0589] thymidylate synthase inhibitors, such as ONX-0801; [0590]
ALK/ROS1 inhibitors, such as lorlatinib; [0591] tankyrase
inhibitors, such as G007-LK; [0592] Mdm2 p53-binding protein
inhibitors, such as CMG-097, HDM-201; [0593] c-PIM inhibitors, such
as PIM447; [0594] BRAF inhibitors, such as dabrafenib, vemurafenib,
encorafenib (LGX818), PLX8394; [0595] sphingosine kinase-2 (SK2)
inhibitors, such as Yeliva.RTM. (ABC294640); [0596] cell cycle
inhibitors, such as selumetinib (MEK1/2), and sapacitabine; [0597]
AKT inhibitors such as MK-2206, ipatasertib, afuresertib, AZD5363,
and ARQ-092, capivasertib, triciribine; [0598] anti-CTLA-4
(cytotoxic T-lymphocyte protein-4) inhibitors, such as
tremelimumab, AGEN-1884, BMS-986218; [0599] c-MET inhibitors, such
as AMG-337, savolitinib, tivantinib (ARQ-197), capmatinib, and
tepotinib, ABT-700, AG213, AMG-208, JNJ-38877618 (OMO-1),
merestinib, HQP-8361; [0600] c-Met/VEGFR inhibitors, such as
BMS-817378, TAS-115; [0601] c-Met/RON inhibitors, such as
BMS-777607; [0602] BRAF/EGFR inhibitors, such as BGB-283; [0603]
bcr/abl inhibitors, such as rebastinib, asciminib; [0604] MNK1/MNK2
inhibitors, such as eFT-508; [0605] mTOR inhibitor/cytochrome P450
3A4 stimulators, such as TYME-88; [0606] lysine-specific
demethylase-1 (LSD1) inhibitors, such as CC-90011; [0607] Pan-RAF
inhibitors, such as LY3009120, LXH254, TAK-580; [0608] Raf/MEK
inhibitors, such as RG7304; [0609] CSF1R/KIT and FLT3 inhibitors,
such as pexidartinib (PLX3397); [0610] kinase inhibitors, such as
vandetanib; [0611] E selectin antagonists, such as GMI-1271; [0612]
differentiation inducers, such as tretinoin; [0613] epidermal
growth factor receptor (EGFR) inhibitors, such as osimertinib
(AZD-9291); [0614] topoisomerase inhibitors, such as doxorubicin,
daunorubicin, dactinomycin, eniposide, epirubicin, etoposide,
idarubicin, irinotecan, mitoxantrone, pixantrone, sobuzoxane,
topotecan, irinotecan, MM-398 (liposomal irinotecan), vosaroxin and
GPX-150, aldoxorubicin, AR-67, mavelertinib, AST-2818, avitinib
(ACEA-0010), irofulven (MGI-114); [0615] corticosteroids, such as
cortisone, dexamethasone, hydrocortisone, methylprednisolone,
prednisone, prednisolone; [0616] growth factor signal transduction
kinase inhibitors; [0617] nucleoside analogs, such as DFP-10917;
[0618] Axl inhibitors, such as BGB-324 (bemcentinib), SLC-0211;
[0619] BET inhibitors, such as INCB-054329, INCB057643, TEN-010,
AZD-5153, ABT-767, BMS-986158, CC-90010, GSK525762 (molibresib),
NHWD-870, ODM-207, GSK-2820151, GSK-1210151A, ZBC246, ZBC260,
ZEN3694, FT-1101, RG-6146, CC-90010, mivebresib, BI-894999,
PLX-2853, PLX-51107, CPI-0610, GS-5829; [0620] PARP inhibitors,
such as olaparib, rucaparib, veliparib, talazoparib, ABT-767,
BGB-290; [0621] Proteasome inhibitors, such as ixazomib,
carfilzomib (Kyprolis.RTM.), marizomib; [0622] Glutaminase
inhibitors, such as CB-839; [0623] Vaccines, such as peptide
vaccine TG-01 (RAS), GALE-301, GALE-302, nelipepimut-s, SurVaxM,
DSP-7888, TPIV-200, PVX-410, VXL-100, DPX-E7, ISA-101, 6MHP,
OSE-2101, galinpepimut-S, SVN53-67/M57-KLH, IMU-131; bacterial
vector vaccines such as CRS-207/GVAX, axalimogene filolisbac
(ADXS11-001); adenovirus vector vaccines such as nadofaragene
firadenovec; autologous Gp96 vaccine; dendritic cells vaccines,
such as CVac.TM., stapuldencel-T, eltrapuldencel-T, SL-701,
BSKO1.TM., rocapuldencel-T (AGS-003), DCVAC, CVac.TM.,
stapuldencel-T, eltrapuldencel-T, SL-701, BSKO1.TM., ADXS31-142;
oncolytic vaccines such as, talimogene laherparepvec, pexastimogene
devacirepvec, GL-ONC1, MG1-MA3, parvovirus H-1, ProstAtak,
enadenotucirev, MG1MA3, ASN-002 (TG-1042); therapeutic vaccines,
such as CVAC-301, CMP-001, PF-06753512, VBI-1901, TG-4010,
ProscaVax.TM.; tumor cell vaccines, such as Vigil.RTM. (IND-14205),
Oncoquest-L vaccine; live attenuated, recombinant, serotype 1
poliovirus vaccine, such as PVS-RIPO; Adagloxad simolenin;
MEDI-0457; DPV-001 a tumor-derived, autophagosome enriched cancer
vaccine; RNA vaccines such as CV-9209, LV-305; DNA vaccines, such
as MEDI-0457, MVI-816, INO-5401; modified vaccinia virus Ankara
vaccine expressing p53, such as MVA-p53; DPX-Survivac; BriaVax.TM.;
GI-6301; GI-6207; GI-4000; [0624] anti-DLL4 (delta like ligand 4)
antibodies, such as demcizumab; [0625] STAT-3 inhibitors, such as
napabucasin (BBI-608); [0626] ATPase p97 inhibitors, such as
CB-5083; [0627] smoothened (SMO) receptor inhibitors, such as
Odomzo.RTM. (sonidegib, formerly LDE-225), LEQ506, vismodegib
(GDC-0449), BMS-833923, glasdegib (PF-04449913), LY2940680, and
itraconazole; [0628] interferon alpha ligand modulators, such as
interferon alpha-2b, interferon alpha-2a biosimilar (Biogenomics),
ropeginterferon alfa-2b (AOP-2014, P-1101, PEG IFN alpha-2b),
Multiferon (Alfanative, Viragen), interferon alpha 1b, Roferon-A
(Canferon, Ro-25-3036), interferon alfa-2a follow-on biologic
(Biosidus)(Inmutag, Inter 2A), interferon alfa-2b follow-on
biologic (Biosidus--Bioferon, Citopheron, Ganapar, Beijing Kawin
Technology--Kaferon), Alfaferone, pegylated interferon alpha-1b,
peginterferon alfa-2b follow-on biologic (Amega), recombinant human
interferon alpha-1b, recombinant human interferon alpha-2a,
recombinant human interferon alpha-2b, veltuzumab-IFN alpha 2b
conjugate, Dynavax (SD-101), and interferon alfa-n1 (Humoferon,
SM-10500, Sumiferon); [0629] interferon gamma ligand modulators,
such as interferon gamma (OH-6000, Ogamma 100); [0630] IL-6
receptor modulators, such as tocilizumab, siltuximab, AS-101
(CB-06-02, IVX-Q-101); [0631] Telomerase modulators, such as,
tertomotide (GV-1001, HR-2802, Riavax) and imetelstat (GRN-163,
JNJ-63935937); [0632] DNA methyltransferases inhibitors, such as
temozolomide (CCRG-81045), decitabine, guadecitabine (5-110,
SGI-110), KRX-0402, RX-3117, RRx-001, and azacitidine; [0633] DNA
gyrase inhibitors, such as pixantrone and sobuzoxane; [0634] Bcl-2
family protein inhibitors, such as ABT-263, venetoclax (ABT-199),
ABT-737, and AT-101; [0635] Notch inhibitors, such as LY3039478
(crenigacestat), tarextumab (anti-Notch2/3), BMS-906024; [0636]
anti-myostatin inhibitors, such as landogrozumab; [0637]
hyaluronidase stimulators, such as PEGPH-20; [0638] Wnt pathway
inhibitors, such as SM-04755, PRI-724, WNT-974; [0639]
gamma-secretase inhibitors, such as PF-03084014, MK-0752,
RO-4929097; [0640] Grb-2 (growth factor receptor bound protein-2)
inhibitors, such as BP1001; [0641] TRAIL pathway-inducing
compounds, such as ONC201, ABBV-621; [0642] Focal adhesion kinase
inhibitors, such as VS-4718, defactinib, GSK2256098; [0643]
hedgehog inhibitors, such as saridegib, sonidegib (LDE225),
glasdegib and vismodegib; [0644] Aurora kinase inhibitors, such as
alisertib (MLN-8237), and AZD-2811, AMG-900, barasertib, ENMD-2076;
[0645] HSPB1 modulators (heat shock protein 27, HSP27), such as
brivudine, apatorsen; [0646] ATR inhibitors, such as BAY-937,
AZD6738, AZD6783, VX-803, VX-970 (berzosertib) and VX-970; [0647]
mTOR inhibitors, such as sapanisertib and vistusertib (AZD2014),
ME-344; [0648] mTOR/PI3K inhibitors, such as gedatolisib,
GSK2141795, omipalisib, RG6114; [0649] Hsp90 inhibitors, such as
AUY922, onalespib (AT13387), SNX-2112, SNX5422; [0650] Murine
double minute (mdm2) oncogene inhibitors, such as DS-3032b, RG7775,
AMG-232, HDM201, and idasanutlin (RG7388); [0651] CD137 agonists,
such as urelumab, utomilumab (PF-05082566); [0652] STING agonists,
such as ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848,
GSK-532, SYN-STING, MSA-1, SR-8291; [0653] FGFR inhibitors, such as
FGF-401, INCB-054828, BAY-1163877, AZD4547, JNJ-42756493,
LY2874455, Debio-1347; [0654] fatty acid synthase (FASN)
inhibitors, such as TVB-2640; [0655] Anti-KIR monoclonal
antibodies, such as lirilumab (IPH-2102), IPH-4102; [0656] Antigen
CD19 inhibitors, such as MOR208, MEDI-551, AFM-11, inebilizumab;
[0657] CD44 binders, such as A6; [0658] protein phosphatase 2A
(PP2A) inhibitors, such as LB-100; [0659] CYP17 inhibitors, such as
seviteronel (VT-464), ASN-001, ODM-204, CFG920, abiraterone
acetate; [0660] RXR agonists, such as IRX4204; [0661]
hedgehog/smoothened (hh/Smo) antagonists, such as taladegib,
patidegib; [0662] complement C3 modulators, such as Imprime PGG;
[0663] IL-15 agonists, such as ALT-803, NKTR-255, and hetIL-15;
[0664] EZH2 (enhancer of zeste homolog 2) inhibitors, such as
tazemetostat, CPI-1205, GSK-2816126; [0665] Oncolytic viruses, such
as pelareorep, CG-0070, MV-NIS therapy, HSV-1716, DS-1647, VCN-01,
ONCOS-102, TBI-1401, tasadenoturev (DNX-2401), vocimagene
amiretrorepvec, RP-1, CVA21, Celyvir, LOAd-703, OBP-301; [0666]
DOT1L (histone methyltransferase) inhibitors, such as pinometostat
(EPZ-5676); [0667] toxins such as Cholera toxin, ricin, Pseudomonas
exotoxin, Bordetella pertussis adenylate cyclase toxin, diphtheria
toxin, and caspase activators; [0668] DNA plasmids, such as BC-819;
[0669] PLK inhibitors of PLK 1, 2, and 3, such as volasertib
(PLK1); [0670] WEEi inhibitors, such as AZD1775 (adavosertib);
[0671] Rho kinase (ROCK) inhibitors, such as AT13148, KD025; [0672]
ERK inhibitors, such as GDC-0994, LY3214996, MK-8353; [0673] IAP
inhibitors, such as ASTX660, debio-1143, birinapant, APG-1387,
LCL-161; [0674] RNA polymerase inhibitors, such has lurbinectedin
(PM-1183), CX-5461; [0675] Tubulin inhibitors, such as PM-184,
BAL-101553 (lisavanbulin), and OXI-4503, fluorapacin (AC-0001),
plinabulin; [0676] Toll-like receptor 4 (TL4) agonists, such as
G100, GSK1795091, and PEPA-10; [0677] Elongation factor 1 alpha 2
inhibitors, such as plitidepsin; [0678] CD95 inhibitors, such as
APG-101, APO-010, asunercept; [0679] WT1 inhibitors, such as
DSP-7888; [0680] splicing factor 3B subunit1 (SF3B1) inhibitors,
such as H3B-8800; [0681] PDGFR alpha/KIT mutant-specific inhibitors
such as BLU-285; [0682] SHP-2 inhibitors, such as TNO155 (SHP-099),
RMC-4550; and [0683] retinoid Z receptor gamma (RORy) agonists,
such as LYC-55716.
[0684] In some embodiments, provided herein are methods of treating
or preventing a hyperproliferative disorder or cancer in a human or
animal having or at risk of having the hyperproliferative disorder
or cancer is provided, comprising administering to the human or
animal a therapeutically effective amount of a compound as
disclosed herein, or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective amount of one or more
(e.g., one, two, three, one or two, or one to three) additional
therapeutic agents selected from the group consisting of apoptosis
signal-regulating kinase (ASK) inhibitors; Bruton's tyrosine kinase
(BTK) inhibitors; cluster of differentiation 47 (CD47) inhibitors;
cyclin-dependent kinase (CDK) inhibitors; discoidin domain receptor
(DDR) inhibitors; histone deacetylase (HDAC) inhibitors;
indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors; Janus kinase
(JAK) inhibitors; lysyl oxidase-like protein (LOXL) inhibitors;
matrix metalloprotease (MMP) inhibitors; mitogen-activated protein
kinase (MEK) inhibitors; phosphatidylinositol 3-kinase (PI3K)
inhibitors; spleen tyrosine kinase (SYK) inhibitors; toll-like
receptor 8 (TLR8) inhibitors; toll-like receptor 9 (TLR9)
inhibitors; tyrosine-kinase inhibitors (TKIs), and any combination
thereof, or a pharmaceutically acceptable salt thereof.
Non-limiting examples include: [0685] Apoptosis Signal-Regulating
Kinase (ASK) Inhibitors: ASK inhibitors include ASK1 inhibitors.
Examples of ASK1 inhibitors include, but are not limited to, those
described in WO 2011/008709 (Gilead Sciences) and WO 2013/112741
(Gilead Sciences); [0686] Bruton's Tyrosine Kinase (BTK)
Inhibitors: Examples of BTK inhibitors include, but are not limited
to,
(S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-pur-
in-8 (9H)-one, acalabrutinib (ACP-196), BGB-3111, CB988, HM71224,
ibrutinib, M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059),
PRN-1008, spebrutinib (CC-292), TAK-020, vecabrutinib, ARQ-531,
SHR-1459, DTRMWXHS-12, TAS-5315; [0687] Cluster ofDifferentiation
47 (CD47) inhibitors: Examples of CD47 inhibitors include, but are
not limited to anti-CD47 mAbs (Vx-1004), anti-human CD47 mAbs
(CNTO-7108), CC-90002, CC-90002-ST-001, humanized anti-CD47
antibody (Hu5F9-G4), NI-1701, NI-1801, RCT-1938, and TTI-621;
[0688] Cyclin-dependentKinase (CDK) Inhibitors: CDK inhibitors
include inhibitors of CDK 1, 2, 3, 4, 6, 7 and 9, such as
abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519,
dinaciclib, ibrance, FLX-925, LEE001, palbociclib, ribociclib,
rigosertib, selinexor, UCN-01, SY1365, CT-7001, SY-1365, G1T38,
milciclib, trilaciclib, and TG-02; [0689] Discoidin Domain Receptor
(DDR) Inhibitors: DDR inhibitors include inhibitors of DDR1 and/or
DDR2. Examples of DDR inhibitors include, but are not limited to,
those disclosed in WO 2014/047624 (Gilead Sciences), US
2009-0142345 (Takeda Pharmaceutical), US 2011-0287011 (Oncomed
Pharmaceuticals), WO 2013/027802 (Chugai Pharmaceutical), and WO
2013/034933 (Imperial Innovations); [0690] Histone Deacetylase
(HDAC) Inhibitors: Examples of HDAC inhibitors include, but are not
limited to, abexinostat, ACY-241, AR-42, BEBT-908, belinostat,
CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat,
givinostat, mocetinostat, panobinostat, pracinostat, quisinostat
(JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid
(VAL-001), vorinostat, tinostamustine, remetinostat, entinostat;
[0691] Indoleamine-pyrrole-2,3-dioxygenase (IDO) inhibitors:
Examples of IDO 1 inhibitors include, but are not limited to,
BLV-0801, epacadostat, F-001287, GBV-1012, GBV-1028, GDC-0919,
indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003,
pyranonaphthoquinone derivatives (SN-35837), resminostat,
SBLK-200802, BMS-986205, and shIDO-ST, EOS-200271, KHK-2455,
LY-3381916; [0692] Janus Kinase (JAK) Inhibitors: JAK inhibitors
inhibit JAK1, JAK2, and/or JAK3. Examples of JAK inhibitors
include, but are not limited to, AT9283, AZD1480, baricitinib,
BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib
(LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib
(CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K),
ruxolitinib, tofacitinib (formerly tasocitinib), INCB052793, and
XL019; [0693] Lysyl Oxidase-Like Protein (LOXL) Inhibitors: LOXL
inhibitors include inhibitors of LOXL1, LOXL2, LOXL3, LOXL4, and/or
LOXL5. Examples of LOXL inhibitors include, but are not limited to,
the antibodies described in WO 2009/017833 (Arresto Biosciences).
Examples of LOXL2 inhibitors include, but are not limited to, the
antibodies described in WO 2009/017833 (Arresto Biosciences), WO
2009/035791 (Arresto Biosciences), and WO 2011/097513 (Gilead
Biologics); [0694] Matrix Metalloprotease (A4HP) Inhibitors: MMP
inhibitors include inhibitors of MMP1 through 10. Examples of MMP9
inhibitors include, but are not limited to, marimastat (BB-2516),
cipemastat (Ro 32-3555), GS-5745 (andecaliximab) and those
described in WO 2012/027721 (Gilead Biologics); [0695]
Mitogen-activated Protein Kinase (MEK) Inhibitors: MEK inhibitors
include antroquinonol, binimetinib, cobimetinib (GDC-0973, XL-518),
MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212),
uprosertib+trametinib, PD-0325901, pimasertib, LTT462, AS703988,
CC-90003, refametinib; [0696] Phosphatidylinositol 3-kinase (PI3K)
Inhibitors: PI3K inhibitors include inhibitors of PI3K.gamma.,
PI3K.delta., PI3K.beta., PI3K.alpha., and/or pan-PI3K. Examples of
PI3K inhibitors include, but are not limited to, ACP-319, AEZA-129,
AMG-319, AS252424, AZD8186, BAY 10824391, BEZ235, buparlisib
(BKM120), BYL719 (alpelisib), CH5132799, copanlisib (BAY 80-6946),
duvelisib, GDC-0032, GDC-0077, GDC-0941, GDC-0980, GSK2636771,
GSK2269557, idelalisib (Zydelig.RTM.), INCB50465, IPI-145, IPI-443,
IPI-549, KAR4141, LY294002, LY3023414, MLN1117, OXY111A, PA799,
PX-866, RG7604, rigosertib, RP5090, RP6530, SRX3177, taselisib,
TG100115, TGR-1202 (umbralisib), TGX221, WX-037, X-339, X-414,
XL147 (SAR245408), XL499, XL756, wortmannin, ZSTK474, and the
compounds described in WO 2005/113556 (ICOS), WO 2013/052699
(Gilead Calistoga), WO 2013/116562 (Gilead Calistoga), WO
2014/100765 (Gilead Calistoga), WO 2014/100767 (Gilead Calistoga),
and WO 2014/201409 (Gilead Sciences); [0697] Spleen Tyrosine Kinase
(SYK) Inhibitors: Examples of SYK inhibitors include, but are not
limited to,
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine,
BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib
(R788), HMPL-523, NVP-QAB 205 AA, R112, R343, tamatinib (R406), and
those described in U.S. Pat. No. 8,450,321 (Gilead Connecticut) and
those described in U.S. 2015/0175616; [0698] Toll-like receptor 8
(TLR8) inhibitors: Examples of TLR8 inhibitors include, but are not
limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465,
MEDI-9197, motolimod, resiquimod, VTX-1463, and VTX-763; [0699]
Toll-like receptor 9 (TLR9) inhibitors: Examples of TLR9 inhibitors
include, but are not limited to, AST-008, IMO-2055, IMO-2125,
lefitolimod, litenimod, MGN-1601, and PUL-042; and [0700]
Tyrosine-kinase Inhibitors (TKIs): TKIs may target epidermal growth
factor receptors (EGFRs) and receptors for fibroblast growth factor
(FGF), platelet-derived growth factor (PDGF), and vascular
endothelial growth factor (VEGF). Examples of TKIs include, but are
not limited to, afatinib, ARQ-087 (derazantinib), asp5878, AZD3759,
AZD4547, bosutinib, brigatinib, cabozantinib, cediranib,
crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib,
erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713,
icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib,
lenvatinib, midostaurin, nintedanib, ODM-203, osimertinib
(AZD-9291), ponatinib, poziotinib, quizartinib, radotinib,
rociletinib, sulfatinib (HMPL-012), sunitinib, tivoanib, and
TH-4000, MEDI-575 (anti-PDGFR antibody).
[0701] As used herein, the term "chemotherapeutic agent" or
"chemotherapeutic" (or "chemotherapy" in the case of treatment with
a chemotherapeutic agent) is meant to encompass any
non-proteinaceous (i.e., non-peptidic) chemical compound useful in
the treatment of cancer. Examples of chemotherapeutic agents
include but are not limited to: alkylating agents such as thiotepa
and cyclophosphamide (CYTOXAN.RTM.); alkyl sulfonates such as
busulfan, improsulfan, and piposulfan; aziridines such as
benzodepa, carboquone, meturedepa, and uredepa; ethylenimines and
methylamelamines including altretamine, triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide, and
trimemylolomelamine; acetogenins, especially bullatacin and
bullatacinone; a camptothecin, including synthetic analog
topotecan; bryostatin, callystatin; CC-1065, including its
adozelesin, carzelesin, and bizelesin synthetic analogs;
cryptophycins, particularly cryptophycin 1 and cryptophycin 8;
dolastatin; duocarmycin, including the synthetic analogs KW-2189
and CBI-TMI; eleutherobin; 5-azacytidine; pancratistatin; a
sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, cyclophosphamide, glufosfamide, evofosfamide,
bendamustine, estramustine, ifosfamide, mechlorethamine,
mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, and uracil mustard;
nitrosoureas such as carmustine, chlorozotocin, foremustine,
lomustine, nimustine, and ranimustine; antibiotics such as the
enediyne antibiotics (e.g., calicheamicin, especially calicheamicin
gammaII and calicheamicin phiIl), dynemicin including dynemicin A,
bisphosphonates such as clodronate, an esperamicin,
neocarzinostatin chromophore and related chromoprotein enediyne
antibiotic chromomophores, aclacinomycins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin,
carrninomycin, carzinophilin, chromomycins, dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin
(including morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin
C, mycophenolic acid, nogalamycin, olivomycins, peplomycin,
porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin;
anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogs such as demopterin, methotrexate, pteropterin,
and trimetrexate; purine analogs such as fludarabine,
6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs
such as ancitabine, azacitidine, 6-azauridine, carmofur,
cytarabine, dideoxyuridine, doxifluridine, enocitabine, and
floxuridine; androgens such as calusterone, dromostanolone
propionate, epitiostanol, mepitiostane, and testolactone;
anti-adrenals such as aminoglutethimide, mitotane, and trilostane;
folic acid replenishers such as frolinic acid; radiotherapeutic
agents such as Radium-223; trichothecenes, especially T-2 toxin,
verracurin A, roridin A, and anguidine; taxoids such as paclitaxel
(TAXOL), abraxane, docetaxel (TAXOTERE.RTM.), cabazitaxel,
BIND-014, tesetaxel; platinum analogs such as cisplatin and
carboplatin, NC-6004 nanoplatin; aceglatone; aldophosphamide
glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elformthine; elliptinium acetate; an epothilone; etoglucid; gallium
nitrate; hydroxyurea; lentinan; leucovorin; lonidamine;
maytansinoids such as maytansine and ansamitocins; mitoguazone;
mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet;
pirarubicin; losoxantrone; fluoropyrimidine; folinic acid;
podophyllinic acid; 2-ethylhydrazide; procarbazine;
polysaccharide-K (PSK); razoxane; rhizoxin; sizofiran;
spirogermanium; tenuazonic acid; trabectedin, triaziquone;
2,2',2''-tricUorotriemylamine; urethane; vindesine; dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;
arabinoside ("Ara-C"); cyclophosphamide; thiopeta; chlorambucil;
gemcitabine (GEMZAR); 6-thioguanine; mercaptopurine; methotrexate;
vinblastine; platinum; etoposide (VP-16); ifosfamide;
mitroxantrone; vancristine; vinorelbine (NAVELBINE.RTM.);
novantrone; teniposide; edatrexate; daunomycin; aminopterin;
xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;
difluoromethylornithine (DFMO); retinoids such as retinoic acid;
capecitabine; NUC-1031; FOLFIRI (fluorouracil, leucovorin, and
irinotecan); and pharmaceutically acceptable salts, acids, or
derivatives of any of the above.
[0702] Also included in the definition of "chemotherapeutic agent"
are anti-hormonal agents such as anti-estrogens and selective
estrogen receptor modulators (SERMs), inhibitors of the enzyme
aromatase, anti-androgens, and pharmaceutically acceptable salts,
acids or derivatives of any of the above that act to regulate or
inhibit hormone action on tumors.
[0703] Anti-Hormonal Agents
[0704] Examples of anti-estrogens and SERMs include, for example,
tamoxifen (including NOLVADEX.TM.), raloxifene, droloxifene,
4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone,
and toremifene (FARESTON.RTM.).
[0705] Inhibitors of the enzyme aromatase regulate estrogen
production in the adrenal glands. Examples include 4
(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGACE.RTM.),
exemestane, formestane, fadrozole, vorozole (RIVISOR.RTM.),
letrozole (FEMARA.RTM.), and anastrozole (ARIMIDEX.RTM.).
[0706] Examples of anti-androgens include apalutamide, abiraterone,
enzalutamide, flutamide, galeterone, nilutamide, bicalutamide,
leuprolide, goserelin, ODM-201, APC-100, ODM-204.
[0707] Examples of progesterone receptor antagonist include
onapristone.
[0708] Anti-Angiogenic Agents
[0709] Anti-angiogenic agents include, but are not limited to,
retinoid acid and derivatives thereof, 2-methoxyestradiol,
ANGIOSTATIN.RTM., ENDOSTATIN.RTM., regorafenib, necuparanib,
suramin, squalamine, tissue inhibitor of metalloproteinase-1,
tissue inhibitor of metalloproteinase-2, plasminogen activator
inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived
inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4,
protamine sulphate (clupeine), sulphated chitin derivatives
(prepared from queen crab shells), sulphated polysaccharide
peptidoglycan complex (sp-pg), staurosporine, modulators of matrix
metabolism including proline analogs such as
1-azetidine-2-carboxylic acid (LACA), cishydroxyproline,
d,I-3,4-dehydroproline, thiaproline, .alpha.,.alpha.'-dipyridyl,
beta-aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2
(3h)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2
macroglobulin-serum, chicken inhibitor of metalloproteinase-3
(ChIMP-3), chymostatin, beta-cyclodextrin tetradecasulfate,
eponemycin, fumagillin, gold sodium thiomalate, d-penicillamine,
beta-1-anticollagenase-serum, alpha-2-antiplasmin, bisantrene,
lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid
disodium or "CCA", thalidomide, angiostatic steroid, carboxy
aminoimidazole, metalloproteinase inhibitors such as BB-94,
inhibitors of S100A9 such as tasquinimod. Other anti-angiogenesis
agents include antibodies, preferably monoclonal antibodies against
these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF
isoforms, VEGF-C, HGF/SF, and Ang-1/Ang-2.
[0710] Anti-Fibrotic Agents
[0711] Anti-fibrotic agents include, but are not limited to, the
compounds such as beta-aminoproprionitrile (BAPN), as well as the
compounds disclosed in U.S. Pat. No. 4,965,288 relating to
inhibitors of lysyl oxidase and their use in the treatment of
diseases and conditions associated with the abnormal deposition of
collagen and U.S. Pat. No. 4,997,854 relating to compounds which
inhibit LOX for the treatment of various pathological fibrotic
states, which are herein incorporated by reference. Further
exemplary inhibitors are described in U.S. Pat. No. 4,943,593
relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or
bromo-allylamine, U.S. Pat. Nos. 5,021,456, 5,059,714, 5,120,764,
5,182,297, 5,252,608 relating to
2-(1-naphthyloxymemyl)-3-fluoroallylamine, and US 2004-0248871,
which are herein incorporated by reference.
[0712] Exemplary anti-fibrotic agents also include the primary
amines reacting with the carbonyl group of the active site of the
lysyl oxidases, and more particularly those which produce, after
binding with the carbonyl, a product stabilized by resonance, such
as the following primary amines: emylenemamine, hydrazine,
phenylhydrazine, and their derivatives; semicarbazide and urea
derivatives; aminonitriles such as BAPN or 2-nitroethylamine;
unsaturated or saturated haloamines such as 2-bromo-ethylamine,
2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, and
p-halobenzylamines; and selenohomocysteine lactone.
[0713] Other anti-fibrotic agents are copper chelating agents
penetrating or not penetrating the cells. Exemplary compounds
include indirect inhibitors which block the aldehyde derivatives
originating from the oxidative deamination of the lysyl and
hydroxylysyl residues by the lysyl oxidases. Examples include the
thiolamines, particularly D-penicillamine, and its analogs such as
2-amino-5-mercapto-5-methylhexanoic acid,
D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid,
p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid,
sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane
sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate, and
sodium-4-mercaptobutanesulphinate trihydrate.
[0714] Immunotherapeutic Agents
[0715] The immunotherapeutic agents include and are not limited to
therapeutic antibodies suitable for treating subjects. Some
examples of therapeutic antibodies include abagovomab, ABP-980,
adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab,
anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab,
bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab,
CC49, cetuximab, citatuzumab, cixutumumab, clivatuzumab,
conatumumab, dacetuzumab, dalotuzumab, daratumumab, detumomab,
dinutuximab, drozitumab, duligotumab, dusigitumab, ecromeximab,
elotuzumab, emibetuzumab, ensituximab, ertumaxomab, etaracizumab,
farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab,
ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab,
igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab,
ipilimumab (YERVOY.RTM., MDX-010, BMS-734016, and MDX-101),
iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab,
lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab,
mitumomab, mogamulizumab, moxetumomab, naptumomab, narnatumab,
necitumumab, nimotuzumab, nofetumomab, OBI-833, obinutuzumab,
ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab,
oregovomab, panitumumab, parsatuzumab, pasudotox, patritumab,
pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab,
radretumab, ramucirumab (Cyramza.RTM.), rilotumumab, rituximab,
robatumumab, samalizumab, satumomab, sibrotuzumab, siltuximab,
solitomab, simtuzumab, tacatuzumab, taplitumomab, tenatumomab,
teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab,
ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, and
3F8. Rituximab can be used for treating indolent B-cell cancers,
including marginal-zone lymphoma, WM, CLL and small lymphocytic
lymphoma. A combination of Rituximab and chemotherapy agents is
especially effective.
[0716] The exemplified therapeutic antibodies may be further
labeled or combined with a radioisotope particle such as
indium-111, yttrium-90 (90Y-clivatuzumab), or iodine-131.
[0717] Cancer Gene Therapy and Cell Therapy
[0718] Cancer Gene Therapy and Cell Therapy includes the insertion
of a normal gene into cancer cells to replace a mutated or altered
gene; genetic modification to silence a mutated gene; genetic
approaches to directly kill the cancer cells; including the
infusion of immune cells designed to replace most of the subject's
own immune system to enhance the immune response to cancer cells,
or activate the subject's own immune system (T cells or Natural
Killer cells) to kill cancer cells, or find and kill the cancer
cells; genetic approaches to modify cellular activity to further
alter endogenous immune responsiveness against cancer.
[0719] Gene Editors
[0720] Examples of genome editing system include a CRISPR/Cas9
system, a zinc finger nuclease system, a TALEN system, a homing
endonucleases system, and a meganuclease system.
[0721] CAR-T Cell Therapy and TCR-T Cell Therapy
[0722] CAR-T cell therapy includes a population of immune effector
cells engineered to express a chimeric antigen receptor (CAR),
wherein the CAR comprises a tumor antigen-binding domain. The
immune effector cell is a T cell or an NK cell. TCR-T cell therapy
includes TCR-T cells that are engineered to target tumor derived
peptides present on the surface of tumor cells. Cells can be
autologous or allogeneic.
[0723] In some embodiments, the CAR comprises an antigen binding
domain, a transmembrane domain, and an intracellular signaling
domain.
[0724] In some embodiments, the intracellular domain comprises a
primary signaling domain, a costimulatory domain, or both of a
primary signaling domain and a costimulatory domain.
[0725] In some embodiments, the primary signaling domain comprises
a functional signaling domain of one or more proteins selected from
the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3
epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon Rlb),
CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12.
[0726] In some embodiments, the costimulatory domain comprises a
functional domain of one or more proteins selected from the group
consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1,
ICOS, lymphocyte function-associated antigen-1 (LFA-I), CD2, CD7,
LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83,
CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFI),
CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R
alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f,
ITGAD, CD 1 ild, ITGAE, CD103, ITGAL, CD 1 la, LFA-1, ITGAM, CD1
lb, ITGAX, CD1 lc, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2,
TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96
(Tactile), CEACAMI, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100
(SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMFI, CD150, IPO-3),
BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp,
NKp44, NKp30, NKp46, and NKG2D.
[0727] In some embodiments, the transmembrane domain comprises a
transmembrane domain of a protein selected from the group
consisting of the alpha, beta or zeta chain of the T-cell receptor,
CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33,
CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2,
CD27, LFA-1 (CD1 la, CD18), ICOS (CD278), 4-1BB (CD137), GITR,
CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19,
IL2R beta, IL2R gamma, IL7R u, ITGA1, VLA1, CD49a, ITGA4, IA4,
CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1 ld, ITGAE, CD103, ITGAL, CD1
la, LFA-1, ITGAM, CD1 lb, ITGAX, CD1 lc, ITGB1, CD29, ITGB2, CD18,
LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96
(Tactile), CEACAMI, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100
(SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMFI, CD150, IPO-3), BLAME
(SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46,
NKG2D, and NKG2C.
[0728] In some embodiments, the antigen binding domain binds a
tumor antigen.
[0729] In some embodiments, the tumor antigen is selected from the
group consisting of: CD19; CD123; CD22; CD30; CD171; CS-1 (also
referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24);
C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal
growth factor receptor variant III (EGFRvlll); ganglioside G2
(GD2); ganglioside GD3
(aNeuSAc(2-8)aNeuSAc(2-3)bDGaip(1-4)bDGIcp(1-1)Cer); TNF receptor
family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or
(GaINAcu-Ser/Thr)); prostate-specific membrane antigen (PSMA);
Receptor tyrosine kinase-like orphan receptor 1 (RORI); Fms-Like,
Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72);
CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell
adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117);
Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2);
Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem
cell antigen (PSCA); Protease Serine 21 (Testisin or PRSS21);
vascular endothelial growth factor receptor 2 (VEGFR2);
Lewis(Y)antigen; CD24; Platelet-derived growth factor receptor beta
(PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20;
delta like 3 (DLL3); Folate receptor alpha; Receptor
tyrosine-protein kinase, ERBB2 (Her2/neu); Mucin 1, cell surface
associated (MUC1); epidermal growth factor receptor (EGFR); neural
cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase
(PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast
activation protein alpha (FAP);insulin-like growth factor 1
receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome
(Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100
(gp100); oncogene fusion protein consisting of breakpoint cluster
region (BCR) and Abelson murine leukemia viral oncogene homolog 1
(Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2);
Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3
(aNeuSAc(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5);
high molecular weight-melanoma associated antigen (HMWMAA);
o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; tumor
endothelial marker 1 (TEM1/CD248); tumor endothelial marker
7-related (TEM7R); six transmembrane epithelial antigen of the
prostate I (STEAP1); claudin 6 (CLDN6); thyroid stimulating hormone
receptor (TSHR); G protein-coupled receptor class C group 5, member
D (GPRCSD); chromosome X open reading frame 61 (CXORF61); CD97;
CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid;
placenta-specific 1 (PLAC1); hexasaccharide portion of globoH
glycoceramide (GoboH); mammary gland differentiation antigen
(NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor
1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G
protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex,
locus K 9 (LY6K); Olfactory receptor 51E2 (ORS IE2); TCR Gamma
Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1);
Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2
(LAGE-la); Melanoma associated antigen 1 (MAGE-A1); ETS
translocation-variant gene 6, located on chromosome 12p (ETV6-AML);
sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGEl);
angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma
cancer testis antigen-1 (MADCT-1); melanoma cancer testis antigen-2
(MAD-CT-2); Fos-related antigen 1; tumor protein p53, (p53); p53
mutant; prostein; survivin; telomerase; prostate carcinoma tumor
antigen-1 (PCTA-1 or Galectin 8), melanoma antigen recognized by T
cells 1 (MelanA or MARTI); Rat sarcoma (Ras) mutant; human
Telomerase reverse transcriptase (hTERT); sarcoma translocation
breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG
(transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene);
N-Acetyl glucosaminyl-transferase V (NA17); paired box protein
Pax-3 (PAX3); Androgen receptor; Cyclin B1;v-myc avian
myelocytomatosis viral oncogene neuroblastoma derived homolog
(MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related
protein 2 (TRP-2); Cytochrome P450 1B1 (CYP IBI); CCCTC-Binding
Factor (Zinc Finger Protein)-Like (BORIS or Brother of the
Regulator of Imprinted Sites), Squamous Cell Carcinoma Antigen
Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5);
proacrosin binding protein sp32 (OY-TES I); lymphocyte-specific
protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4);
synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced
Glycation Endproducts (RAGE-I); renal ubiquitous 1 (RUI); renal
ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6);
human papilloma virus E7 (HPV E7); intestinal carboxyl esterase;
heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72;
Leukocyte-associated immunoglobulin-like receptor 1 (LAIRI); Fc
fragment of IgA receptor (FCAR or CD89); Leukocyte
immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300
molecule-like family member f (CD300LF); C-type lectin domain
family 12 member A (CLECi2A); bone marrow stromal cell antigen 2
(BST2); EGF-like module containing mucin-like hormone receptor-like
2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc
receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide
1 (IGLL1).
[0730] In some embodiments, the tumor antigen is selected from
CD150, 5T4, ActRIIA, B7, BMCA, CA-125, CCNA1, CD123, CD126, CD138,
CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25,
CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40,
CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8,
CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII,
EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, GD2, GD3, HER1-HER2
in combination, HER2-HER3 in combination, HERV-K, HIV-1 envelope
glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR,
HM1.24, HMW-MAA, Her2, Her2/neu, IGF-1R, IL-11Ralpha,
IL-13R-alpha2, IL-2, IL-22R-alpha, IL-6, IL-6R, Ia, Ii, L1-CAM,
L1-cell adhesion molecule, Lewis Y, Ll-CAM, MAGE A3, MAGE-A1,
MART-1, MUC1, NKG2C ligands, NKG2D Ligands, NYESO-1, OEPHa2, PIGF,
PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-Rl
(DR4), TRAIL-R2 (DR5), VEGF, VEGFR2, WT-I, a G-protein coupled
receptor, alphafetoprotein (AFP), an angiogenesis factor, an
exogenous cognate binding molecule (ExoCBM), oncogene product,
anti-folate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin
(D 1), ephrinB2, epithelial tumor antigen, estrogen receptor, fetal
acetylcholine receptor, folate binding protein, gp100, hepatitis B
surface antigen, kappa chain, kappa light chain, kdr, lambda chain,
livin, melanoma-associated antigen, mesothelin, mouse double minute
2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras,
necrosis antigens, oncofetal antigen, ROR2, progesterone receptor,
prostate specific antigen, tEGFR, tenascin, P2-Microgiobuiin, Fc
Receptor-like 5 (FcRL5).
[0731] Non limiting examples of cell therapies include
Algenpantucel-L, Sipuleucel-T, (BPX-501) rivogenlecleucel U.S. Pat.
No. 9,089,520, WO2016100236, AU-105, ACTR-087, activated allogeneic
natural killer cells CNDO-109-AANK, MG-4101, AU-101, BPX-601,
FATE-NK100, LFU-835 hematopoietic stem cells, Imilecleucel-T,
baltaleucel-T, PNK-007, UCARTCS1, ET-1504, ET-1501, ET-1502,
ET-190, CD19-ARTEMIS, ProHema, FT-1050-treated bone marrow stem
cell therapy, CD4CARNK-92 cells, CryoStim, AlloStim, lentiviral
transduced huCART-meso cells, CART-22 cells, EGFRt/19-28z/4-1BBL
CAR T cells, autologous 4H11-28z/fIL-12/EFGRt T cell,
CCR5-SBC-728-HSPC, CAR4-1BBZ, CH-296, dnTGFbRII-NY-ESOc259T,
Ad-RTS-IL-12, IMA-101, IMA-201, CARMA-0508, TT-18, CMD-501,
CMD-503, CMD-504, CMD-502, CMD-601, CMD-602, CSG-005.
[0732] In some embodiments, the tumor targeting antigen includes:
Alpha-fetoprotein, such as ET-1402, and AFP-TCR; Anthrax toxin
receptor 1, such as anti-TEM8 CAR T-cell therapy; B cell maturation
antigens (BCMA), such as bb-2121, UCART-BCMA, ET-140, KITE-585,
MCM-998, LCAR-B38M, CART-BCMA, SEA-BCMA, BB212, UCART-BCMA, ET-140,
P-BCMA-101, AUTO-2 (APRIL-CAR); Anti-CLL-1 antibodies, such as
KITE-796; B7 homolog 6, such as CAR-NKp30 and CAR-B7H6;
B-lymphocyte antigen CD19, such as TBI-1501, CTL-119 huCART-19 T
cells, JCAR-015 U.S. Pat. No. 7,446,190, JCAR-014, JCAR-017,
(WO2016196388, WO2016033570, WO2015157386), axicabtagene ciloleucel
(KTE-C19), U.S. Pat. Nos. 7,741,465, 6,319,494, UCART-19, EBV-CTL,
T tisagenlecleucel-T (CTL019), WO2012079000, WO2017049166,
CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells, CD19/4-1BBL armored
CAR T cell therapy, C-CAR-O11, CIK-CAR.CD19, CD19CAR-28-zeta T
cells, PCAR-019, MatchCART, DSCAR-01, IM19 CAR-T; B-lymphocyte
antigen CD20, such as ATTCK-20; B-lymphocyte cell adhesion, such as
UCART-22, JCAR-018 WO2016090190; NY-ESO-1, such as GSK-3377794,
TBI-1301; Carbonic anhydrase, such as DC-Ad-GMCAIX; Caspase 9
suicide gene, such as CaspaCIDe DLI, BPX-501; CCR5, such as SB-728;
CDwl23, such as MB-102, UCART-123; CD20m such as CBM-C20.1; CD4,
such as ICG-122; CD30, such as CART30 (CBM-C30.1); CD33, such as
CIK-CAR.CD33; CD38, such as T-007, UCART-38; CD40 ligand, such as
BPX-201; CEACAM protein 4 modulators, such as MG7-CART; Claudin 6,
such as CSG-002; EBV targeted, such as CMD-003; EGFR, such as
autologous 4H11-28z/fIL-12/EFGRt T cell; Endonuclease, such as
PGN-514, PGN-201; Epstein-Barr virus specific T-lymphocytes, such
as TT-10; Erbb2, such as CST-102, CIDeCAR; Ganglioside (GD2), such
as 4SCAR-GD2; Glutamate carboxypeptidase II, such as CIK-CAR.PSMA,
CART-PSMA-TGFBRDN, P-PSMA-101; Glypican-3 (GPC3), such as TT-16,
GLYCAR; Hemoglobin, such as PGN-236; Hepatocyte growth factor
receptor, such as anti-cMet RNA CAR T; Human papillomavirus E7
protein, such as KITE-439; Immunoglobulin gamma Fc receptor III,
such as ACTR087; IL-12, such as DC-RTS-IL-12; IL-12 agonist/mucin
16, such as JCAR-020; IL-13 alpha 2, such as MB-101; IL-2, such as
CST-101; K-Ras GTPase, such as anti-KRAS G12V mTCR cell therapy;
Neural cell adhesion molecule L1 LlCAM (CD171), such as JCAR-023;
Latent membrane protein 1/Latent membrane protein 2, such as
Ad5f35-LMPd1-2-transduced autologous dendritic cells; Melanoma
associated antigen 10, such as MAGE-A10C796T MAGE-A10 TCR; Melanoma
associated antigen 3/Melanoma associated antigen 6 (MAGE A3/A6)
such as KITE-718; Mesothelin, such as CSG-MESO, TC-210; NKG2D, such
as NKR-2; Ntrkr1 tyrosine kinase receptor, such as JCAR-024; T cell
receptors, such as BPX-701, IMCgp100; T-lymphocyte, such as TT-12;
Tumor infiltrating lymphocytes, such as LN-144, LN-145; and Wilms
tumor protein, such as JTCR-016, WT1-CTL.
[0733] Lymphoma or Leukemia Combination Therapy
[0734] In some embodiments, the additional therapeutic agents are
suitable for treating lymphoma or leukemia. These agents include
aldesleukin, alvocidib, amifostine trihydrate, aminocamptothecin,
antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin,
arsenic trioxide, Bcl-2 family protein inhibitor ABT-263, beta
alethine, BMS-345541, bortezomib (VELCADE.RTM.), bortezomib
(VELCADE.RTM., PS-341), bryostatin 1, bulsulfan, campath-1H,
carboplatin, carfilzomib (Kyprolis.RTM.), carmustine, caspofungin
acetate, CC-5103, chlorambucil, CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone), cisplatin, cladribine,
clofarabine, curcumin, CVP (cyclophosphamide, vincristine, and
prednisone), cyclophosphamide, cyclosporine, cytarabine, denileukin
diftitox, dexamethasone, docetaxel, dolastatin 10, doxorubicin,
doxorubicin hydrochloride, DT-PACE (dexamethasone, thalidomide,
cisplatin, doxorubicin, cyclophosphamide, and etoposide),
enzastaurin, epoetin alfa, etoposide, everolimus (RAD001), FCM
(fludarabine, cyclophosphamide, and mitoxantrone), FCR
(fludarabine, cyclophosphamide, and rituximab), fenretinide,
filgrastim, flavopiridol, fludarabine, FR (fludarabine and
rituximab), geldanamycin (17-AAG), hyperCVAD (hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone,
methotrexate, and cytarabine), ICE (iphosphamide, carboplatin, and
etoposide), ifosfamide, irinotecan hydrochloride, interferon
alpha-2b, ixabepilone, lenalidomide (REVLIMID.RTM., CC-5013),
lymphokine-activated killer cells, MCP (mitoxantrone, chlorambucil,
and prednisolone), melphalan, mesna, methotrexate, mitoxantrone
hydrochloride, motexafin gadolinium, mycophenolate mofetil,
nelarabine, obatoclax (GX15-070), oblimersen, octreotide acetate,
omega-3 fatty acids, Omr-IgG-am (WNIG, Omrix), oxaliplatin,
paclitaxel, palbociclib (PD0332991), pegfilgrastim, PEGylated
liposomal doxorubicin hydrochloride, perifosin, prednisolone,
prednisone, recombinant flt3 ligand, recombinant human
thrombopoietin, recombinant interferon alfa, recombinant
interleukin-11, recombinant interleukin-12, rituximab, R-CHOP
(rituximab and CHOP), R-CVP (rituximab and CVP), R-FCM (rituximab
and FCM), R-ICE (rituximab and ICE), and R-MCP (rituximab and MCP),
R-roscovitine (seliciclib, CYC202), sargramostim, sildenafil
citrate, simvastatin, sirolimus, styryl sulphones, tacrolimus,
tanespimycin, temsirolimus (CCl-779), thalidomide, therapeutic
allogeneic lymphocytes, thiotepa, tipifarnib, vincristine,
vincristine sulfate, vinorelbine ditartrate, SAHA
(suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic
acid), vemurafenib (Zelboraf.RTM.), venetoclax (ABT-199).
[0735] One modified approach is radioimmunotherapy, wherein a
monoclonal antibody is combined with a radioisotope particle, such
as indium-111, yttrium-90, and iodine-131. Examples of combination
therapies include, but are not limited to, iodine-131 tositumomab
(BEXXAR.RTM.), yttrium-90 ibritumomab tiuxetan (ZEVALIN.RTM.), and
BEXXAR.RTM. with CHOP.
[0736] The abovementioned therapies can be supplemented or combined
with stem cell transplantation or treatment. Therapeutic procedures
include peripheral blood stem cell transplantation, autologous
hematopoietic stem cell transplantation, autologous bone marrow
transplantation, antibody therapy, biological therapy, enzyme
inhibitor therapy, total body irradiation, infusion of stem cells,
bone marrow ablation with stem cell support, in vitro-treated
peripheral blood stem cell transplantation, umbilical cord blood
transplantation, immunoenzyme technique, low-LET cobalt-60 gamma
ray therapy, bleomycin, conventional surgery, radiation therapy,
and nonmyeloablative allogeneic hematopoietic stem cell
transplantation.
[0737] Non-Hodgkin's Lymphomas Combination Therapy
[0738] In some embodiments, the additional therapeutic agents are
suitable for treating non-Hodgkin's lymphomas (NHL), especially
those of B cell origin, which include monoclonal antibodies,
standard chemotherapy approaches (e.g., CHOP, CVP, FCM, MCP, and
the like), radioimmunotherapy, and combinations thereof, especially
integration of an antibody therapy with chemotherapy.
[0739] Examples of unconjugated monoclonal antibodies for the
treatment of NHL/B-cell cancers include rituximab, alemtuzumab,
human or humanized anti-CD20 antibodies, lumiliximab,
anti-TNF-related apoptosis-inducing ligand (anti-TRAIL),
bevacizumab, galiximab, epratuzumab, SGN-40, and anti-CD74.
[0740] Examples of experimental antibody agents used in treatment
of NHL/B-cell cancers include ofatumumab, ha20, PRO131921,
alemtuzumab, galiximab, SGN-40, CHIR-12.12, epratuzumab,
lumiliximab, apolizumab, milatuzumab, and bevacizumab.
[0741] Examples of standard regimens of chemotherapy for NHL/B-cell
cancers include CHOP, FCM, CVP, MCP, R-CHOP, R-FCM, R-CVP, and
R-MCP.
[0742] Examples of radioimmunotherapy for NHL/B-cell cancers
include yttrium-90 ibritumomab tiuxetan (ZEVALIN) and iodine-131
tositumomab (BEXXAR.RTM.).
[0743] Mantle Cell Lymphoma Combination Therapy
[0744] In some embodiments, the additional therapeutic agents are
suitable for treating mantle cell lymphoma (MCL), which include
combination chemotherapies such as CHOP, hyperCVAD, and FCM. These
regimens can also be supplemented with the monoclonal antibody
rituximab to form combination therapies R-CHOP, hyperCVAD-R, and
R-FCM. Any of the abovementioned therapies may be combined with
stem cell transplantation or ICE in order to treat MCL.
[0745] Other examples of therapeutic agents suitable for treating
MCL include: [0746] immunotherapy, such as monoclonal antibodies
(like rituximab) and cancer vaccines, such as GTOP-99, which are
based on the genetic makeup of an individual subject's tumor;
[0747] radioimmunotherapy, wherein a monoclonal antibody is
combined with a radioisotope particle, such as iodine-131
tositumomab (BEXXAR.RTM.), yttrium-90 ibritumomab tiuxetan
(ZEVALIN.RTM.), and BEXXAR.RTM. in sequential treatment with CHOP;
[0748] autologous stem cell transplantation coupled with high-dose
chemotherapy, administering proteasome inhibitors such as
bortezomib (VELCADE.RTM. or PS-341), or administering
antiangiogenesis agents such as thalidomide, especially in
combination with rituximab; [0749] drugs that lead to the
degradation of Bcl-2 protein and increase cancer cell sensitivity
to chemotherapy, such as oblimersen, in combination with other
chemotherapeutic agents; [0750] mTOR inhibitors, which can lead to
inhibition of cell growth and even cell death. Non-limiting
examples are sirolimus, temsirolimus (TORISEL.RTM., CCI-779),
CC-115, CC-223, SF-1126, PQR-309 (bimiralisib), voxtalisib,
GSK-2126458, and temsirolimus in combination with RITUXAN.RTM.,
VELCADE.RTM., or other chemotherapeutic agents; [0751] other agents
such as flavopiridol, palbociclib (PD0332991), R-roscovitine
(selicicilib, CYC202), styryl sulphones, obatoclax (GX15-070),
TRAIL, Anti-TRAIL death receptors DR4 and DR5 antibodies,
temsirolimus (TORISEL.RTM., CC-779), everolimus (RAD001),
BMS-345541, curcumin, SAHA, thalidomide, lenalidomide
(REVLIMID.RTM., CC-5013), and geldanamycin (17-AAG).
[0752] Waldenstrom's Macroglobulinemia Combination Therapy
[0753] In some embodiments, the additional therapeutic agents are
suitable for treating Waldenstrom's Macroglobulinemia (WM), which
include aldesleukin, alemtuzumab, alvocidib, amifostine trihydrate,
aminocamptothecin, antineoplaston A10, antineoplaston AS2-1,
anti-thymocyte globulin, arsenic trioxide, autologous human
tumor-derived HSPPC-96, Bcl-2 family protein inhibitor ABT-263,
beta alethine, bortezomib (VELCADE.RTM.), bryostatin 1, busulfan,
campath-1H, carboplatin, carmustine, caspofungin acetate, CC-5103,
cisplatin, clofarabine, cyclophosphamide, cyclosporine, cytarabine,
denileukin diftitox, dexamethasone, docetaxel, dolastatin 10,
doxorubicin hydrochloride, DT-PACE, enzastaurin, epoetin alfa,
epratuzumab (hLL2-anti-CD22 humanized antibody), etoposide,
everolimus, fenretinide, filgrastim, fludarabine, ifosfamide,
indium-111 monoclonal antibody MN-14, iodine-131 tositumomab,
irinotecan hydrochloride, ixabepilone, lymphokine-activated killer
cells, melphalan, mesna, methotrexate, mitoxantrone hydrochloride,
monoclonal antibody CD19 (such as tisagenlecleucel-T, CART-19,
CTL-019), monoclonal antibody CD20, motexafin gadolinium,
mycophenolate mofetil, nelarabine, oblimersen, octreotide acetate,
omega-3 fatty acids, oxaliplatin, paclitaxel, pegfilgrastim,
PEGylated liposomal doxorubicin hydrochloride, pentostatin,
perifosine, prednisone, recombinant flt3 ligand, recombinant human
thrombopoietin, recombinant interferon alfa, recombinant
interleukin-11, recombinant interleukin-12, rituximab,
sargramostim, sildenafil citrate (VIAGRA.RTM.), simvastatin,
sirolimus, tacrolimus, tanespimycin, thalidomide, therapeutic
allogeneic lymphocytes, thiotepa, tipifarnib, tositumomab,
veltuzumab, vincristine sulfate, vinorelbine ditartrate,
vorinostat, WT1 126-134 peptide vaccine, WT-1 analog peptide
vaccine, yttrium-90 ibritumomab tiuxetan, yttrium-90 humanized
epratuzumab, and any combination thereof.
[0754] Other examples of therapeutic procedures used to treat WM
include peripheral blood stem cell transplantation, autologous
hematopoietic stem cell transplantation, autologous bone marrow
transplantation, antibody therapy, biological therapy, enzyme
inhibitor therapy, total body irradiation, infusion of stem cells,
bone marrow ablation with stem cell support, in vitro-treated
peripheral blood stem cell transplantation, umbilical cord blood
transplantation, immunoenzyme techniques, low-LET cobalt-60 gamma
ray therapy, bleomycin, conventional surgery, radiation therapy,
and nonmyeloablative allogeneic hematopoietic stem cell
transplantation.
[0755] Diffuse Large B-cell Lymphoma Combination Therapy
[0756] In some embodiments, the additional therapeutic agents are
suitable for treating diffuse large B-cell lymphoma (DLBCL), which
include cyclophosphamide, doxorubicin, vincristine, prednisone,
anti-CD20 monoclonal antibodies, etoposide, bleomycin, many of the
agents listed for WM, and any combination thereof, such as ICE and
R-ICE.
[0757] Chronic Lymphocytic Leukemia Combination Therapy
[0758] In some embodiments, the additional therapeutic agents are
suitable for treating chronic lymphocytic leukemia (CLL), which
include chlorambucil, cyclophosphamide, fludarabine, pentostatin,
cladribine, doxorubicin, vincristine, prednisone, prednisolone,
alemtuzumab, many of the agents listed for WM, and combination
chemotherapy and chemoimmunotherapy, including the following common
combination regimens: CVP, R-CVP, ICE, R-ICE, FCR, and FR.
[0759] Myelofibrosis Combination Therapy
[0760] In some embodiments, the additional therapeutic agents are
suitable for treating myelofibrosis, which include hedgehog
inhibitors, histone deacetylase (HDAC) inhibitors, and tyrosine
kinase inhibitors. Non-limiting examples of hedgehog inhibitors are
saridegib and vismodegib.
[0761] Examples of HDAC inhibitors include, but are not limited to,
pracinostat and panobinostat.
[0762] Non-limiting examples of tyrosine kinase inhibitors are
lestaurtinib, bosutinib, imatinib, gilteritinib, radotinib, and
cabozantinib.
[0763] Hyperproliferative Disease Combination Therapy
[0764] In some embodiments, the additional therapeutic agents are
suitable for treating a hyperproliferative disease, which include
gemcitabine, nab-paclitaxel, and gemcitabine/nab-paclitaxel with a
JAK inhibitor and/or PI3K6 inhibitor.
[0765] Bladder Cancer Combination Therapy
[0766] In some embodiments, the additional therapeutic agents are
suitable for treating bladder cancer, which include atezolizumab,
carboplatin, cisplatin, docetaxel, doxorubicin, fluorouracil
(5-FU), gemcitabine, idosfamide, Interferon alfa-2b, methotrexate,
mitomycin, nab-paclitaxel, paclitaxel, pemetrexed, thiotepa,
vinblastine, and any combination thereof.
[0767] Breast Cancer Combination Therapy
[0768] In some embodiments, the additional therapeutic agents are
suitable for treating breast cancer, which include albumin-bound
paclitaxel, anastrozole, capecitabine, carboplatin, cisplatin,
cyclophosphamide, docetaxel, doxorubicin, epirubicin, everolimus,
exemestane, fluorouracil, fulvestrant, gemcitabine, Ixabepilone,
lapatinib, Letrozole, methotrexate, mitoxantrone, paclitaxel,
pegylated liposomal doxorubicin, pertuzumab, tamoxifen, toremifene,
trastuzumab, vinorelbine, and any combinations thereof.
[0769] Triple Negative Breast Cancer Combination Therapy
[0770] In some embodiments, the additional therapeutic agents are
suitable for treating triple negative breast cancer, which include
cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil,
paclitaxel, and combinations thereof.
[0771] Colorectal Cancer Combination Therapy
[0772] In some embodiments, the additional therapeutic agents are
suitable for treating colorectal cancer, which include bevacizumab,
capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin,
oxaliplatin, panitumumab, ziv-aflibercept, and any combinations
thereof.
[0773] Castration-Resistant Prostate Cancer Combination Therapy
[0774] In some embodiments, the additional therapeutic agents are
suitable for treating castration-resistant prostate cancer, which
include abiraterone, cabazitaxel, docetaxel, enzalutamide,
prednisone, sipuleucel-T, and any combinations thereof.
[0775] Esophageal and Esophagogastric Junction Cancer Combination
Therapy
[0776] In some embodiments, the additional therapeutic agents are
suitable for treating esophageal and esophagogastric junction
cancer, which include capecitabine, carboplatin, cisplatin,
docetaxel, epirubicin, fluoropyrimidine, fluorouracil, irinotecan,
leucovorin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and
any combinations thereof.
[0777] Gastric Cancer Combination Therapy
[0778] In some embodiments, the additional therapeutic agents are
suitable for treating gastric cancer, which include capecitabine,
carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine,
fluorouracil, Irinotecan, leucovorin, mitomycin, oxaliplatin,
paclitaxel, ramucirumab, trastuzumab, and any combinations
thereof.
[0779] Head & Neck Cancer Combination Therapy
[0780] In some embodiments, the additional therapeutic agents are
suitable for treating head & neck cancer, which include
afatinib, bleomycin, capecitabine, carboplatin, cetuximab,
cisplatin, docetaxel, fluorouracil, gemcitabine, hydroxyurea,
methotrexate, nivolumab, paclitaxel, pembrolizumab, vinorelbine,
and any combinations thereof.
[0781] Hepatobiliary Cancer Combination Therapy
[0782] In some embodiments, the additional therapeutic agents are
suitable for treating hepatobiliary cancer, which include
capecitabine, cisplatin, fluoropyrimidine, 5-fluorourcil,
gemcitabine, oxaliplatin, sorafenib, and any combinations
thereof.
[0783] Hepatocellular Carcinoma Combination Therapy
[0784] In some embodiments, the additional therapeutic agents are
suitable for treating hepatocellular carcinoma, which include
capecitabine, doxorubicin, gemcitabine, sorafenib, and any
combinations thereof.
[0785] Non-Small Cell Lung Cancer Combination Therapy
[0786] In some embodiments, the additional therapeutic agents are
suitable for treating non-small cell lung cancer (NSCLC), which
include afatinib, albumin-bound paclitaxel, alectinib, bevacizumab,
bevacizumab, cabozantinib, carboplatin, cisplatin, crizotinib,
dabrafenib, docetaxel, erlotinib, etoposide, gemcitabine,
nivolumab, paclitaxel, pembrolizumab, pemetrexed, ramucirumab,
trametinib, trastuzumab, vandetanib, vemurafenib, vinblastine,
vinorelbine, and any combinations thereof.
[0787] Small Cell Lung Cancer Combination Therapy
[0788] In some embodiments, the additional therapeutic agents are
suitable for treating small cell lung cancer (SCLC), which include
bendamustine, carboplatin, cisplatin, cyclophosphamide, docetaxel,
doxorubicin, etoposide, gemcitabine, ipilimumab, irinotecan,
nivolumab, paclitaxel, temozolomide, topotecan, vincristine,
vinorelbine, and any combinations thereof.
[0789] Melanoma Combination Therapy
[0790] In some embodiments, the additional therapeutic agents are
suitable for treating melanoma, which include albumin bound
paclitaxel, carboplatin, cisplatin, cobimetinib, dabrafenib,
dacarbazine, IL-2, imatinib, interferon alfa-2b, ipilimumab,
nitrosourea, nivolumab, paclitaxel, pembrolizumab, ipilimumab,
temozolomide, trametinib, vemurafenib, vinblastine, and any
combinations thereof.
[0791] Ovarian Cancer Combination Therapy
[0792] In some embodiments, the additional therapeutic agents are
suitable for treating ovarian cancer, which include 5-flourouracil,
albumin bound paclitaxel, altretamine, anastrozole, bevacizumab,
capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel,
doxorubicin, etoposide, exemestane, gemcitabine, ifosfamide,
irinotecan, letrozole, leuprolide acetate, liposomal doxorubicin,
megestrol acetate, melphalan, olaparib, oxaliplatin, paclitaxel,
Pazopanib, pemetrexed, tamoxifen, topotecan, vinorelbine, and any
combinations thereof.
[0793] Pancreatic Cancer Combination Therapy
[0794] In some embodiments, the additional therapeutic agents are
suitable for treating pancreatic cancer, which include
5-fluorourcil, albumin-bound paclitaxel, capecitabine, cisplatin,
docetaxel, erlotinib, fluoropyrimidine, gemcitabine, irinotecan,
leucovorin, oxaliplatin, paclitaxel, and any combinations
thereof.
[0795] Renal Cell Carcinoma Combination Therapy
[0796] In some embodiments, the additional therapeutic agents are
suitable for treating renal cell carcinoma, which include axitinib,
bevacizumab, cabozantinib, erlotinib, everolimus, lenvatinib,
nivolumab, pazopanib, sorafenib, sunitinib, temsirolimus, and any
combinations thereof.
VIII. Kits
[0797] The present disclosure provides a kit comprising a compound
of the present disclosure or a pharmaceutically acceptable salt
thereof. The kit may further comprise instructions for use, e.g.,
for use in treating a viral infection. The instructions for use are
generally written instructions, although electronic storage media
(e.g., magnetic diskette or optical disk) containing instructions
are also acceptable.
[0798] The present disclosure also provides a pharmaceutical kit
comprising one or more containers comprising a compound of the
present disclosure or a pharmaceutically acceptable salt thereof.
Optionally associated with such container(s) can be a notice in the
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals, which notice reflects
approval by the agency for the manufacture, use or sale for human
administration. Each component (if there is more than one
component) can be packaged in separate containers or some
components can be combined in one container where cross-reactivity
and shelf life permit. The kits may be in unit dosage forms, bulk
packages (e.g., multi-dose packages) or sub-unit doses. Kits may
also include multiple unit doses of the compounds and instructions
for use and be packaged in quantities sufficient for storage and
use in pharmacies (e.g., hospital pharmacies and compounding
pharmacies).
[0799] Also provided are articles of manufacture comprising a unit
dosage of a compound of the present disclosure or a
pharmaceutically acceptable salt thereof, in suitable packaging for
use in the methods described herein. Suitable packaging is known in
the art and includes, for example, vials, vessels, ampules,
bottles, jars, flexible packaging and the like. An article of
manufacture may further be sterilized and/or sealed.
IX. Examples
[0800] Abbreviations as used herein have respective meanings as
follows:
TABLE-US-00001 Ac Acetate ACN Acetonitrile BippyPhos
5-(di-tert-butylphosphino)-1',3',5'- triphenyl-1'H-[1,4']bipyrazole
Bn Benzyl br. s Broad singlet Bu Butyl dba Dibenzylideneacetone DCM
Dichloromethane dd Doublet of doublets ddd Doublet of doublet of
doublets DIPE diisopropyl ether DMF Dimethylformamide DMSO
Dimethylsulfoxide dr Diastereomeric ratio DSC Differential scanning
calorimetry DVS Dynamic vapor sorption ee Enantiomeric excess equiv
Equivalents Et Ethyl EtOAc Ethyl acetate EtOH Ethanol ft Foot
(length) g Gram GC Gas chromatography h Hour HBV Hepatitis B virus
HCV Hepatitis C virus HFIPA hexafluoroisopropanol HIV Human
Immunodeficiency virus HPLC High-pressure liquid chromatography IPA
Isopropyl alcohol IPAc Isopropyl acetate iPr Isopropyl iPrOAc or
IPAc isopropyl acetate kg Kilogram L Liter m Multiplet M Molar Me
Methyl MEK methyl ethyl ketone MeOH methanol Me-THF 2 methyl
tetrahydrofuran mg Milligram MHz Mega hertz MIBK Methylisobutyl
ketone min Minute mL Milliliter mmol Millimole mol Mole MTBE
Methyl-tert-butyl ether N Normal NLT No less than NMR Nuclear
magnetic resonance Ph Phenyl RH Relative humidity s Singlet t-Bu
tert-Butyl td Triplet of doublets Tf Trifluoromethanesulfonate TFE
trifluoroethanol TGA Thermogravimetric analysis THF Tetrahydrofuran
TMS Trimethylsilyl vol Volume wt Weight XRPD X-ray powder
diffraction .delta. Chemical shift .mu.L Microliter
[0801] The solid forms (polymorphs, solvates and hydrates) of
Compound I were characterized by a variety of the following
methods.
[0802] XRPD patterns were collected with a PANalytical X'Pert PRO
MPD diffractometer using an incident beam of Cu K.alpha. radiation
produced using a long, fine-focus source and a nickel filter. The
diffractometer was configured using the symmetric Bragg-Brentano
geometry. Prior to the analysis, a silicon specimen (NIST SRM 640e)
was analyzed to verify the observed position of the Si 111 peak is
consistent with the NIST-certified position. A specimen of the
sample was prepared as a thin, circular layer centered on a silicon
zero-background substrate. Antiscatter slits (SS) were used to
minimize the background generated by air. Soller slits for the
incident and diffracted beams were used to minimize broadening from
axial divergence. Diffraction patterns were collected using a
scanning position-sensitive detector (X'Celerator) located 240 mm
from the sample and Data Collector software v. 2.2b.
[0803] Differential Scanning Calorimetry (DSC) data were collected
using a TA Instruments 2920 and Q2000 differential scanning
calorimeter. Temperature calibration was performed using
NIST-traceable indium metal. The sample was placed into a T zero
aluminum DSC pan, covered with a lid and crimped. The weight was
then accurately recorded. A weighed aluminum pan configured as the
sample pan was placed on the reference side of the cell. The sample
was heated from -30.degree. C. to 250.degree. C. at 10.degree.
C./minute.
[0804] Thermogravimetric Analysis (TGA) data were collected using a
TA Instruments Discovery thermogravimetric analyzer. Temperature
calibration was performed using nickel and Alumel.TM.. Each sample
was placed in an aluminum pan and inserted into the TG furnace. The
furnace was heated under a nitrogen purge. The sample was heated
from ambient to 350.degree. C. at 10.degree. C./minute.
[0805] Moisture sorption/desorption data were collected on a VTI
SGA-100 Vapor Sorption Analyzer. NaCl and PVP were used as
calibration standards. Samples were not dried prior to analysis.
Sorption and desorption data were collected over a range from 5% to
95% RH at 10% RH increments under a nitrogen purge. The equilibrium
criterion used for analysis was less than 0.0100% weight change in
5 minutes with a maximum equilibration time of 3 hours. Weight
percentages reported in the data section are relative to the total
sample mass introduced prior to equilibration at 5% RH as measured
on the instrument.
Example 1. Preparation of Compound I
##STR00020##
[0807] To a nitrogen flushed 50-L jacketed reactor was charged
Compound A (2.69 kg, 6.07 moles, 1.0 equiv). This was followed by
the addition of dichloromethane (10.13 L, 13.44 kg). Agitation was
set to 175 RPM and the contents were agitated until a solution was
observed. Trifluoroacetic acid (4.53 L, 6.75 kg) was charged at a
rate such that the internal temperature did not exceed 35.degree.
C. (ca. 30 min.). After the addition of trifluoroacetic acid, the
jacket was set to 46.degree. C. (to maintain a gentle reflux). The
contents were agitated at this temperature for 3 h and then the
jacket was set to 15.degree. C. Once the internal temperature
reached 20.degree. C., ethanol (denatured from n-heptane) (8.56 L,
6.75 kg) was charged and the contents were allowed to agitate at
20.degree. C. for 14 h. After this amount of time, the
heterogeneous contents were filtered through a benchtop poly-filter
into a nitrogen flushed 100-L jacketed reactor.
[0808] Dichloromethane (5.21 L, 6.91 kg) was charged to the 50-L
reactor and the solution was rinsed through the filter into the
100-L reactor. To the 100-L reactor was then charged water (15.5 L,
15.5 kg) and ethyl acetate (19.0 L, 17.0 kg). Agitation was set to
175 RPM and the jacket was set to 87.degree. C. The contents were
allowed to heat to reflux for 30 min. After this amount of time,
the jacket was set to 20.degree. C. The aqueous layer was
discharged. To the reactor was charged water (18.4 L. 18.4 kg), and
agitation was set to 200 RPM. 30% w/w NaOH (8.61 kg) was charged
and the contents were agitated for 30 min. at 30.degree. C. (jacket
was set at 40.degree. C.). Ethyl acetate (45.0 L, 40.4 kg) was then
charged and the jacket was set to 55.degree. C. Once the internal
temperature reached 45.degree. C., the contents were agitated at
200 RPM for 30 min. After this amount of time, agitation was
stopped and the phases were allowed to separate and the aqueous
layer was discharged. 4.5% w/w aqueous sodium bicarbonate (prepared
from 605 g sodium bicarbonate and 12.8 kg water) solution was
charged and the contents were agitated at 200 RPM at an internal
temperature of 45.degree. C. for 30 min. After this amount of time,
agitation was stopped and the layers were allowed to separate. The
aqueous layer was discharged and the jacket was set to 20.degree.
C. The contents were aged at this temperature under nitrogen for 14
h. The jacket was then set to 55.degree. C. Once the internal
temperature reached 45.degree. C., 4.5% w/w aqueous sodium
bicarbonate (prepared from 605 g sodium bicarbonate and 12.8 kg
water) was charged and the contents were agitated (200 RPM) at
45.degree. C. for 30 min. Agitation was then stopped, the phases
were allowed to separate and the aqueous layer was discharged. 4.5%
w/w aqueous sodium bicarbonate (prepared from 605 g sodium
bicarbonate and 12.8 kg water). The contents were agitated (200
RPM) at 45.degree. C. for 30 min. Agitation was then stopped, the
phases were allowed to separate and the aqueous layer was
discharged. Water (13.6 L, 13.6 kg) was added and the contents were
agitated (150 RPM) at 45.degree. C. for 30 min. After this amount
of time, agitation was stopped and the phases were allowed to
separate and the aqueous layer was discharged.
[0809] Alternatively, to a nitrogen flushed reaction vessel was
charged Compound A (scaling factor, 1.0 part). This was followed by
the addition of dichloromethane (2.5 parts). The contents were
agitated until a homogenous solution was observed. Trifluoroacetic
acid (2.0 parts) was charged at a rate such that the internal
temperature did not exceed 35.degree. C. (ca. 30 min.). After the
addition of trifluoroacetic acid, the jacket was set to maintain an
internal temperature at ca. 30.degree. C. The contents were
agitated at this temperature for approximately 10 h and then the
jacket was set to 22.degree. C. Once the internal temperature
reached 22.degree. C., ethanol (2.0 parts) was charged and the
contents were allowed to agitate at 22.degree. C. for 14 h. After
this amount of time, the contents were filtered. The filter was
rinsed with ethanol (2.0 parts) and the contents were distilled to
approximately 3 L/kg. The contents were cooled to 22.degree. C. and
ethanol (1 part) and water (1 part) were charged to the contents.
To this was charged 50% wt/wt aqueous sodium hydroxide solution
(ca. 0.7 parts) until a pH of 12-14 was achieved. The internal
temperature of the contents were adjusted to 22.degree. C. and
water (3.0 parts) was charged over 30 min. The contents were cooled
to approximately 0.degree. C. over 2 h and held at this temperature
for 2 h. The slurry was filtered and the cake was rinsed with a 1:1
wt/wt ratio of water and ethanol (2 parts). The contents were dried
at 45.degree. C. until a constant weight is achieved. Compound I
(Form I) was discharged and packaged.
Example 2. Form I (Ethyl Acetate)
[0810] The reactor was configured for vacuum distillation and the
jacket was set to 70.degree. C. and agitation was set to 150 RPM.
The solvent was removed via vacuum distillation to ca. 30 L. The
jacket was set to 35.degree. C. and the reactor was backfilled with
nitrogen. Ethyl acetate (45 L, 40.4 kg) was charged and the reactor
was heated to 70.degree. C., agitation was set to 150 RPM and the
pressure was reduced. The solvent was removed via vacuum
distillation to ca. 30 L. The jacket was set to 35.degree. C. and
the reactor was backfilled with nitrogen. The ethyl acetate
distillation sequence was repeated as described 5 X. Final volumes
for the five distillations were ca. 30 L after charging 45 L ethyl
acetate for each sequence. The contents were sampled for water
content (target <0.5% H.sub.2O). After passing the water content
criteria, the jacket was heated to 70.degree. C., agitation was set
to 150 RPM and the pressure was reduced and the distillation was
continued to ca. 22 L. The jacket was set to 35.degree. C. and the
reactor was backfilled with nitrogen. Ethyl acetate (15 L, 13.5 kg)
was charged and the contents were polish filtered through a 1.0 m
filter into the crystallizer. The jacket on the crystallizer was
set to 70.degree. C. and agitation was set to 150 RPM. The pressure
of the vessel was reduced and the distillation was continued to ca.
18 L. Once this target volume was reached, the crystallizer was
backfilled with nitrogen and the jacket was set to 87.degree. C.
Ethyl acetate (9.5 L, 8.5 kg) was charged and the contents were
agitated until a homogenous solution was observed. After all solids
dissolved, a cooling ramp from 85.degree. C. to 20.degree. C. over
8 h was initiated.
[0811] The solids were filtered and the wet-cake was washed with
ethyl acetate (6.1 L, 5.5 kg). The jacket on the filter was set to
46.degree. C. and the contents were dried for 24 h under reduced
pressure with a nitrogen bleed. Compound I (Form I) was isolated in
good purity (99.6% Assay, 99.7% AN).
[0812] Optionally, Compound I (1.2 kg, 4.0 mol) was charged to a
50-L jacketed reactor followed by ethyl acetate (25 L, 22 kg). The
jacket on the reactor was set to 87.degree. C. and agitation was
set to 150 RPM. The contents were agitated until a solution was
observed. After all solids dissolved, a cooling ramp from
85.degree. C. to 20.degree. C. over 8 h was initiated. The solids
were filtered and the wet-cake was washed with ethyl acetate (6.1
L, 5.5 kg). The jacket on the filter was set to 46.degree. C. and
the contents were dried for 24 h under reduced pressure with a
nitrogen bleed. Compound I Form I was isolated.
[0813] Form I is an unsolvated phase. Its XRPD pattern is shown in
FIG. 1.
TABLE-US-00002 TABLE 1 Crystal Data and Data Collection Parameters
for Compound I Form I Empirical formula C.sub.14H.sub.20FN.sub.5O
Formula weight 293.35 Temperature 100(2) K Wavelength 1.54178 .ANG.
Crystal system Tetragonal Space group P4.sub.1 Unit cell dimensions
a = 8.0344(2) .ANG. .alpha. = 90.degree.. b = 8.0344(2) .ANG.
.beta. = 90.degree.. c = 23.7871(7) .ANG. .gamma. = 90.degree..
Volume 1535.49(9) .ANG..sup.3 Z 4 Density (calculated) 1.269
Mg/m.sup.3 Absorption coefficient 0.766 mm.sup.-1 F(000) 624
Crystal size 0.450 .times. 0.320 .times. 0.290 mm.sup.3 Theta range
for data collection 5.506 to 71.991.degree. Index ranges -9 <= h
<= 9, -9 <= k <= 9, -27 <= l <= 28 Reflections
collected 36463 Independent reflections 2954 [R(int) = 0.0397]
Completeness to theta = 67.679.degree. 99.4% Refinement method
Full-matrix least-squares on F.sup.2 Data/restraints/parameters
2954/1/203 Goodness-of-fit on F.sup.2 1.219 Final R indices [I >
2sigma(I)] R1 = 0.0339, wR2 = 0.0824 R indices (all data) R1 =
0.0341, wR2 = 0.0827 Absolute structure parameter Flack parameter:
0.12(4) Hooft parameter: 0.10(4) Extinction coefficient 0.0098(8)
Largest diff. peeak and hole 0.146 and -0.147 e.ANG..sup.-3
TABLE-US-00003 TABLE 2 Peak Table for Form I Pos.
[.degree.2.theta.] Rel. Int. [%] 10.9 42.72 11.5 17.57 13.2 47.27
14.7 38.18 15.5 53.84 15.6 39.90 18.4 2.21 19.0 8.77 21.4 66.66
21.9 100.00 22.3 5.33 23.2 30.44 24.2 4.77 24.6 6.37 24.9 26.03
25.7 8.09 26.5 4.13 27.0 11.23 28.8 2.99 29.7 3.56 30.4 3.53 30.9
1.12 31.8 3.44 33.2 4.08 34.0 4.63 34.7 4.13 35.4 3.16 36.1 4.79
38.2 3.29 39.1 3.36
[0814] The DSC curve is shown in FIG. 2 and displays one
endothermic transition at about 164.degree. C. The TGA curve is
shown in FIG. 3 and indicates that the phase is unsolvated. The
dynamic vapor sorption curve is shown in FIG. 4 and the data
indicates that the form absorbs about 0.89% of water up to 95% RH
at 25.degree. C. The material was found to not have changed forms
post experiment.
[0815] Single crystal data was collected on Form I and the data are
summarized in Table 1. The crystal was made by dissolved Form I in
tetrahydrofuran. The solution was filtered through a 0.2 m nylon
filter into an Erlenmeyer flask. Water was added for a 4/1 (v/v)
tetrahydrofuran/water ratio. The flask was capped with perforated
aluminum foil and the solution was allowed to evaporate to dryness
under ambient conditions. The tetragonal cell parameters and
calculated volume are: a=b=8.0344 (2) .ANG., c=23.7871 (7) .ANG.
(.alpha.=.beta.=.gamma.=90.degree.), V=1535.49 (9) .ANG..sup.3. The
molecular weight of the asymmetric unit in the crystal structure of
Compound I Form I is 293.35 g mol.sup.-1 with Z=4, resulting in a
calculated density of 1.269 g cm.sup.-3. The space group was
determined to be P4.sub.1 (no. 76).
Example 3. Form I (Ethanol)
[0816] To an inert reaction vessel was charged Compound I (1 part,
scaling factor) followed by absolute ethanol (12 parts). The
contents were heated until all solids are dissolved (ca. 75.degree.
C.). Once all of the solids have dissolved the internal temperature
was adjusted to approximately 65.degree. C. and the contents were
polish filtered. Ethanol (1 part) was used to rinse the filter. The
contents were distilled to approximately 8 L/kg. The internal
temperature was adjusted to 75.degree. C. and any solids were
dissolved. The contents were cooled to 0.degree. C. over 8 h and
held at this temperature for an additional 6 h. After this about of
time, the contents were filtered and the cake was washed with cold
(ca. 0.degree. C.) absolute ethanol (2 parts) and the cake was
dried at 45.degree. C. until a constant weight is achieved.
Compound I (Form I) was discharged and packaged.
Example 4. Form I (Ethanol/Water)
[0817] To an inert reaction vessel was charged Compound I (1 part,
scaling factor) followed by absolute ethanol (12 parts). The
contents were heated until all solids were dissolved (ca.
75.degree. C.). Once all of the solids were dissolved, the internal
temperature was adjusted to approximately 65.degree. C. and the
contents were polish filtered. Ethanol (1 part) was used to rinse
the filter. The contents were distilled to approximately 7 L/kg.
The internal temperature was adjusted to 75.degree. C. and any
solids were dissolved. To this solution was charged water (5 parts)
over 1 hour. The contents were cooled to 22.degree. C. over 3 h and
held at this temperature for an additional 2 h. After this amount
of time, the slurry was filtered and the cake was rinsed with a 1:1
wt/wt ratio of water and ethanol (2 parts). The contents were dried
at 45.degree. C. until a constant weight was achieved. Compound I
(Form I) was discharged and packaged.
Example 5. HCl Salt, Form I
[0818] Compound I Form 1 (35.18 mg), approximately one molar
equivalent of hydrochloric acid (96 .mu.l, 1.25 M in EtOH), and
methyl ethyl ketone (300 .mu.l) were heated to about 50.degree. C.
in an Avantium Crystal 16.RTM. multiple-reactor system. After
approximately 15 minutes, the reactor system was turned off for
fast cooling to ambient temperature. After reaching ambient
temperature, samples were re-heated to about 50.degree. C. for
about 4 hours and then cooled to about 10.degree. C. at 0.1.degree.
C./min. Solids were collected by vacuum filtration and
analyzed.
[0819] In another experiment, Compound 1 (43.8 mg), and
approximately one molar equivalent of hydrochloric acid (120 .mu.l,
1.25 M in EtOH) were dissolved in methyl ethyl ketone (500 .mu.l)
at ambient temperature. Upon the addition of hydrochloric acid, the
solution turned pink, but then changed to yellow upon mixing. The
vial was capped with perforated aluminum foil, and the solution was
evaporated. A gel resulted upon drying and trituration was
attempted with ethyl acetate and then diethyl ether. Some
precipitation was observed after the addition of diethyl ether, and
the mixture was seeded with the crystalline HCl salt Form I. After
stirring at ambient temperature for 1 day, solids were isolated by
vacuum filtration and analyzed.
[0820] Compound I HCl Form I is an unsolvated phase. Its XRPD
pattern is shown in FIG. 5.
TABLE-US-00004 TABLE 3 Peak Table for HCl Salt Form I Pos.
[.degree.2Th.] Rel. Int. [%] 6.1 100.00 9.0 8.83 10.0 8.74 11.7
4.17 12.2 30.63 14.0 13.15 15.0 43.44 16.4 8.97 17.3 17.32 17.8
93.00 18.2 7.53 18.9 35.59 20.3 13.57 21.2 4.22 22.1 2.47 23.2
13.88 23.7 5.56 24.1 36.76 24.5 4.93 26.1 9.41 26.3 8.04 27.4 3.56
28.1 5.96 28.8 11.13 29.6 8.05 30.3 4.74 30.9 11.67 31.2 13.80 32.1
5.19 33.3 3.38 34.1 3.43 35.0 3.52 36.2 2.62 36.8 1.81 38.3 1.64
38.9 2.56
[0821] The DSC curve is shown in FIG. 6 and displays one
endothermic transition at about 135.degree. C. The TGA curve is
shown in FIG. 7 and indicates that the phase is unsolvated. The
dynamic vapor sorption curve is shown in FIG. 8 and indicated the
material is hygroscopic. The sorption-desorption curve showed two
distinct plateaus. During the sorption cycle, the sample showed a
relatively stable gain between 5% and 55% RH, showing only
approximately 0.6% weight gain. After 65% RH, a sharp uptake in
water was observed, approximately 28.1% weight gain was observed
between 65% RH and 95% RH. The desorption curve showed
approximately 11.2% weight loss from 95% to 85% RH, and a slow
steady loss of 1.8% weight between 85% and 65% RH. No further
weight % loss was observed down to 5% RH. Post-DVS XRPD analysis
indicated the sample was composed of a new crystalline material,
designated Compound I Hydrochloride Form II.
Example 6. HCl Salt, Form II
[0822] HCl salt Form II was prepared as a result of HCl salt Form I
being run on a moisture balance over a range from 5% to 95% RH at
10% RH increments under a nitrogen purge.
[0823] Compound I HCl Form II is a hydrated/solvated phase. Its
XRPD pattern is shown in FIG. 9.
TABLE-US-00005 TABLE 4 Peak Table for HCl Form II Pos.
[.degree.2Th.] Rel. Int. [%] 7.1 99.65 9.7 35.87 10.4 9.55 14.3
63.55 15.3 81.42 16.1 58.99 16.4 19.08 16.8 18.88 18.5 10.75 19.1
24.59 20.9 23.31 21.5 18.10 21.8 20.49 22.5 63.88 24.0 100.00 24.8
21.94 25.6 16.17 26.0 37.87 26.5 19.67 27.0 10.18 27.9 9.96 29.8
19.84 31.0 12.57 31.7 13.33 32.1 8.93 32.8 10.76 34.1 3.15 38.0
6.20
[0824] The DSC curve is shown in FIG. 10 and displays one
endothermic transition at about 58.degree. C. The TGA curve is
shown in FIG. 11 and indicates that the phase is likely
hydrated/solvated. The dynamic vapor sorption curve is shown in
FIG. 12 and the data indicates that during the sorption cycle, the
material exhibited a weight gain of approximately 19.8% from 5% to
95% RH. The material was found to not have changed forms post
experiment.
Example 7. Tartaric Acid
[0825] Compound I Form I (37.53 mg), approximately one molar
equivalent of L-(+)-tartaric acid (19.3 mg), and ethyl acetate (300
.mu.l) was heated to about 50.degree. C. in an Avantium
Crystal16.RTM. multiple-reactor system. After approximately 15
minutes, the reactor system was turned off for fast cooling to
ambient temperature. After reaching ambient temperature, samples
were re-heated to about 50.degree. C. for about 4 hours, and then
cooled to about 10.degree. C. at 0.1.degree. C./min. A mixture of
solids and gel resulted. Heptane (600 .mu.l) was added to the
mixture and it was stirred at ambient temperature for about 6 days.
Solids were collected by vacuum filtration, added to acetone (0.5
ml) and stirred at ambient temperature. After about 5 hours, solids
were collected by vacuum filtration and analyzed.
[0826] Compound I Tartaric Acid is a possible hydrated/solvated
phase. Its XRPD pattern is shown in FIG. 13.
TABLE-US-00006 TABLE 5 Peak Table for Tartaric Acid Pos.
[.degree.2Th.] Rel. Int. [%] 6.3 100.00 9.4 4.60 9.9 12.85 11.3
4.73 12.5 12.08 13.4 0.80 14.6 3.75 15.7 4.05 16.2 6.43 17.7 13.40
18.3 14.31 19.2 8.42 19.7 4.39 20.5 1.29 21.1 4.18 21.4 3.39 21.7
2.86 22.3 1.74 23.0 3.25 23.4 16.64 24.0 2.05 25.2 3.42 25.7 11.00
28.1 7.69 29.4 1.16 30.7 2.57 31.2 2.15 33.4 0.75 34.0 1.00 34.4
1.18 37.1 0.63
[0827] The DSC curve is shown in FIG. 14 and displays one
endothermic transition at about 157.degree. C. The TGA curve is
shown in FIG. 15 and indicates that the phase is possibly
hydrated/solvated. The dynamic vapor sorption curve is shown in
FIG. 16 and the data indicates that the form absorbs about 1.5% of
water up to 95% RH at 25.degree. C. The material was found to not
have changed forms post experiment.
Example 8. Maleic Acid
[0828] Compound I Form 1 (36.49 mg), approximately one molar
equivalent of maleic acid (15.7 mg), and ethyl acetate (300 .mu.l)
were heated to about 50.degree. C. in an Avantium Crystal16.RTM.
multiple-reactor system. After approximately 15 min, the reactor
system was turned off for fast cooling to ambient temperature.
After reaching ambient temperature, samples were re-heated to about
50.degree. C. for about 4 hours and then cooled to about 10.degree.
C. at 0.1.degree. C./min. Solids were collected by vacuum
filtration and analyzed.
[0829] Compound I Maleic Acid is an unsolvated phase. Its XRPD
pattern is shown in FIG. 17.
TABLE-US-00007 TABLE 6 Peak Table for Maleic Acid Pos.
[.degree.2Th.] Rel. Int. [%] 7.3 100.00 8.4 20.37 8.8 29.38 12.4
12.06 13.0 19.97 13.9 50.72 15.4 18.06 15.6 37.79 16.4 6.94 17.4
13.69 17.7 66.93 18.5 5.17 20.7 21.80 20.9 8.65 21.5 3.02 22.0
11.14 22.8 13.30 23.2 7.06 23.7 4.59 24.7 86.71 25.0 11.17 25.7
24.53 25.9 16.83 27.4 39.84 28.3 3.32 29.5 5.56 29.8 8.30 31.5 2.78
33.0 2.97 33.8 3.79 35.6 1.30 37.4 4.70 39.4 3.74
[0830] The DSC curve is shown in FIG. 18 and displays one
endothermic transition at about 143.degree. C. The TGA curve is
shown in FIG. 19 and indicates that the phase is unsolvated. The
dynamic vapor sorption curve is shown in FIG. 20 and the data
indicates that the form absorbs about 0.11% of water up to 95% RH
at 25.degree. C. The material was found to not have changed forms
post experiment.
Example 9. Fumaric Acid
[0831] Compound I Form 1 (32.53 mg), approximately one molar
equivalent of fumaric acid (13.2 mg), and acetone (300 .mu.l) were
heated to 50.degree. C. in an Avantium Crystal16.RTM.
multiple-reactor system. After approximately 15 minutes, the
reactor system was turned off for fast cooling to ambient
temperature. After reaching ambient temperature, samples were
re-heated to about 50.degree. C. for about 4 hours and then cooled
to about 10.degree. C. at 0.1.degree. C./min. Solids were collected
by vacuum filtration and analyzed.
[0832] Compound I Fumaric Acid is a solvated/hydrated phase. Its
XRPD pattern is shown in FIG. 21.
TABLE-US-00008 TABLE 7 Peak Table for Fumaric Acid Pos.
[.degree.2Th.] Rel. Int. [%] 6.7 78.94 6.8 73.75 8.3 100.00 8.6
35.60 10.1 9.50 12.6 15.95 16.1 16.94 18.5 21.05 20.6 26.45 22.8
9.63 25.2 78.37 25.7 64.90 26.4 17.11 27.6 19.76
[0833] The DSC curve is shown in FIG. 22 and displays two
endothermic transitions at about 70 and 167.degree. C. The TGA
curve is shown in FIG. 23 and indicates that the phase is solvated.
The dynamic vapor sorption curve is shown in FIG. 24 and the data
indicates that the form absorbs about 2.3% of water up to 95% RH at
25.degree. C. The material was found to not have changed forms post
experiment.
Example 10. Methanesulfonic Acid
[0834] Compound I Form 1 (34.21 mg), approximately one molar
equivalent of methanesulfonic acid (10 .mu.l), and ethyl acetate
(300 .mu.l) were heated to 50.degree. C. in an Avantium
Crystal16.RTM. multiple-reactor system. After approximately 15
minutes, the reactor system was turned off for fast cooling to
ambient temperature. After reaching ambient temperature, samples
were re-heated to about 50.degree. C. for about 4 hours and then
cooled to about 10.degree. C. at 0.1.degree. C./min. Solids were
collected by vacuum filtration and analyzed.
[0835] Compound I Methanesulfonic Acid is a potential
hydrated/solvated phase. Its XRPD pattern is shown in FIG. 25.
TABLE-US-00009 TABLE 8 Peak Table for Methanesulfonic Acid Pos.
[.degree.2Th.] Rel. Int. [%] 5.4 100.00 8.7 10.19 10.4 18.09 10.8
16.50 14.0 5.47 15.8 41.54 16.3 6.12 17.3 26.10 18.1 77.71 18.6
11.25 20.5 56.63 20.8 27.10 21.2 4.57 21.8 7.34 22.2 12.25 23.2
4.82 23.9 37.55 28.0 10.59 28.6 5.41 29.0 3.27 30.7 9.74 31.2 9.12
32.7 3.21 35.5 3.04 39.1 4.07
[0836] The DSC curve is shown in FIG. 26 and displays two
endothermic transitions at about 30 and 147.degree. C. The TGA
curve is shown in FIG. 27 and indicates that the phase is
potentially hydrated/solvated. The dynamic vapor sorption curve is
shown in FIG. 28 and the data indicates that the form absorbs about
38% of water up to 95% RH at 25.degree. C. The material was found
to not have changed forms post experiment.
Example 11. Amorphous Compound I
[0837] Compound I amorphous was isolated when 208 mg of Form I was
dissolved in t-BuOH (13 ml) at 50.degree. C. The solution was
filtered through a 0.2 .mu.m cellulose filter to remove any seeds.
The sample was frozen in dry ice/acetone and was freeze dried for
3.25 hours. Its XRPD pattern is shown in FIG. 29 and is
characterized by a broad hump. The DSC curve is shown in FIG. 30
indicating a glass transition around 24.degree. C.
[0838] Although the foregoing disclosure has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, one of skill in the art will appreciate that
certain changes and modifications may be practiced within the scope
of the appended claims. In addition, each reference, including all
of the U.S. patents, U.S. patent application publications, U.S.
patent applications, foreign patents, foreign patent applications
and non-patent publications referred to in this specification are
incorporated herein by reference, in their entirety, to the extent
not inconsistent with the present description. Where a conflict
exists between the instant application and a reference provided
herein, the instant application shall dominate.
* * * * *